Dossier zur Nutzenbewertung gemäß § 35a SGB V

Clesrovimab (ENFLONSIA®)

MSD Sharp & Dohme GmbH

Modul 4A

Anhang 4-G: Weitere Ergebnisse

Neugeborene und Säuglinge mit Indikation zur Sekundärprophylaxe von Erkrankungen der unteren Atemwege verursacht durch RSV, während ihrer ersten RSV-Saison

Stand: 28.05.2026

Inhaltsverzeichnis

Seite

Inhaltsverzeichnis **1**
Tabellenverzeichnis **2**
Anhang 4-G: Weitere Ergebnisse **3**
Anhang 4-G1 Charakterisierung der Studienpopulation **4**
Anhang 4-G2: Ergebnisse der Subgruppen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) **94**
Anhang 4-G2.2: Morbidität 95
Anhang 4-G2.3: Nebenwirkungen 98
Unerwünschte Ereignisse Gesamtraten 98
Unerwünschte Ereignisse (gegliedert nach SOC und PT) 103

Tabellenverzeichnis

Tabelle 4G-1: Disposition der Studienpopulation – RCT mit dem zu bewertenden Arzneimittel 4

Tabelle 4G-2: Übersicht der Beobachtungszeiten auf Endpunktebene – RCT mit dem zu bewertenden Arzneimittel 5

Tabelle 4G-3: Krankengeschichte der Studienpopulation – RCT mit dem zu bewertenden Arzneimittel 6

Tabelle 4G-4: Begleitmedikation der Studienpopulation – RCT mit dem zu bewertenden Arzneimittel 32

Tabelle 4G-5: Koadministrationen der Studienpopulation – RCT mit dem zu bewertenden Arzneimittel 89

Tabelle 4G-6: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt RSV-assoziierte MALRI (Tag 1 bis 150) – RCT mit dem zu bewertenden Arzneimittel 95

Tabelle 4G-7: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt RSV-assoziierte Hospitalisierungen (Tag 1 bis 150) – RCT mit dem zu bewertenden Arzneimittel 96

Tabelle 4G-8: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt Unerwünschte Ereignisse gesamt – RCT mit dem zu bewertenden Arzneimittel 98

Tabelle 4G-9: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt Schwerwiegende unerwünschte Ereignisse– RCT mit dem zu bewertenden Arzneimittel 99

Tabelle 4G-10: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt Schwere unerwünschte Ereignisse (CTCAE-Grad 3-5) – RCT mit dem zu bewertenden Arzneimittel 100

Tabelle 4G-11: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt Unerwünschte Ereignisse, die zum Tod führen – RCT mit dem zu bewertenden Arzneimittel 101

Tabelle 4G-12: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt Therapieabbruch wegen unerwünschter Ereignisse – RCT mit dem zu bewertenden Arzneimittel 102

Tabelle 4G-13: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt Unerwünschte Ereignisse gesamt (SOC) – RCT mit dem zu bewertenden Arzneimittel 103

Tabelle 4G-14: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt Unerwünschte Ereignisse gesamt (PT) – RCT mit dem zu bewertenden Arzneimittel 106

Tabelle 4G-15: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt Unerwünschte Ereignisse gesamt (PT) – RCT mit dem zu bewertenden Arzneimittel 111

Anhang 4-G: Weitere Ergebnisse

Alle Ergebnisse beziehen sich auf den finalen Datenschnitt vom 01. August 2025.

Anhang 4-G1 Charakterisierung der Studienpopulation

Tabelle 4G-1: Disposition der Studienpopulation – RCT mit dem zu bewertenden Arzneimittel

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Participants in population	502		501		1,003	
Dosed with						
Dose 1 (Day 1)	498	(99.2)	499	(99.6)	997	(99.4)
Dose 2[a] (Day 28)	484	(96.4)	494	(98.6)	978	(97.5)
Dose 3 (Day 60)	0	(0.0)	485	(96.8)	485	(48.4)
Dose 4 (Day 90)	0	(0.0)	398	(79.4)	398	(39.7)
Dose 5 (Day 120)	0	(0.0)	324	(64.7)	324	(32.3)
Unscheduled[b]	3	(0.6)	2	(0.4)	5	(0.5)
Trial Disposition						
Completed[c]	465	(92.6)	462	(92.2)	927	(92.4)
Discontinued	37	(7.4)	39	(7.8)	76	(7.6)
Death	8	(1.6)	4	(0.8)	12	(1.2)
Lost To Follow-Up	9	(1.8)	13	(2.6)	22	(2.2)
Physician Decision	2	(0.4)	1	(0.2)	3	(0.3)
Randomized By Mistake Without Study Treatment	1	(0.2)	1	(0.2)	2	(0.2)
Withdrawal By Parent/Guardian	17	(3.4)	20	(4.0)	37	(3.7)

Each participant is counted once for Trial Disposition based on the latest corresponding disposition record

a: Participants in the Clesrovimab group received placebo at Dose 2

b: Participants who receive an additional unscheduled dose of study treatment after undergoing ECMO or cardiopulmonary bypass during the RSV season

c: Participants who are continuing in the study in RSV Season 2 are counted under the 'Completed' category for RSV Season 1

ECMO: Extra-Corporeal Membrane Oxygenation; RSV: Respiratory Syncytial Virus

Tabelle 4G-2: Übersicht der Beobachtungszeiten auf Endpunktebene – RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	Clesrovimab	Palivizumab
Observation Period		
RSV-associated MALRI Post Dose 1, Days 1 to 150 (Months)[b,c]		
N[d]	495	485
Mean (SD)	4.8 (0.8)	4.8 (0.8)
Median (Q1; Q3)	5.0 (5.0; 5.0)	5.0 (5.0; 5.0)
Min; Max	0.2; 5.0	0.1; 5.0
RSV-associated Hospitalization Post Dose 1, Days 1 to 150 (Months)[c,e]		
N[d]	495	485
Mean (SD)	4.8 (0.8)	4.9 (0.6)
Median (Q1; Q3)	5.0 (5.0; 5.0)	5.0 (5.0; 5.0)
Min; Max	0.2; 5.0	0.4; 5.0
Adverse Event (Months)		
Season 1 period[f]		
N[g]	497	499
Mean (SD)	1.4 (0.1)	2.5 (0.4)
Median (Q1; Q3)	1.4 (1.3; 1.4)	2.7 (2.3; 2.8)
Min; Max	0.2; 1.9	1.0; 4.6
Season 1 blinded period[h]		
N[g]	497	499
Mean (SD)	1.4 (0.1)	1.4 (0.0)
Median (Q1; Q3)	1.4 (1.4; 1.4)	1.4 (1.4; 1.4)
Min; Max	0.2; 1.4	1.0; 1.4
Serious Adverse Event (Months)[i]		
N[g]	497	499
Mean (SD)	23.7 (10.8)	24.0 (10.6)
Median (Q1; Q3)	25.8 (12.1; 32.4)	25.7 (12.5; 32.2)
Min; Max	0.2; 44.0	1.0; 44.0

a: Database Cutoff Date: 01AUG2025

b: Calculated from date of first dose to the earliest date of becoming a case of RSV-associated MALRI at Post Dose 1 Days 1 to 150, or the date of early dropout, or the end of the efficacy follow-up period (Day 150) whichever occurs first

c: One month is defined as 30 days, consistent to the total follow-up time calculation applied for the efficacy analyses

d: Number of participants: full analysis set population

e: Calculated from date of first dose to the earliest date of becoming a case of RSV-associated Hospitalization at Post Dose 1, Days 1 to 150, or the date of early dropout, or the end of the efficacy follow-up period (Day 150) whichever occurs first

f: Adverse event follow-up duration for Season 1 is defined as the time from the first dose at RSV Season 1 to the earliest date of this dose + 42 days (if only one dose is administered) or from the first dose to the day prior to second dose and 14 days after each subsequent dose (if multiple doses are administered) in RSV Season 1, date of death, or the database cutoff date if the participant is still alive

g: Number of participants: all-participants-as-treated population

h: Adverse event follow-up duration for blinded period of Season 1 is defined as the time from the first dose at RSV Season 1 to the earliest date of this dose + 42 days, date of death, or the database cutoff date if the participant is still alive

i: Serious Adverse event follow-up duration is defined as the time from the first dose at RSV Season 1 to earliest date of the day prior to first dose at RSV Season 2, the date of death, or the database cutoff date if the participant is still alive

MALRI: Medically Attended Lower Respiratory Infection; Max: Maximum; Min: Minimum; Q1: First Quartile; Q3: Third Quartile; RSV: Respiratory Syncytial Virus; SD: Standard Deviation

Tabelle 4G-3: Krankengeschichte der Studienpopulation – RCT mit dem zu bewertenden Arzneimittel

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Participants in population	498		499		997	
with one or more condition	473	(95.0)	467	(93.6)	940	(94.3)
with no condition	25	(5.0)	32	(6.4)	57	(5.7)
Blood and lymphatic system disorders	**174**	**(34.9)**	**142**	**(28.5)**	**316**	**(31.7)**
Anaemia	68	(13.7)	58	(11.6)	126	(12.6)
Anaemia macrocytic	1	(0.2)	0	(0.0)	1	(0.1)
Anaemia neonatal	89	(17.9)	73	(14.6)	162	(16.2)
Blood loss anaemia	1	(0.2)	0	(0.0)	1	(0.1)
Coagulopathy	1	(0.2)	0	(0.0)	1	(0.1)
Disseminated intravascular coagulation	3	(0.6)	1	(0.2)	4	(0.4)
Hypoglobulinaemia	0	(0.0)	1	(0.2)	1	(0.1)
Hypoprothrombinaemia	1	(0.2)	0	(0.0)	1	(0.1)
Iron deficiency anaemia	2	(0.4)	1	(0.2)	3	(0.3)
Leukocytosis	0	(0.0)	3	(0.6)	3	(0.3)
Leukopenia	1	(0.2)	1	(0.2)	2	(0.2)
Lymphadenopathy	1	(0.2)	0	(0.0)	1	(0.1)
Methaemoglobinaemia	1	(0.2)	0	(0.0)	1	(0.1)
Neutropenia	5	(1.0)	5	(1.0)	10	(1.0)
Neutropenia neonatal	2	(0.4)	2	(0.4)	4	(0.4)
Neutrophilia	1	(0.2)	0	(0.0)	1	(0.1)
Normochromic normocytic anaemia	1	(0.2)	0	(0.0)	1	(0.1)
Normocytic anaemia	0	(0.0)	1	(0.2)	1	(0.1)
Placental transfusion syndrome	3	(0.6)	9	(1.8)	12	(1.2)
Polycythaemia	4	(0.8)	3	(0.6)	7	(0.7)
Polycythaemia neonatorum	0	(0.0)	2	(0.4)	2	(0.2)
Thrombocytopenia	25	(5.0)	16	(3.2)	41	(4.1)
Thrombocytopenia neonatal	2	(0.4)	0	(0.0)	2	(0.2)
Thrombocytosis	2	(0.4)	3	(0.6)	5	(0.5)
Cardiac disorders	**46**	**(9.2)**	**41**	**(8.2)**	**87**	**(8.7)**
Accessory cardiac pathway	1	(0.2)	0	(0.0)	1	(0.1)
Aortic valve incompetence	1	(0.2)	0	(0.0)	1	(0.1)
Aortic valve stenosis	1	(0.2)	2	(0.4)	3	(0.3)
Atrial flutter	1	(0.2)	0	(0.0)	1	(0.1)
Atrial tachycardia	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Cardiac disorders	**46**	**(9.2)**	**41**	**(8.2)**	**87**	**(8.7)**
Atrioventricular dissociation	1	(0.2)	0	(0.0)	1	(0.1)
Bradycardia	12	(2.4)	5	(1.0)	17	(1.7)
Bradycardia neonatal	0	(0.0)	1	(0.2)	1	(0.1)
Bundle branch block left	1	(0.2)	0	(0.0)	1	(0.1)
Cardiac aneurysm	1	(0.2)	1	(0.2)	2	(0.2)
Cardiac arrest	1	(0.2)	1	(0.2)	2	(0.2)
Cardiac disorder	1	(0.2)	0	(0.0)	1	(0.1)
Cardiac dysfunction	1	(0.2)	1	(0.2)	2	(0.2)
Cardiac failure	4	(0.8)	4	(0.8)	8	(0.8)
Cardiac failure congestive	1	(0.2)	0	(0.0)	1	(0.1)
Cardiac perforation	1	(0.2)	0	(0.0)	1	(0.1)
Cardio-respiratory arrest	1	(0.2)	0	(0.0)	1	(0.1)
Cardiogenic shock	0	(0.0)	1	(0.2)	1	(0.1)
Cardiomegaly	2	(0.4)	1	(0.2)	3	(0.3)
Cor pulmonale	1	(0.2)	0	(0.0)	1	(0.1)
Dilatation ventricular	1	(0.2)	1	(0.2)	2	(0.2)
Dilated cardiomyopathy	1	(0.2)	0	(0.0)	1	(0.1)
Extrasystoles	0	(0.0)	1	(0.2)	1	(0.1)
Heart valve incompetence	2	(0.4)	0	(0.0)	2	(0.2)
Left atrial dilatation	1	(0.2)	0	(0.0)	1	(0.1)
Left ventricular dilatation	1	(0.2)	1	(0.2)	2	(0.2)
Left ventricular dysfunction	1	(0.2)	1	(0.2)	2	(0.2)
Left ventricular hypertrophy	2	(0.4)	1	(0.2)	3	(0.3)
Mitral valve incompetence	2	(0.4)	1	(0.2)	3	(0.3)
Mitral valve stenosis	1	(0.2)	0	(0.0)	1	(0.1)
Myocarditis	0	(0.0)	1	(0.2)	1	(0.1)
Neonatal tachycardia	1	(0.2)	1	(0.2)	2	(0.2)
Pericardial calcification	1	(0.2)	0	(0.0)	1	(0.1)
Pericardial effusion	3	(0.6)	0	(0.0)	3	(0.3)
Pericardial haemorrhage	0	(0.0)	1	(0.2)	1	(0.1)
Pulmonary valve calcification	1	(0.2)	0	(0.0)	1	(0.1)
Pulmonary valve incompetence	1	(0.2)	0	(0.0)	1	(0.1)
Pulmonary valve stenosis	9	(1.8)	8	(1.6)	17	(1.7)
Right ventricular dysfunction	0	(0.0)	1	(0.2)	1	(0.1)
Right ventricular hypertrophy	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Cardiac disorders	**46**	**(9.2)**	**41**	**(8.2)**	**87**	**(8.7)**
Sinus tachycardia	2	(0.4)	1	(0.2)	3	(0.3)
Subvalvular aortic stenosis	0	(0.0)	1	(0.2)	1	(0.1)
Supraventricular extrasystoles	1	(0.2)	0	(0.0)	1	(0.1)
Supraventricular tachycardia	1	(0.2)	0	(0.0)	1	(0.1)
Tachycardia	2	(0.4)	1	(0.2)	3	(0.3)
Tachycardia foetal	1	(0.2)	0	(0.0)	1	(0.1)
Tricuspid valve incompetence	4	(0.8)	6	(1.2)	10	(1.0)
Tricuspid valve stenosis	1	(0.2)	1	(0.2)	2	(0.2)
Wolff-Parkinson-White syndrome	1	(0.2)	0	(0.0)	1	(0.1)
Congenital, familial and genetic disorders	**198**	**(39.8)**	**186**	**(37.3)**	**384**	**(38.5)**
ABO haemolytic disease of newborn	1	(0.2)	1	(0.2)	2	(0.2)
Aberrant aortic arch	2	(0.4)	0	(0.0)	2	(0.2)
Adrenogenital syndrome	0	(0.0)	1	(0.2)	1	(0.1)
Amniotic band syndrome	2	(0.4)	0	(0.0)	2	(0.2)
Anal atresia	0	(0.0)	1	(0.2)	1	(0.1)
Anomalous pulmonary venous connection	2	(0.4)	0	(0.0)	2	(0.2)
Anophthalmos	1	(0.2)	0	(0.0)	1	(0.1)
Anorectal malformation	0	(0.0)	2	(0.4)	2	(0.2)
Asplenia	1	(0.2)	0	(0.0)	1	(0.1)
Atrial septal defect	63	(12.7)	56	(11.2)	119	(11.9)
Atrioventricular septal defect	6	(1.2)	1	(0.2)	7	(0.7)
Bicuspid aortic valve	1	(0.2)	1	(0.2)	2	(0.2)
Blood incompatibility haemolytic anaemia of newborn	0	(0.0)	1	(0.2)	1	(0.1)
Brachydactyly	1	(0.2)	0	(0.0)	1	(0.1)
Brain malformation	2	(0.4)	0	(0.0)	2	(0.2)
Camptodactyly congenital	1	(0.2)	0	(0.0)	1	(0.1)
Cleft lip and palate	1	(0.2)	0	(0.0)	1	(0.1)
Cleft palate	3	(0.6)	2	(0.4)	5	(0.5)
Coarctation of the aorta	3	(0.6)	3	(0.6)	6	(0.6)
Congenital arterial malformation	2	(0.4)	1	(0.2)	3	(0.3)
Congenital central nervous system anomaly	1	(0.2)	0	(0.0)	1	(0.1)
Congenital cerebral cyst	2	(0.4)	2	(0.4)	4	(0.4)
Congenital choroid plexus cyst	4	(0.8)	1	(0.2)	5	(0.5)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Congenital, familial and genetic disorders	**198**	**(39.8)**	**186**	**(37.3)**	**384**	**(38.5)**
Congenital coronary artery malformation	1	(0.2)	0	(0.0)	1	(0.1)
Congenital cystic kidney disease	0	(0.0)	1	(0.2)	1	(0.1)
Congenital cytomegalovirus infection	0	(0.0)	2	(0.4)	2	(0.2)
Congenital diaphragmatic hernia	0	(0.0)	1	(0.2)	1	(0.1)
Congenital eye disorder	1	(0.2)	0	(0.0)	1	(0.1)
Congenital great vessel anomaly	0	(0.0)	1	(0.2)	1	(0.1)
Congenital hydronephrosis	1	(0.2)	0	(0.0)	1	(0.1)
Congenital hypothyroidism	4	(0.8)	2	(0.4)	6	(0.6)
Congenital laryngeal stridor	1	(0.2)	0	(0.0)	1	(0.1)
Congenital megacolon	0	(0.0)	1	(0.2)	1	(0.1)
Congenital pneumonia	6	(1.2)	11	(2.2)	17	(1.7)
Congenital pulmonary artery anomaly	0	(0.0)	1	(0.2)	1	(0.1)
Congenital pulmonary valve atresia	3	(0.6)	0	(0.0)	3	(0.3)
Congenital pulmonary valve disorder	1	(0.2)	0	(0.0)	1	(0.1)
Congenital renal cyst	0	(0.0)	1	(0.2)	1	(0.1)
Congenital syphilis	1	(0.2)	0	(0.0)	1	(0.1)
Congenital torticollis	1	(0.2)	0	(0.0)	1	(0.1)
Congenital toxoplasmosis	1	(0.2)	0	(0.0)	1	(0.1)
Congenital tricuspid valve atresia	2	(0.4)	2	(0.4)	4	(0.4)
Congenital umbilical hernia	4	(0.8)	1	(0.2)	5	(0.5)
Corrected transposition of great vessels	1	(0.2)	0	(0.0)	1	(0.1)
Craniosynostosis	1	(0.2)	0	(0.0)	1	(0.1)
Cryptorchism	4	(0.8)	4	(0.8)	8	(0.8)
Cytogenetic abnormality	0	(0.0)	1	(0.2)	1	(0.1)
Dandy-Walker syndrome	0	(0.0)	1	(0.2)	1	(0.1)
Developmental hip dysplasia	1	(0.2)	2	(0.4)	3	(0.3)
Dextrocardia	2	(0.4)	0	(0.0)	2	(0.2)
DiGeorge's syndrome	1	(0.2)	1	(0.2)	2	(0.2)
Double outlet right ventricle	2	(0.4)	3	(0.6)	5	(0.5)
Dysmorphism	3	(0.6)	3	(0.6)	6	(0.6)
Exomphalos	1	(0.2)	2	(0.4)	3	(0.3)
Fallot's tetralogy	4	(0.8)	1	(0.2)	5	(0.5)
Foetal alcohol syndrome	1	(0.2)	0	(0.0)	1	(0.1)
Frenulum breve	0	(0.0)	1	(0.2)	1	(0.1)
Gastrointestinal malformation	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Congenital, familial and genetic disorders	**198**	**(39.8)**	**186**	**(37.3)**	**384**	**(38.5)**
Glucose-6-phosphate dehydrogenase deficiency	2	(0.4)	2	(0.4)	4	(0.4)
Haemangioma congenital	1	(0.2)	2	(0.4)	3	(0.3)
Heart disease congenital	19	(3.8)	17	(3.4)	36	(3.6)
Hemivertebra	1	(0.2)	0	(0.0)	1	(0.1)
Heterotaxia	1	(0.2)	0	(0.0)	1	(0.1)
High arched palate	1	(0.2)	2	(0.4)	3	(0.3)
Hydrocele	6	(1.2)	5	(1.0)	11	(1.1)
Hypertrophic cardiomyopathy	1	(0.2)	0	(0.0)	1	(0.1)
Hypoplastic left heart syndrome	3	(0.6)	4	(0.8)	7	(0.7)
Hypoplastic right heart syndrome	0	(0.0)	1	(0.2)	1	(0.1)
Hypospadias	3	(0.6)	3	(0.6)	6	(0.6)
Intestinal atresia	1	(0.2)	0	(0.0)	1	(0.1)
Intestinal malrotation	0	(0.0)	1	(0.2)	1	(0.1)
Laryngomalacia	3	(0.6)	1	(0.2)	4	(0.4)
Left-to-right cardiac shunt	3	(0.6)	1	(0.2)	4	(0.4)
Limb hypoplasia congenital	1	(0.2)	0	(0.0)	1	(0.1)
Macrocephaly	2	(0.4)	0	(0.0)	2	(0.2)
Microcephaly	1	(0.2)	3	(0.6)	4	(0.4)
Microencephaly	0	(0.0)	1	(0.2)	1	(0.1)
Microphthalmos	1	(0.2)	0	(0.0)	1	(0.1)
Mitral valve atresia	1	(0.2)	0	(0.0)	1	(0.1)
Mitral valve dysplasia	1	(0.2)	0	(0.0)	1	(0.1)
Muscular dystrophy	1	(0.2)	0	(0.0)	1	(0.1)
Naevus flammeus	2	(0.4)	1	(0.2)	3	(0.3)
Newborn persistent pulmonary hypertension	0	(0.0)	3	(0.6)	3	(0.3)
Patent ductus arteriosus	69	(13.9)	84	(16.8)	153	(15.3)
Persistent left superior vena cava	1	(0.2)	2	(0.4)	3	(0.3)
Phimosis	2	(0.4)	0	(0.0)	2	(0.2)
Plagiocephaly	4	(0.8)	2	(0.4)	6	(0.6)
Polydactyly	0	(0.0)	1	(0.2)	1	(0.1)
Porencephaly	0	(0.0)	1	(0.2)	1	(0.1)
Preauricular cyst	1	(0.2)	0	(0.0)	1	(0.1)
Pulmonary arteriovenous fistula	1	(0.2)	0	(0.0)	1	(0.1)
Pulmonary artery atresia	0	(0.0)	1	(0.2)	1	(0.1)
Pulmonary artery stenosis congenital	3	(0.6)	3	(0.6)	6	(0.6)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Congenital, familial and genetic disorders	**198**	**(39.8)**	**186**	**(37.3)**	**384**	**(38.5)**
Pulmonary hypoplasia	3	(0.6)	0	(0.0)	3	(0.3)
Pulmonary valve stenosis congenital	0	(0.0)	1	(0.2)	1	(0.1)
Pyloric stenosis	1	(0.2)	0	(0.0)	1	(0.1)
Renal dysplasia	1	(0.2)	1	(0.2)	2	(0.2)
Renal fusion anomaly	1	(0.2)	0	(0.0)	1	(0.1)
Right aortic arch	2	(0.4)	0	(0.0)	2	(0.2)
Right ventricle outflow tract obstruction	2	(0.4)	0	(0.0)	2	(0.2)
Septum pellucidum agenesis	1	(0.2)	0	(0.0)	1	(0.1)
Spina bifida occulta	1	(0.2)	0	(0.0)	1	(0.1)
Straddling tricuspid valve	1	(0.2)	0	(0.0)	1	(0.1)
Talipes	2	(0.4)	0	(0.0)	2	(0.2)
Tethered oral tissue	3	(0.6)	2	(0.4)	5	(0.5)
Thalassaemia alpha	0	(0.0)	1	(0.2)	1	(0.1)
Transposition of the great vessels	3	(0.6)	3	(0.6)	6	(0.6)
Trisomy 21	6	(1.2)	12	(2.4)	18	(1.8)
Urachal abnormality	1	(0.2)	0	(0.0)	1	(0.1)
Ventricular hypoplasia	1	(0.2)	1	(0.2)	2	(0.2)
Ventricular septal defect	24	(4.8)	29	(5.8)	53	(5.3)
Vitello-intestinal duct remnant	1	(0.2)	0	(0.0)	1	(0.1)
Ear and labyrinth disorders	**0**	**(0.0)**	**1**	**(0.2)**	**1**	**(0.1)**
Hypoacusis	0	(0.0)	1	(0.2)	1	(0.1)
Endocrine disorders	**9**	**(1.8)**	**14**	**(2.8)**	**23**	**(2.3)**
Adrenal insufficiency	0	(0.0)	5	(1.0)	5	(0.5)
Euthyroid sick syndrome	1	(0.2)	0	(0.0)	1	(0.1)
Glucocorticoid deficiency	1	(0.2)	1	(0.2)	2	(0.2)
Hyperparathyroidism	0	(0.0)	1	(0.2)	1	(0.1)
Hypothyroidism	5	(1.0)	6	(1.2)	11	(1.1)
Primary hypogonadism	1	(0.2)	0	(0.0)	1	(0.1)
Thyroid disorder	1	(0.2)	0	(0.0)	1	(0.1)
Transient neonatal hyperthyrotropinaemia	1	(0.2)	1	(0.2)	2	(0.2)
Eye disorders	**98**	**(19.7)**	**88**	**(17.6)**	**186**	**(18.7)**
Dacryostenosis acquired	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Eye disorders	**98**	**(19.7)**	**88**	**(17.6)**	**186**	**(18.7)**
Eye movement disorder	1	(0.2)	0	(0.0)	1	(0.1)
Eyelid ptosis	1	(0.2)	0	(0.0)	1	(0.1)
Ocular vascular disorder	1	(0.2)	1	(0.2)	2	(0.2)
Pupillary reflex impaired	1	(0.2)	0	(0.0)	1	(0.1)
Retinal disorder	2	(0.4)	0	(0.0)	2	(0.2)
Retinal haemorrhage	1	(0.2)	1	(0.2)	2	(0.2)
Retinopathy	7	(1.4)	7	(1.4)	14	(1.4)
Retinopathy of prematurity	83	(16.7)	78	(15.6)	161	(16.1)
Strabismus	1	(0.2)	0	(0.0)	1	(0.1)
Swelling of eyelid	1	(0.2)	0	(0.0)	1	(0.1)
Gastrointestinal disorders	**124**	**(24.9)**	**127**	**(25.5)**	**251**	**(25.2)**
Abdominal distension	3	(0.6)	3	(0.6)	6	(0.6)
Abdominal mass	1	(0.2)	0	(0.0)	1	(0.1)
Abdominal pain	0	(0.0)	2	(0.4)	2	(0.2)
Constipation	4	(0.8)	5	(1.0)	9	(0.9)
Diarrhoea	2	(0.4)	0	(0.0)	2	(0.2)
Duodenal ulcer	0	(0.0)	1	(0.2)	1	(0.1)
Dyspepsia	2	(0.4)	2	(0.4)	4	(0.4)
Dysphagia	5	(1.0)	4	(0.8)	9	(0.9)
Enterocolitis	5	(1.0)	3	(0.6)	8	(0.8)
Faeces hard	0	(0.0)	1	(0.2)	1	(0.1)
Flatulence	0	(0.0)	5	(1.0)	5	(0.5)
Gastric haemorrhage	1	(0.2)	0	(0.0)	1	(0.1)
Gastric perforation	2	(0.4)	2	(0.4)	4	(0.4)
Gastritis erosive	0	(0.0)	1	(0.2)	1	(0.1)
Gastrointestinal disorder	3	(0.6)	0	(0.0)	3	(0.3)
Gastrointestinal haemorrhage	2	(0.4)	1	(0.2)	3	(0.3)
Gastrointestinal motility disorder	1	(0.2)	5	(1.0)	6	(0.6)
Gastrointestinal wall thickening	1	(0.2)	0	(0.0)	1	(0.1)
Gastrooesophageal reflux disease	36	(7.2)	32	(6.4)	68	(6.8)
Haematochezia	3	(0.6)	2	(0.4)	5	(0.5)
Ileal perforation	1	(0.2)	0	(0.0)	1	(0.1)
Ileus	1	(0.2)	1	(0.2)	2	(0.2)
Incarcerated inguinal hernia	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Gastrointestinal disorders	**124**	**(24.9)**	**127**	**(25.5)**	**251**	**(25.2)**
Infantile colic	0	(0.0)	1	(0.2)	1	(0.1)
Infantile spitting up	1	(0.2)	2	(0.4)	3	(0.3)
Inguinal hernia	13	(2.6)	27	(5.4)	40	(4.0)
Intestinal haemorrhage	0	(0.0)	1	(0.2)	1	(0.1)
Intestinal obstruction	1	(0.2)	1	(0.2)	2	(0.2)
Intestinal perforation	1	(0.2)	0	(0.0)	1	(0.1)
Large intestine perforation	1	(0.2)	0	(0.0)	1	(0.1)
Lip disorder	1	(0.2)	0	(0.0)	1	(0.1)
Malabsorption	1	(0.2)	0	(0.0)	1	(0.1)
Meconium ileus	0	(0.0)	1	(0.2)	1	(0.1)
Meconium plug syndrome	2	(0.4)	1	(0.2)	3	(0.3)
Necrotising colitis	27	(5.4)	28	(5.6)	55	(5.5)
Neonatal gastrointestinal disorder	1	(0.2)	1	(0.2)	2	(0.2)
Neonatal intestinal obstruction	0	(0.0)	1	(0.2)	1	(0.1)
Neonatal intestinal perforation	0	(0.0)	1	(0.2)	1	(0.1)
Oesophageal dilatation	0	(0.0)	1	(0.2)	1	(0.1)
Oesophageal motility disorder	1	(0.2)	0	(0.0)	1	(0.1)
Pneumatosis intestinalis	1	(0.2)	0	(0.0)	1	(0.1)
Rectal haemorrhage	0	(0.0)	1	(0.2)	1	(0.1)
Rectal perforation	0	(0.0)	1	(0.2)	1	(0.1)
Short-bowel syndrome	0	(0.0)	1	(0.2)	1	(0.1)
Stomatitis	2	(0.4)	0	(0.0)	2	(0.2)
Tongue thrust	1	(0.2)	1	(0.2)	2	(0.2)
Umbilical hernia	27	(5.4)	26	(5.2)	53	(5.3)
Upper gastrointestinal haemorrhage	1	(0.2)	2	(0.4)	3	(0.3)
Vomiting	4	(0.8)	2	(0.4)	6	(0.6)
General disorders and administration site conditions	**12**	**(2.4)**	**15**	**(3.0)**	**27**	**(2.7)**
Developmental delay	1	(0.2)	1	(0.2)	2	(0.2)
Disturbance of thermoregulation of newborn	1	(0.2)	0	(0.0)	1	(0.1)
Drug intolerance	0	(0.0)	1	(0.2)	1	(0.1)
Drug withdrawal syndrome	1	(0.2)	1	(0.2)	2	(0.2)
Drug withdrawal syndrome neonatal	0	(0.0)	1	(0.2)	1	(0.1)
Extravasation	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
General disorders and administration site conditions	**12**	**(2.4)**	**15**	**(3.0)**	**27**	**(2.7)**
Hypothermia	1	(0.2)	1	(0.2)	2	(0.2)
Ill-defined disorder	5	(1.0)	8	(1.6)	13	(1.3)
Oedema	0	(0.0)	1	(0.2)	1	(0.1)
Oedema peripheral	1	(0.2)	1	(0.2)	2	(0.2)
Oral administration complication	1	(0.2)	0	(0.0)	1	(0.1)
Pyrexia	1	(0.2)	0	(0.0)	1	(0.1)
Stenosis	1	(0.2)	0	(0.0)	1	(0.1)
Systemic inflammatory response syndrome	0	(0.0)	1	(0.2)	1	(0.1)
Therapeutic response unexpected	1	(0.2)	0	(0.0)	1	(0.1)
Hepatobiliary disorders	**135**	**(27.1)**	**131**	**(26.3)**	**266**	**(26.7)**
Cholestasis	11	(2.2)	8	(1.6)	19	(1.9)
Hepatic cyst	1	(0.2)	0	(0.0)	1	(0.1)
Hepatic haemorrhage	0	(0.0)	1	(0.2)	1	(0.1)
Hepatomegaly	0	(0.0)	1	(0.2)	1	(0.1)
Hepatosplenomegaly	1	(0.2)	0	(0.0)	1	(0.1)
Hyperbilirubinaemia	62	(12.4)	66	(13.2)	128	(12.8)
Hyperbilirubinaemia neonatal	17	(3.4)	21	(4.2)	38	(3.8)
Jaundice	47	(9.4)	38	(7.6)	85	(8.5)
Jaundice cholestatic	1	(0.2)	1	(0.2)	2	(0.2)
Liver disorder	1	(0.2)	1	(0.2)	2	(0.2)
Neonatal cholestasis	0	(0.0)	2	(0.4)	2	(0.2)
Portal shunt	0	(0.0)	1	(0.2)	1	(0.1)
Portal vein thrombosis	1	(0.2)	0	(0.0)	1	(0.1)
Immune system disorders	**8**	**(1.6)**	**8**	**(1.6)**	**16**	**(1.6)**
ABO incompatibility	0	(0.0)	1	(0.2)	1	(0.1)
Drug hypersensitivity	1	(0.2)	0	(0.0)	1	(0.1)
Hypogammaglobulinaemia	1	(0.2)	0	(0.0)	1	(0.1)
Milk allergy	6	(1.2)	7	(1.4)	13	(1.3)
Infections and infestations	**187**	**(37.6)**	**181**	**(36.3)**	**368**	**(36.9)**
Amniotic cavity infection	0	(0.0)	3	(0.6)	3	(0.3)
Anal abscess	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Infections and infestations	**187**	**(37.6)**	**181**	**(36.3)**	**368**	**(36.9)**
Anal candidiasis	1	(0.2)	0	(0.0)	1	(0.1)
Atypical pneumonia	0	(0.0)	1	(0.2)	1	(0.1)
Bacteraemia	0	(0.0)	5	(1.0)	5	(0.5)
Bacterial disease carrier	3	(0.6)	6	(1.2)	9	(0.9)
Bacterial sepsis	4	(0.8)	3	(0.6)	7	(0.7)
Body tinea	1	(0.2)	4	(0.8)	5	(0.5)
Bronchiolitis	4	(0.8)	2	(0.4)	6	(0.6)
Bronchitis	0	(0.0)	1	(0.2)	1	(0.1)
COVID-19	3	(0.6)	3	(0.6)	6	(0.6)
Candida infection	2	(0.4)	2	(0.4)	4	(0.4)
Clostridium difficile colitis	0	(0.0)	1	(0.2)	1	(0.1)
Conjunctivitis	11	(2.2)	12	(2.4)	23	(2.3)
Conjunctivitis bacterial	1	(0.2)	2	(0.4)	3	(0.3)
Coronavirus infection	1	(0.2)	0	(0.0)	1	(0.1)
Cytomegalovirus infection	4	(0.8)	1	(0.2)	5	(0.5)
Device related sepsis	0	(0.0)	3	(0.6)	3	(0.3)
Enterobacter pneumonia	0	(0.0)	1	(0.2)	1	(0.1)
Enterobacter sepsis	1	(0.2)	0	(0.0)	1	(0.1)
Enterococcal bacteraemia	1	(0.2)	0	(0.0)	1	(0.1)
Enterovirus infection	1	(0.2)	1	(0.2)	2	(0.2)
Escherichia bacteraemia	0	(0.0)	1	(0.2)	1	(0.1)
Escherichia sepsis	1	(0.2)	2	(0.4)	3	(0.3)
Eye infection bacterial	0	(0.0)	1	(0.2)	1	(0.1)
Folliculitis	1	(0.2)	1	(0.2)	2	(0.2)
Fungaemia	1	(0.2)	0	(0.0)	1	(0.1)
Fungal infection	1	(0.2)	1	(0.2)	2	(0.2)
Fungal skin infection	3	(0.6)	3	(0.6)	6	(0.6)
Gastroenteritis	0	(0.0)	3	(0.6)	3	(0.3)
Gastroenteritis rotavirus	1	(0.2)	0	(0.0)	1	(0.1)
Impetigo	1	(0.2)	0	(0.0)	1	(0.1)
Infection	4	(0.8)	3	(0.6)	7	(0.7)
Influenza	1	(0.2)	1	(0.2)	2	(0.2)
Intestinal sepsis	2	(0.4)	1	(0.2)	3	(0.3)
Intrauterine infection	1	(0.2)	1	(0.2)	2	(0.2)
Klebsiella infection	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Infections and infestations	**187**	**(37.6)**	**181**	**(36.3)**	**368**	**(36.9)**
Klebsiella sepsis	5	(1.0)	3	(0.6)	8	(0.8)
Lower respiratory tract infection	1	(0.2)	6	(1.2)	7	(0.7)
Mediastinitis	1	(0.2)	0	(0.0)	1	(0.1)
Meningitis	2	(0.4)	2	(0.4)	4	(0.4)
Meningitis bacterial	1	(0.2)	0	(0.0)	1	(0.1)
Meningitis neonatal	1	(0.2)	0	(0.0)	1	(0.1)
Metapneumovirus pneumonia	0	(0.0)	1	(0.2)	1	(0.1)
Neonatal candida infection	0	(0.0)	1	(0.2)	1	(0.1)
Neonatal infection	9	(1.8)	8	(1.6)	17	(1.7)
Neonatal pneumonia	1	(0.2)	0	(0.0)	1	(0.1)
Nosocomial infection	1	(0.2)	3	(0.6)	4	(0.4)
Omphalitis	1	(0.2)	0	(0.0)	1	(0.1)
Ophthalmia neonatorum	2	(0.4)	1	(0.2)	3	(0.3)
Oral candidiasis	3	(0.6)	2	(0.4)	5	(0.5)
Oral fungal infection	0	(0.0)	1	(0.2)	1	(0.1)
Osteomyelitis	2	(0.4)	0	(0.0)	2	(0.2)
Otitis media	1	(0.2)	1	(0.2)	2	(0.2)
Parainfluenzae virus infection	1	(0.2)	0	(0.0)	1	(0.1)
Pathogen resistance	2	(0.4)	0	(0.0)	2	(0.2)
Peritonitis	1	(0.2)	1	(0.2)	2	(0.2)
Pertussis	0	(0.0)	1	(0.2)	1	(0.1)
Pneumonia	21	(4.2)	12	(2.4)	33	(3.3)
Pneumonia aspiration	0	(0.0)	1	(0.2)	1	(0.1)
Pneumonia bacterial	1	(0.2)	1	(0.2)	2	(0.2)
Pneumonia escherichia	1	(0.2)	0	(0.0)	1	(0.1)
Pneumonia klebsiella	2	(0.4)	3	(0.6)	5	(0.5)
Pneumonia pseudomonal	1	(0.2)	1	(0.2)	2	(0.2)
Pneumonia respiratory syncytial viral	0	(0.0)	1	(0.2)	1	(0.1)
Pneumonia staphylococcal	1	(0.2)	0	(0.0)	1	(0.1)
Pneumonia streptococcal	2	(0.4)	0	(0.0)	2	(0.2)
Postoperative wound infection	1	(0.2)	1	(0.2)	2	(0.2)
Pseudomonal sepsis	0	(0.0)	3	(0.6)	3	(0.3)
Pseudomonas infection	1	(0.2)	1	(0.2)	2	(0.2)
Pulmonary sepsis	0	(0.0)	1	(0.2)	1	(0.1)
Pyelonephritis	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Infections and infestations	**187**	**(37.6)**	**181**	**(36.3)**	**368**	**(36.9)**
Pyuria	1	(0.2)	0	(0.0)	1	(0.1)
Respiratory syncytial virus infection	0	(0.0)	2	(0.4)	2	(0.2)
Respiratory tract infection	1	(0.2)	1	(0.2)	2	(0.2)
Rhinitis	5	(1.0)	2	(0.4)	7	(0.7)
Rhinovirus infection	2	(0.4)	2	(0.4)	4	(0.4)
Sepsis	49	(9.8)	41	(8.2)	90	(9.0)
Sepsis neonatal	59	(11.8)	75	(15.0)	134	(13.4)
Septic shock	5	(1.0)	3	(0.6)	8	(0.8)
Serratia sepsis	2	(0.4)	0	(0.0)	2	(0.2)
Skin candida	0	(0.0)	2	(0.4)	2	(0.2)
Staphylococcal bacteraemia	1	(0.2)	3	(0.6)	4	(0.4)
Staphylococcal infection	0	(0.0)	2	(0.4)	2	(0.2)
Staphylococcal sepsis	7	(1.4)	4	(0.8)	11	(1.1)
Stenotrophomonas maltophilia pneumonia	0	(0.0)	1	(0.2)	1	(0.1)
Streptococcal sepsis	1	(0.2)	0	(0.0)	1	(0.1)
Systemic candida	0	(0.0)	2	(0.4)	2	(0.2)
Tinea infection	1	(0.2)	0	(0.0)	1	(0.1)
Tracheitis	1	(0.2)	1	(0.2)	2	(0.2)
Tracheobronchitis	1	(0.2)	0	(0.0)	1	(0.1)
Upper respiratory tract infection	21	(4.2)	8	(1.6)	29	(2.9)
Ureaplasma infection	0	(0.0)	1	(0.2)	1	(0.1)
Urinary tract candidiasis	0	(0.0)	1	(0.2)	1	(0.1)
Urinary tract infection	6	(1.2)	5	(1.0)	11	(1.1)
Urinary tract infection bacterial	1	(0.2)	0	(0.0)	1	(0.1)
Urinary tract infection enterococcal	1	(0.2)	0	(0.0)	1	(0.1)
Urinary tract infection neonatal	1	(0.2)	0	(0.0)	1	(0.1)
Urosepsis	0	(0.0)	2	(0.4)	2	(0.2)
Vaccination site abscess	1	(0.2)	0	(0.0)	1	(0.1)
Viral hepatitis carrier	1	(0.2)	0	(0.0)	1	(0.1)
Viral rash	0	(0.0)	1	(0.2)	1	(0.1)
Viral upper respiratory tract infection	0	(0.0)	2	(0.4)	2	(0.2)
Injury, poisoning and procedural complications	**26**	**(5.2)**	**25**	**(5.0)**	**51**	**(5.1)**
Anaemia postoperative	0	(0.0)	1	(0.2)	1	(0.1)
Chemical burn	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Injury, poisoning and procedural complications	**26**	**(5.2)**	**25**	**(5.0)**	**51**	**(5.1)**
Clavicle fracture	0	(0.0)	1	(0.2)	1	(0.1)
Craniofacial injury	1	(0.2)	0	(0.0)	1	(0.1)
Exposure to communicable disease	16	(3.2)	16	(3.2)	32	(3.2)
Femur fracture	1	(0.2)	0	(0.0)	1	(0.1)
Humerus fracture	0	(0.0)	1	(0.2)	1	(0.1)
Joint dislocation	1	(0.2)	0	(0.0)	1	(0.1)
Nasal injury	1	(0.2)	0	(0.0)	1	(0.1)
Neck injury	1	(0.2)	0	(0.0)	1	(0.1)
Post procedural haemorrhage	0	(0.0)	1	(0.2)	1	(0.1)
Postoperative ileus	0	(0.0)	1	(0.2)	1	(0.1)
Re-opening of ductus arteriosus	0	(0.0)	1	(0.2)	1	(0.1)
Rib fracture	0	(0.0)	1	(0.2)	1	(0.1)
Scar	0	(0.0)	1	(0.2)	1	(0.1)
Spinal cord injury	1	(0.2)	0	(0.0)	1	(0.1)
Subdural haemorrhage	0	(0.0)	1	(0.2)	1	(0.1)
Ulna fracture	1	(0.2)	0	(0.0)	1	(0.1)
Weaning failure	1	(0.2)	0	(0.0)	1	(0.1)
Wound dehiscence	1	(0.2)	0	(0.0)	1	(0.1)
Investigations	**58**	**(11.6)**	**58**	**(11.6)**	**116**	**(11.6)**
Abdominal X-ray	3	(0.6)	9	(1.8)	12	(1.2)
Acoustic stimulation tests abnormal	1	(0.2)	1	(0.2)	2	(0.2)
Activated partial thromboplastin time prolonged	1	(0.2)	0	(0.0)	1	(0.1)
Adenovirus test positive	1	(0.2)	0	(0.0)	1	(0.1)
Angiocardiogram	0	(0.0)	1	(0.2)	1	(0.1)
Angiogram	0	(0.0)	1	(0.2)	1	(0.1)
Aortogram	0	(0.0)	1	(0.2)	1	(0.1)
Barium enema	1	(0.2)	0	(0.0)	1	(0.1)
Biopsy kidney	0	(0.0)	1	(0.2)	1	(0.1)
Biopsy rectum	1	(0.2)	0	(0.0)	1	(0.1)
Blood alkaline phosphatase increased	1	(0.2)	1	(0.2)	2	(0.2)
Blood bilirubin increased	0	(0.0)	1	(0.2)	1	(0.1)
Blood creatine increased	0	(0.0)	1	(0.2)	1	(0.1)
Blood creatinine increased	1	(0.2)	1	(0.2)	2	(0.2)
Blood culture	1	(0.2)	1	(0.2)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Investigations	**58**	**(11.6)**	**58**	**(11.6)**	**116**	**(11.6)**
Blood gases abnormal	0	(0.0)	1	(0.2)	1	(0.1)
Blood lactic acid increased	0	(0.0)	1	(0.2)	1	(0.1)
Blood potassium decreased	1	(0.2)	0	(0.0)	1	(0.1)
Blood pressure increased	1	(0.2)	0	(0.0)	1	(0.1)
Blood triglycerides increased	0	(0.0)	1	(0.2)	1	(0.1)
Brain scan abnormal	0	(0.0)	2	(0.4)	2	(0.2)
Breath sounds abnormal	0	(0.0)	1	(0.2)	1	(0.1)
Cardiac murmur	8	(1.6)	9	(1.8)	17	(1.7)
Catheterisation cardiac	2	(0.4)	3	(0.6)	5	(0.5)
Chest X-ray	10	(2.0)	10	(2.0)	20	(2.0)
Citrobacter test positive	0	(0.0)	1	(0.2)	1	(0.1)
Colonoscopy	1	(0.2)	0	(0.0)	1	(0.1)
Coombs test positive	1	(0.2)	0	(0.0)	1	(0.1)
Cortisol decreased	1	(0.2)	0	(0.0)	1	(0.1)
Culture	0	(0.0)	1	(0.2)	1	(0.1)
Echocardiogram	19	(3.8)	17	(3.4)	36	(3.6)
Electroencephalogram	1	(0.2)	1	(0.2)	2	(0.2)
Endocrine test abnormal	0	(0.0)	1	(0.2)	1	(0.1)
Endoscopy upper gastrointestinal tract	0	(0.0)	1	(0.2)	1	(0.1)
Enterobacter test positive	0	(0.0)	1	(0.2)	1	(0.1)
Enterococcus test positive	0	(0.0)	1	(0.2)	1	(0.1)
Escherichia test positive	1	(0.2)	0	(0.0)	1	(0.1)
Gastric fluid analysis abnormal	1	(0.2)	1	(0.2)	2	(0.2)
HIV test negative	6	(1.2)	7	(1.4)	13	(1.3)
Head lag	2	(0.4)	0	(0.0)	2	(0.2)
Hepatic enzyme increased	1	(0.2)	0	(0.0)	1	(0.1)
Human rhinovirus test positive	2	(0.4)	0	(0.0)	2	(0.2)
Influenza A virus test positive	1	(0.2)	0	(0.0)	1	(0.1)
Intestinal transit time decreased	3	(0.6)	1	(0.2)	4	(0.4)
Klebsiella test positive	0	(0.0)	1	(0.2)	1	(0.1)
Liver function test	1	(0.2)	0	(0.0)	1	(0.1)
Lumbar puncture	0	(0.0)	1	(0.2)	1	(0.1)
Magnetic resonance imaging	0	(0.0)	1	(0.2)	1	(0.1)
Magnetic resonance imaging abdominal	0	(0.0)	1	(0.2)	1	(0.1)
Magnetic resonance imaging head	1	(0.2)	2	(0.4)	3	(0.3)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Investigations	**58**	**(11.6)**	**58**	**(11.6)**	**116**	**(11.6)**
Magnetic resonance imaging heart	1	(0.2)	0	(0.0)	1	(0.1)
Magnetic resonance imaging pelvic	0	(0.0)	1	(0.2)	1	(0.1)
Medical observation	1	(0.2)	0	(0.0)	1	(0.1)
Metabolic function test abnormal	1	(0.2)	0	(0.0)	1	(0.1)
Oesophagram	2	(0.4)	2	(0.4)	4	(0.4)
Oxygen saturation decreased	3	(0.6)	3	(0.6)	6	(0.6)
Pharyngography	3	(0.6)	2	(0.4)	5	(0.5)
Platelet count decreased	0	(0.0)	1	(0.2)	1	(0.1)
Polymerase chain reaction negative	1	(0.2)	0	(0.0)	1	(0.1)
Pulmonary function test decreased	1	(0.2)	0	(0.0)	1	(0.1)
Staphylococcus test positive	0	(0.0)	2	(0.4)	2	(0.2)
Stenotrophomonas test positive	0	(0.0)	1	(0.2)	1	(0.1)
Ultrasound abdomen	3	(0.6)	3	(0.6)	6	(0.6)
Ultrasound biliary tract	0	(0.0)	1	(0.2)	1	(0.1)
Ultrasound head	15	(3.0)	13	(2.6)	28	(2.8)
Ultrasound head abnormal	4	(0.8)	9	(1.8)	13	(1.3)
Ultrasound head normal	0	(0.0)	1	(0.2)	1	(0.1)
Ultrasound kidney	0	(0.0)	1	(0.2)	1	(0.1)
Ultrasound liver	0	(0.0)	1	(0.2)	1	(0.1)
Ultrasound liver abnormal	0	(0.0)	1	(0.2)	1	(0.1)
Ultrasound pancreas	0	(0.0)	1	(0.2)	1	(0.1)
Ultrasound urinary system	6	(1.2)	5	(1.0)	11	(1.1)
Urine output decreased	0	(0.0)	1	(0.2)	1	(0.1)
Weight decreased	3	(0.6)	2	(0.4)	5	(0.5)
Weight normal	0	(0.0)	1	(0.2)	1	(0.1)
X-ray gastrointestinal tract	0	(0.0)	1	(0.2)	1	(0.1)
Metabolism and nutrition disorders	**134**	**(26.9)**	**141**	**(28.3)**	**275**	**(27.6)**
Acidosis	1	(0.2)	0	(0.0)	1	(0.1)
Amino acid metabolism disorder	1	(0.2)	0	(0.0)	1	(0.1)
Carbohydrate intolerance	0	(0.0)	1	(0.2)	1	(0.1)
Dehydration	4	(0.8)	1	(0.2)	5	(0.5)
Electrolyte imbalance	5	(1.0)	5	(1.0)	10	(1.0)
Failure to thrive	2	(0.4)	1	(0.2)	3	(0.3)
Feeding disorder	4	(0.8)	1	(0.2)	5	(0.5)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Metabolism and nutrition disorders	**134**	**(26.9)**	**141**	**(28.3)**	**275**	**(27.6)**
Feeding intolerance	10	(2.0)	15	(3.0)	25	(2.5)
Food intolerance	2	(0.4)	0	(0.0)	2	(0.2)
Hypercalcaemia	4	(0.8)	4	(0.8)	8	(0.8)
Hyperchloraemia	1	(0.2)	0	(0.0)	1	(0.1)
Hyperglycaemia	9	(1.8)	9	(1.8)	18	(1.8)
Hyperinsulinaemic hypoglycaemia	0	(0.0)	2	(0.4)	2	(0.2)
Hyperkalaemia	3	(0.6)	3	(0.6)	6	(0.6)
Hyperlipidaemia	0	(0.0)	1	(0.2)	1	(0.1)
Hypermagnesaemia	4	(0.8)	7	(1.4)	11	(1.1)
Hypernatraemia	7	(1.4)	4	(0.8)	11	(1.1)
Hyperphosphataemia	4	(0.8)	2	(0.4)	6	(0.6)
Hyperphosphatasaemia	1	(0.2)	2	(0.4)	3	(0.3)
Hypertriglyceridaemia	3	(0.6)	3	(0.6)	6	(0.6)
Hypervitaminosis D	1	(0.2)	0	(0.0)	1	(0.1)
Hypervolaemia	2	(0.4)	1	(0.2)	3	(0.3)
Hypoalbuminaemia	3	(0.6)	2	(0.4)	5	(0.5)
Hypocalcaemia	16	(3.2)	14	(2.8)	30	(3.0)
Hypochloraemia	0	(0.0)	1	(0.2)	1	(0.1)
Hypoglycaemia	21	(4.2)	29	(5.8)	50	(5.0)
Hypoglycaemia neonatal	7	(1.4)	8	(1.6)	15	(1.5)
Hypokalaemia	18	(3.6)	15	(3.0)	33	(3.3)
Hypomagnesaemia	0	(0.0)	4	(0.8)	4	(0.4)
Hyponatraemia	29	(5.8)	33	(6.6)	62	(6.2)
Hypophosphataemia	12	(2.4)	5	(1.0)	17	(1.7)
Hypozincaemia	1	(0.2)	0	(0.0)	1	(0.1)
Iron deficiency	0	(0.0)	1	(0.2)	1	(0.1)
Lactose intolerance	1	(0.2)	1	(0.2)	2	(0.2)
Malnutrition	2	(0.4)	2	(0.4)	4	(0.4)
Metabolic acidosis	9	(1.8)	10	(2.0)	19	(1.9)
Metabolic disorder	2	(0.4)	0	(0.0)	2	(0.2)
Metabolic syndrome	1	(0.2)	0	(0.0)	1	(0.1)
Neonatal hyperglycaemia	1	(0.2)	0	(0.0)	1	(0.1)
Neonatal hypocalcaemia	1	(0.2)	2	(0.4)	3	(0.3)
Neonatal hyponatraemia	1	(0.2)	1	(0.2)	2	(0.2)
Poor feeding infant	29	(5.8)	25	(5.0)	54	(5.4)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Metabolism and nutrition disorders	**134**	**(26.9)**	**141**	**(28.3)**	**275**	**(27.6)**
Underweight	1	(0.2)	0	(0.0)	1	(0.1)
Vitamin D deficiency	7	(1.4)	5	(1.0)	12	(1.2)
Vitamin K deficiency	1	(0.2)	1	(0.2)	2	(0.2)
Weight gain poor	3	(0.6)	1	(0.2)	4	(0.4)
Musculoskeletal and connective tissue disorders	**41**	**(8.2)**	**50**	**(10.0)**	**91**	**(9.1)**
Bone hypertrophy	0	(0.0)	1	(0.2)	1	(0.1)
Bone metabolism disorder	18	(3.6)	17	(3.4)	35	(3.5)
Foot deformity	2	(0.4)	1	(0.2)	3	(0.3)
Growth disorder	1	(0.2)	0	(0.0)	1	(0.1)
Growth failure	1	(0.2)	1	(0.2)	2	(0.2)
Growth retardation	1	(0.2)	1	(0.2)	2	(0.2)
Hypotonia neonatal	0	(0.0)	1	(0.2)	1	(0.1)
Joint instability	2	(0.4)	0	(0.0)	2	(0.2)
Neonatal metabolic bone disease	4	(0.8)	6	(1.2)	10	(1.0)
Newborn head moulding	1	(0.2)	1	(0.2)	2	(0.2)
Osteopenia	12	(2.4)	22	(4.4)	34	(3.4)
Rickets	1	(0.2)	1	(0.2)	2	(0.2)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	**19**	**(3.8)**	**30**	**(6.0)**	**49**	**(4.9)**
Cerebral haemangioma	0	(0.0)	1	(0.2)	1	(0.1)
Eyelid haemangioma	0	(0.0)	1	(0.2)	1	(0.1)
Haemangioma	9	(1.8)	16	(3.2)	25	(2.5)
Haemangioma of bone	1	(0.2)	2	(0.4)	3	(0.3)
Haemangioma of skin	8	(1.6)	6	(1.2)	14	(1.4)
Infantile haemangioma	2	(0.4)	3	(0.6)	5	(0.5)
Skin papilloma	0	(0.0)	1	(0.2)	1	(0.1)
Nervous system disorders	**93**	**(18.7)**	**84**	**(16.8)**	**177**	**(17.8)**
Altered state of consciousness	1	(0.2)	0	(0.0)	1	(0.1)
Arachnoid cyst	0	(0.0)	1	(0.2)	1	(0.1)
Cerebral cyst	7	(1.4)	8	(1.6)	15	(1.5)
Cerebral disorder	1	(0.2)	0	(0.0)	1	(0.1)
Cerebral haemorrhage	5	(1.0)	4	(0.8)	9	(0.9)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Nervous system disorders	**93**	**(18.7)**	**84**	**(16.8)**	**177**	**(17.8)**
Cerebral haemosiderin deposition	0	(0.0)	1	(0.2)	1	(0.1)
Cerebral infarction	2	(0.4)	0	(0.0)	2	(0.2)
Cerebral microhaemorrhage	1	(0.2)	0	(0.0)	1	(0.1)
Cerebral ventricle dilatation	6	(1.2)	5	(1.0)	11	(1.1)
Coordination abnormal	1	(0.2)	0	(0.0)	1	(0.1)
Developmental coordination disorder	1	(0.2)	0	(0.0)	1	(0.1)
Dyskinesia	1	(0.2)	1	(0.2)	2	(0.2)
Encephalomalacia	2	(0.4)	0	(0.0)	2	(0.2)
Encephalopathy neonatal	1	(0.2)	0	(0.0)	1	(0.1)
Epilepsy	1	(0.2)	1	(0.2)	2	(0.2)
Facial paralysis	0	(0.0)	1	(0.2)	1	(0.1)
Haemorrhage intracranial	2	(0.4)	0	(0.0)	2	(0.2)
Hypotonia	5	(1.0)	4	(0.8)	9	(0.9)
Intracranial haemorrhage neonatal	0	(0.0)	1	(0.2)	1	(0.1)
Intraventricular haemorrhage	27	(5.4)	20	(4.0)	47	(4.7)
Intraventricular haemorrhage neonatal	26	(5.2)	24	(4.8)	50	(5.0)
Language disorder	0	(0.0)	1	(0.2)	1	(0.1)
Lenticulostriatal vasculopathy	1	(0.2)	4	(0.8)	5	(0.5)
Muscle tone disorder	0	(0.0)	1	(0.2)	1	(0.1)
Neonatal seizure	0	(0.0)	1	(0.2)	1	(0.1)
Nystagmus	1	(0.2)	0	(0.0)	1	(0.1)
Opisthotonus	1	(0.2)	0	(0.0)	1	(0.1)
Paraparesis	1	(0.2)	0	(0.0)	1	(0.1)
Periventricular leukomalacia	6	(1.2)	7	(1.4)	13	(1.3)
Poor sucking reflex	0	(0.0)	1	(0.2)	1	(0.1)
Post cardiac arrest syndrome	1	(0.2)	0	(0.0)	1	(0.1)
Posthaemorrhagic hydrocephalus	3	(0.6)	2	(0.4)	5	(0.5)
Psychomotor skills impaired	1	(0.2)	0	(0.0)	1	(0.1)
Sedation	1	(0.2)	0	(0.0)	1	(0.1)
Seizure	6	(1.2)	2	(0.4)	8	(0.8)
Spinal cord ischaemia	0	(0.0)	1	(0.2)	1	(0.1)
Subdural effusion	1	(0.2)	0	(0.0)	1	(0.1)
Subependymal cyst	3	(0.6)	0	(0.0)	3	(0.3)
Suck-swallow breathing coordination disturbance	7	(1.4)	7	(1.4)	14	(1.4)
Vocal cord paralysis	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Pregnancy, puerperium and perinatal conditions	**295**	**(59.2)**	**282**	**(56.5)**	**577**	**(57.9)**
Birth weight normal	4	(0.8)	3	(0.6)	7	(0.7)
Breech delivery	0	(0.0)	1	(0.2)	1	(0.1)
Breech presentation	9	(1.8)	7	(1.4)	16	(1.6)
Cephalhaematoma	0	(0.0)	1	(0.2)	1	(0.1)
Delivery	0	(0.0)	1	(0.2)	1	(0.1)
Discordant twin	0	(0.0)	1	(0.2)	1	(0.1)
Foetal distress syndrome	3	(0.6)	1	(0.2)	4	(0.4)
Foetal growth restriction	20	(4.0)	16	(3.2)	36	(3.6)
Foetal macrosomia	1	(0.2)	0	(0.0)	1	(0.1)
Gestational diabetes	1	(0.2)	0	(0.0)	1	(0.1)
High risk infant	0	(0.0)	1	(0.2)	1	(0.1)
Hydrops foetalis	0	(0.0)	1	(0.2)	1	(0.1)
Jaundice neonatal	125	(25.1)	96	(19.2)	221	(22.2)
Large for dates baby	3	(0.6)	0	(0.0)	3	(0.3)
Low birth weight baby	108	(21.7)	109	(21.8)	217	(21.8)
Maternal condition affecting foetus	7	(1.4)	5	(1.0)	12	(1.2)
Meconium abnormal	1	(0.2)	0	(0.0)	1	(0.1)
Meconium in amniotic fluid	1	(0.2)	1	(0.2)	2	(0.2)
Placenta praevia	1	(0.2)	0	(0.0)	1	(0.1)
Placenta praevia haemorrhage	1	(0.2)	0	(0.0)	1	(0.1)
Poor weight gain neonatal	0	(0.0)	1	(0.2)	1	(0.1)
Pre-eclampsia	2	(0.4)	2	(0.4)	4	(0.4)
Premature baby	210	(42.2)	196	(39.3)	406	(40.7)
Premature delivery	0	(0.0)	2	(0.4)	2	(0.2)
Premature labour	3	(0.6)	2	(0.4)	5	(0.5)
Premature rupture of membranes	1	(0.2)	2	(0.4)	3	(0.3)
Premature separation of placenta	1	(0.2)	2	(0.4)	3	(0.3)
Preterm premature rupture of membranes	0	(0.0)	1	(0.2)	1	(0.1)
Small for dates baby	18	(3.6)	15	(3.0)	33	(3.3)
Term baby	2	(0.4)	1	(0.2)	3	(0.3)
Transverse presentation	1	(0.2)	0	(0.0)	1	(0.1)
Twin pregnancy	17	(3.4)	12	(2.4)	29	(2.9)
Umbilical granuloma	3	(0.6)	2	(0.4)	5	(0.5)
Vanishing twin syndrome	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Psychiatric disorders	**6**	**(1.2)**	**5**	**(1.0)**	**11**	**(1.1)**
Adjustment disorder	1	(0.2)	1	(0.2)	2	(0.2)
Autism spectrum disorder	0	(0.0)	2	(0.4)	2	(0.2)
Body dysmorphic disorder	1	(0.2)	0	(0.0)	1	(0.1)
Eating disorder	1	(0.2)	2	(0.4)	3	(0.3)
Irritability	2	(0.4)	0	(0.0)	2	(0.2)
Mental disorder	1	(0.2)	0	(0.0)	1	(0.1)
Renal and urinary disorders	**40**	**(8.0)**	**37**	**(7.4)**	**77**	**(7.7)**
Acute kidney injury	11	(2.2)	10	(2.0)	21	(2.1)
Hydronephrosis	10	(2.0)	7	(1.4)	17	(1.7)
Nephrectasia	1	(0.2)	0	(0.0)	1	(0.1)
Nephrocalcinosis	5	(1.0)	6	(1.2)	11	(1.1)
Nephrolithiasis	0	(0.0)	1	(0.2)	1	(0.1)
Polyuria	1	(0.2)	2	(0.4)	3	(0.3)
Proteinuria	1	(0.2)	0	(0.0)	1	(0.1)
Pyelocaliectasis	9	(1.8)	8	(1.6)	17	(1.7)
Renal artery thrombosis	0	(0.0)	1	(0.2)	1	(0.1)
Renal cyst	2	(0.4)	0	(0.0)	2	(0.2)
Renal impairment	1	(0.2)	0	(0.0)	1	(0.1)
Renal injury	1	(0.2)	0	(0.0)	1	(0.1)
Renal tubular disorder	0	(0.0)	1	(0.2)	1	(0.1)
Renal tubular necrosis	1	(0.2)	0	(0.0)	1	(0.1)
Urinary tract disorder	0	(0.0)	1	(0.2)	1	(0.1)
Reproductive system and breast disorders	**2**	**(0.4)**	**3**	**(0.6)**	**5**	**(0.5)**
Labia enlarged	1	(0.2)	0	(0.0)	1	(0.1)
Ovarian cyst	0	(0.0)	1	(0.2)	1	(0.1)
Penile adhesion	1	(0.2)	0	(0.0)	1	(0.1)
Polycystic ovaries	0	(0.0)	1	(0.2)	1	(0.1)
Uterine haemorrhage	0	(0.0)	1	(0.2)	1	(0.1)
Respiratory, thoracic and mediastinal disorders	**373**	**(74.9)**	**350**	**(70.1)**	**723**	**(72.5)**
Acute respiratory distress syndrome	3	(0.6)	11	(2.2)	14	(1.4)
Apnoea	20	(4.0)	21	(4.2)	41	(4.1)
Asphyxia	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Respiratory, thoracic and mediastinal disorders	**373**	**(74.9)**	**350**	**(70.1)**	**723**	**(72.5)**
Asthma	1	(0.2)	0	(0.0)	1	(0.1)
Atelectasis	8	(1.6)	7	(1.4)	15	(1.5)
Brief resolved unexplained event	1	(0.2)	0	(0.0)	1	(0.1)
Bronchial disorder	0	(0.0)	1	(0.2)	1	(0.1)
Bronchial dysplasia	2	(0.4)	6	(1.2)	8	(0.8)
Bronchopulmonary dysplasia	99	(19.9)	89	(17.8)	188	(18.9)
Bronchostenosis	0	(0.0)	1	(0.2)	1	(0.1)
Chronic respiratory disease	43	(8.6)	51	(10.2)	94	(9.4)
Chylothorax	1	(0.2)	1	(0.2)	2	(0.2)
Cough	1	(0.2)	1	(0.2)	2	(0.2)
Dyspnoea	2	(0.4)	4	(0.8)	6	(0.6)
Emphysema	0	(0.0)	1	(0.2)	1	(0.1)
Epistaxis	1	(0.2)	1	(0.2)	2	(0.2)
Hypoxia	3	(0.6)	1	(0.2)	4	(0.4)
Immature respiratory system	4	(0.8)	6	(1.2)	10	(1.0)
Infantile apnoea	72	(14.5)	62	(12.4)	134	(13.4)
Interstitial lung disease	1	(0.2)	2	(0.4)	3	(0.3)
Laryngeal cyst	0	(0.0)	1	(0.2)	1	(0.1)
Laryngeal oedema	1	(0.2)	1	(0.2)	2	(0.2)
Laryngeal stenosis	1	(0.2)	0	(0.0)	1	(0.1)
Lung cyst	0	(0.0)	1	(0.2)	1	(0.1)
Lung disorder	1	(0.2)	0	(0.0)	1	(0.1)
Lung infiltration	1	(0.2)	0	(0.0)	1	(0.1)
Lung opacity	1	(0.2)	0	(0.0)	1	(0.1)
Nasal congestion	7	(1.4)	12	(2.4)	19	(1.9)
Nasal disorder	0	(0.0)	1	(0.2)	1	(0.1)
Nasal oedema	1	(0.2)	0	(0.0)	1	(0.1)
Neonatal asphyxia	6	(1.2)	4	(0.8)	10	(1.0)
Neonatal dyspnoea	6	(1.2)	1	(0.2)	7	(0.7)
Neonatal hypoxia	2	(0.4)	1	(0.2)	3	(0.3)
Neonatal pneumothorax	0	(0.0)	1	(0.2)	1	(0.1)
Neonatal respiratory depression	3	(0.6)	2	(0.4)	5	(0.5)
Neonatal respiratory distress	12	(2.4)	18	(3.6)	30	(3.0)
Neonatal respiratory distress syndrome	61	(12.2)	60	(12.0)	121	(12.1)
Neonatal respiratory failure	0	(0.0)	4	(0.8)	4	(0.4)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Respiratory, thoracic and mediastinal disorders	**373**	**(74.9)**	**350**	**(70.1)**	**723**	**(72.5)**
Neonatal tachypnoea	14	(2.8)	8	(1.6)	22	(2.2)
Pleural effusion	3	(0.6)	2	(0.4)	5	(0.5)
Pneumomediastinum	0	(0.0)	2	(0.4)	2	(0.2)
Pneumothorax	4	(0.8)	5	(1.0)	9	(0.9)
Pneumothorax spontaneous	0	(0.0)	1	(0.2)	1	(0.1)
Pulmonary arterial hypertension	2	(0.4)	1	(0.2)	3	(0.3)
Pulmonary artery dilatation	1	(0.2)	1	(0.2)	2	(0.2)
Pulmonary artery stenosis	4	(0.8)	5	(1.0)	9	(0.9)
Pulmonary congestion	0	(0.0)	1	(0.2)	1	(0.1)
Pulmonary haemorrhage	3	(0.6)	5	(1.0)	8	(0.8)
Pulmonary hypertension	10	(2.0)	11	(2.2)	21	(2.1)
Pulmonary interstitial emphysema syndrome	1	(0.2)	0	(0.0)	1	(0.1)
Pulmonary oedema	3	(0.6)	2	(0.4)	5	(0.5)
Pulmonary pneumatocele	0	(0.0)	1	(0.2)	1	(0.1)
Reflux laryngitis	1	(0.2)	0	(0.0)	1	(0.1)
Respiratory acidosis	0	(0.0)	2	(0.4)	2	(0.2)
Respiratory depression	2	(0.4)	1	(0.2)	3	(0.3)
Respiratory disorder	4	(0.8)	2	(0.4)	6	(0.6)
Respiratory disorder neonatal	1	(0.2)	1	(0.2)	2	(0.2)
Respiratory distress	187	(37.6)	154	(30.9)	341	(34.2)
Respiratory failure	9	(1.8)	5	(1.0)	14	(1.4)
Respiratory tract haemorrhage	0	(0.0)	1	(0.2)	1	(0.1)
Rhinorrhoea	4	(0.8)	0	(0.0)	4	(0.4)
Sleep apnoea syndrome	0	(0.0)	1	(0.2)	1	(0.1)
Stridor	1	(0.2)	1	(0.2)	2	(0.2)
Tachypnoea	4	(0.8)	9	(1.8)	13	(1.3)
Transient tachypnoea of the newborn	14	(2.8)	13	(2.6)	27	(2.7)
Skin and subcutaneous tissue disorders	**42**	**(8.4)**	**34**	**(6.8)**	**76**	**(7.6)**
Cutaneous calcification	0	(0.0)	1	(0.2)	1	(0.1)
Decubitus ulcer	1	(0.2)	0	(0.0)	1	(0.1)
Dermal cyst	0	(0.0)	1	(0.2)	1	(0.1)
Dermatitis	5	(1.0)	3	(0.6)	8	(0.8)
Dermatitis allergic	1	(0.2)	0	(0.0)	1	(0.1)
Dermatitis atopic	1	(0.2)	1	(0.2)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Skin and subcutaneous tissue disorders	**42**	**(8.4)**	**34**	**(6.8)**	**76**	**(7.6)**
Dermatitis contact	1	(0.2)	2	(0.4)	3	(0.3)
Dermatitis diaper	18	(3.6)	13	(2.6)	31	(3.1)
Dry skin	1	(0.2)	1	(0.2)	2	(0.2)
Eczema infantile	1	(0.2)	1	(0.2)	2	(0.2)
Erythema	1	(0.2)	0	(0.0)	1	(0.1)
Erythema toxicum neonatorum	0	(0.0)	1	(0.2)	1	(0.1)
Hypertrichosis	1	(0.2)	0	(0.0)	1	(0.1)
Intertrigo	1	(0.2)	0	(0.0)	1	(0.1)
Macule	1	(0.2)	0	(0.0)	1	(0.1)
Milia	2	(0.4)	1	(0.2)	3	(0.3)
Miliaria	2	(0.4)	0	(0.0)	2	(0.2)
Papule	0	(0.0)	1	(0.2)	1	(0.1)
Petechiae	2	(0.4)	0	(0.0)	2	(0.2)
Rash	3	(0.6)	3	(0.6)	6	(0.6)
Seborrhoea	0	(0.0)	1	(0.2)	1	(0.1)
Seborrhoeic dermatitis	5	(1.0)	4	(0.8)	9	(0.9)
Skin lesion	2	(0.4)	1	(0.2)	3	(0.3)
Skin ulcer	0	(0.0)	1	(0.2)	1	(0.1)
Social circumstances	**3**	**(0.6)**	**0**	**(0.0)**	**3**	**(0.3)**
Bottle feeding	1	(0.2)	0	(0.0)	1	(0.1)
Breast feeding	1	(0.2)	0	(0.0)	1	(0.1)
Disease risk factor	2	(0.4)	0	(0.0)	2	(0.2)
Familial risk factor	1	(0.2)	0	(0.0)	1	(0.1)
Surgical and medical procedures	**58**	**(11.6)**	**58**	**(11.6)**	**116**	**(11.6)**
Abdominal cavity drainage	1	(0.2)	0	(0.0)	1	(0.1)
Antibiotic prophylaxis	2	(0.4)	0	(0.0)	2	(0.2)
Antibiotic therapy	1	(0.2)	0	(0.0)	1	(0.1)
Aorta coarctation repair	1	(0.2)	1	(0.2)	2	(0.2)
Aortic surgery	1	(0.2)	0	(0.0)	1	(0.1)
Appendicectomy	0	(0.0)	2	(0.4)	2	(0.2)
Arterial catheterisation	1	(0.2)	3	(0.6)	4	(0.4)
Arterial switch operation	2	(0.4)	1	(0.2)	3	(0.3)
Atrial septal defect repair	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Surgical and medical procedures	**58**	**(11.6)**	**58**	**(11.6)**	**116**	**(11.6)**
Atrial septostomy	2	(0.4)	0	(0.0)	2	(0.2)
Bladder catheterisation	1	(0.2)	0	(0.0)	1	(0.1)
Blue light therapy	2	(0.4)	0	(0.0)	2	(0.2)
CSF shunt operation	1	(0.2)	0	(0.0)	1	(0.1)
Caesarean section	1	(0.2)	1	(0.2)	2	(0.2)
Cardiac operation	1	(0.2)	0	(0.0)	1	(0.1)
Catheterisation venous	4	(0.8)	4	(0.8)	8	(0.8)
Cavopulmonary anastomosis	0	(0.0)	1	(0.2)	1	(0.1)
Central venous catheterisation	4	(0.8)	4	(0.8)	8	(0.8)
Cerebrospinal fluid reservoir placement	0	(0.0)	1	(0.2)	1	(0.1)
Chest tube insertion	0	(0.0)	2	(0.4)	2	(0.2)
Circumcision	0	(0.0)	1	(0.2)	1	(0.1)
Colectomy	1	(0.2)	0	(0.0)	1	(0.1)
Coronary arterial stent insertion	0	(0.0)	1	(0.2)	1	(0.1)
Endotracheal intubation	4	(0.8)	6	(1.2)	10	(1.0)
Enema administration	0	(0.0)	1	(0.2)	1	(0.1)
Enteral nutrition	2	(0.4)	0	(0.0)	2	(0.2)
Eye laser surgery	0	(0.0)	1	(0.2)	1	(0.1)
Gastrointestinal dilation procedure	1	(0.2)	0	(0.0)	1	(0.1)
Gastrointestinal tube insertion	0	(0.0)	1	(0.2)	1	(0.1)
Gastrostomy	2	(0.4)	4	(0.8)	6	(0.6)
Hernia diaphragmatic repair	1	(0.2)	0	(0.0)	1	(0.1)
Hernia repair	0	(0.0)	1	(0.2)	1	(0.1)
Hospitalisation	3	(0.6)	3	(0.6)	6	(0.6)
Ileectomy	1	(0.2)	0	(0.0)	1	(0.1)
Ileocolostomy	1	(0.2)	0	(0.0)	1	(0.1)
Ileostomy	1	(0.2)	0	(0.0)	1	(0.1)
Ileostomy closure	0	(0.0)	1	(0.2)	1	(0.1)
Inguinal hernia repair	2	(0.4)	4	(0.8)	6	(0.6)
Intensive care	9	(1.8)	12	(2.4)	21	(2.1)
Intermittent positive pressure breathing	2	(0.4)	1	(0.2)	3	(0.3)
Intestinal anastomosis	1	(0.2)	0	(0.0)	1	(0.1)
Intra-ocular injection	1	(0.2)	0	(0.0)	1	(0.1)
Lung assist device therapy	1	(0.2)	0	(0.0)	1	(0.1)
Lung cyst removal	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Surgical and medical procedures	**58**	**(11.6)**	**58**	**(11.6)**	**116**	**(11.6)**
Mechanical ventilation	5	(1.0)	1	(0.2)	6	(0.6)
Medical device implantation	0	(0.0)	1	(0.2)	1	(0.1)
Medical device removal	0	(0.0)	1	(0.2)	1	(0.1)
Nephrectomy	0	(0.0)	1	(0.2)	1	(0.1)
Nutritional supplementation	4	(0.8)	5	(1.0)	9	(0.9)
Oesophagogastric fundoplasty	0	(0.0)	2	(0.4)	2	(0.2)
Orchidopexy	1	(0.2)	0	(0.0)	1	(0.1)
Oxygen therapy	1	(0.2)	1	(0.2)	2	(0.2)
Pain management	1	(0.2)	1	(0.2)	2	(0.2)
Patent ductus arteriosus repair	6	(1.2)	10	(2.0)	16	(1.6)
Patent ductus arteriosus stent placement	1	(0.2)	0	(0.0)	1	(0.1)
Phototherapy	16	(3.2)	15	(3.0)	31	(3.1)
Platelet transfusion	1	(0.2)	0	(0.0)	1	(0.1)
Positive airway pressure therapy	3	(0.6)	2	(0.4)	5	(0.5)
Psychosocial support	1	(0.2)	2	(0.4)	3	(0.3)
Pulmonary artery banding	2	(0.4)	1	(0.2)	3	(0.3)
Pulmonary valvotomy	1	(0.2)	1	(0.2)	2	(0.2)
Respiratory therapy	1	(0.2)	0	(0.0)	1	(0.1)
Resuscitation	0	(0.0)	3	(0.6)	3	(0.3)
Retinopexy	2	(0.4)	0	(0.0)	2	(0.2)
Surgery	1	(0.2)	0	(0.0)	1	(0.1)
Systemic-pulmonary artery shunt	3	(0.6)	1	(0.2)	4	(0.4)
Thoracic cavity drainage	1	(0.2)	1	(0.2)	2	(0.2)
Thoracotomy	0	(0.0)	1	(0.2)	1	(0.1)
Transfusion	1	(0.2)	0	(0.0)	1	(0.1)
Transpupillary thermotherapy	1	(0.2)	0	(0.0)	1	(0.1)
Umbilical hernia repair	1	(0.2)	0	(0.0)	1	(0.1)
Valvuloplasty cardiac	1	(0.2)	0	(0.0)	1	(0.1)
Ventricular assist device insertion	1	(0.2)	0	(0.0)	1	(0.1)
Ventricular cisternostomy	0	(0.0)	1	(0.2)	1	(0.1)
Ventricular drainage	0	(0.0)	1	(0.2)	1	(0.1)
Ventricular septal defect repair	1	(0.2)	1	(0.2)	2	(0.2)
Ventriculo-peritoneal shunt	0	(0.0)	1	(0.2)	1	(0.1)
Vascular disorders	**29**	**(5.8)**	**20**	**(4.0)**	**49**	**(4.9)**

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Vascular disorders	**29**	**(5.8)**	**20**	**(4.0)**	**49**	**(4.9)**
Angiodysplasia	0	(0.0)	1	(0.2)	1	(0.1)
Aortic dilatation	2	(0.4)	0	(0.0)	2	(0.2)
Aortic stenosis	1	(0.2)	0	(0.0)	1	(0.1)
Aortic thrombosis	0	(0.0)	1	(0.2)	1	(0.1)
Circulatory collapse	1	(0.2)	0	(0.0)	1	(0.1)
Circulatory failure neonatal	0	(0.0)	1	(0.2)	1	(0.1)
Cyanosis	5	(1.0)	0	(0.0)	5	(0.5)
Haematoma	1	(0.2)	0	(0.0)	1	(0.1)
Hypertension	8	(1.6)	9	(1.8)	17	(1.7)
Hypertension neonatal	1	(0.2)	0	(0.0)	1	(0.1)
Hypotension	5	(1.0)	4	(0.8)	9	(0.9)
Jugular vein thrombosis	1	(0.2)	0	(0.0)	1	(0.1)
Neonatal hypotension	1	(0.2)	1	(0.2)	2	(0.2)
Phlebitis	0	(0.0)	2	(0.4)	2	(0.2)
Superior vena cava dilatation	1	(0.2)	0	(0.0)	1	(0.1)
Superior vena cava syndrome	1	(0.2)	1	(0.2)	2	(0.2)
Thrombophlebitis	2	(0.4)	0	(0.0)	2	(0.2)
Thrombosis	0	(0.0)	1	(0.2)	1	(0.1)
Vasospasm	1	(0.2)	1	(0.2)	2	(0.2)
Vena cava embolism	0	(0.0)	1	(0.2)	1	(0.1)

Every participant is counted a single time for each applicable specific condition. A participant with multiple conditions within a system organ class is counted a single time for that system organ class.

MedDRA version 28.1 was used in the reporting of this study.

Any changes to medical history collected during RSV Season 1 are not included in the analysis

RSV: Respiratory Syncytial Virus

Tabelle 4G-4: Begleitmedikation der Studienpopulation – RCT mit dem zu bewertenden Arzneimittel

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Participants in population	498		499		997	
with one or more concomitant medications	455	(91.4)	462	(92.6)	917	(92.0)
with no concomitant medication	43	(8.6)	37	(7.4)	80	(8.0)
Alimentary Tract And Metabolism						
Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents	**155**	**(31.1)**	**167**	**(33.5)**	**322**	**(32.3)**
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)
Amphotericin B	1	(0.2)	1	(0.2)	2	(0.2)
Antibiotics	2	(0.4)	0	(0.0)	2	(0.2)
Antibiotics-Resistant Lactic Acid Bacteriae	1	(0.2)	2	(0.4)	3	(0.3)
Antidiarrheal Microorganisms	1	(0.2)	3	(0.6)	4	(0.4)
Bacillus Clausii	5	(1.0)	4	(0.8)	9	(0.9)
Bacillus Subtilis;Enterococcus Faecalis	0	(0.0)	2	(0.4)	2	(0.2)
Bacitracin	0	(0.0)	1	(0.2)	1	(0.1)
Beclometasone	5	(1.0)	5	(1.0)	10	(1.0)
Beclometasone Dipropionate	1	(0.2)	2	(0.4)	3	(0.3)
Betamethasone	6	(1.2)	3	(0.6)	9	(0.9)
Betamethasone Dipropionate	0	(0.0)	2	(0.4)	2	(0.2)
Betamethasone Valerate	0	(0.0)	2	(0.4)	2	(0.2)
Bifidobacterium Animalis	1	(0.2)	0	(0.0)	1	(0.1)
Bifidobacterium Bifidum;Lactobacillus Acidophilus	3	(0.6)	7	(1.4)	10	(1.0)
Bifidobacterium Breve	2	(0.4)	0	(0.0)	2	(0.2)
Bifidobacterium Breve;Bifidobacterium Infantis;Bifidobacterium Longum;Lactiplantibacillus Plantarum;Lactobacillus Acidophilus;Lactobacillus Bulgaricus;Lactobacillus Paracasei;	0	(0.0)	1	(0.2)	1	(0.1)
Bifidobacterium Infantis;Bifidobacterium Longum	0	(0.0)	1	(0.2)	1	(0.1)
Bifidobacterium Infantis;Lactobacillus Acidophilus	0	(0.0)	1	(0.2)	1	(0.1)
Bifidobacterium Lactis	4	(0.8)	6	(1.2)	10	(1.0)
Bifidobacterium Lactis;Inulin;Lactobacillus Acidophilus;Lactobacillus Casei	1	(0.2)	1	(0.2)	2	(0.2)
Bifidobacterium Lactis;Lactobacillus Acidophilus	1	(0.2)	0	(0.0)	1	(0.1)
Bifidobacterium Longum;Pediococcus Pentosaceus	1	(0.2)	0	(0.0)	1	(0.1)
Bifidobacterium Nos	0	(0.0)	1	(0.2)	1	(0.1)
Bifidobacterium Nos;Lactobacillus Nos	1	(0.2)	0	(0.0)	1	(0.1)
Bismuth Subsalicylate	1	(0.2)	1	(0.2)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents	**155**	**(31.1)**	**167**	**(33.5)**	**322**	**(32.3)**
Budesonide	31	(6.2)	22	(4.4)	53	(5.3)
Calcium Chloride;Glucose;Magnesium Chloride;Potassium Chloride;Sodium Chloride;Sodium Lactate	0	(0.0)	1	(0.2)	1	(0.1)
Chlorine;Citric Acid;Glucose;Potassium;Sodium	2	(0.4)	0	(0.0)	2	(0.2)
Citric Acid;Glucose;Potassium Citrate;Sodium Chloride	1	(0.2)	0	(0.0)	1	(0.1)
Colecalciferol;Lactobacillus Reuteri	1	(0.2)	2	(0.4)	3	(0.3)
Colistin	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)
Cromoglicate Sodium	0	(0.0)	2	(0.4)	2	(0.2)
Diosmectite	2	(0.4)	2	(0.4)	4	(0.4)
Electrolytes Nos;Glucose	4	(0.8)	5	(1.0)	9	(0.9)
Enterococcus Faecium	0	(0.0)	1	(0.2)	1	(0.1)
Gelatin Tannate;Lactobacillus Nos	0	(0.0)	1	(0.2)	1	(0.1)
Glucose Monohydrate;Potassium Chloride;Sodium Chloride;Sodium Citrate	1	(0.2)	0	(0.0)	1	(0.1)
Glucose Monohydrate;Sodium Chloride	0	(0.0)	2	(0.4)	2	(0.2)
Glucose;Potassium Chloride;Sodium Bicarbonate	1	(0.2)	0	(0.0)	1	(0.1)
Glucose;Potassium Chloride;Sodium Bicarbonate;Sodium Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Glucose;Potassium Chloride;Sodium Bicarbonate;Sodium Chloride;Sucrose	2	(0.4)	1	(0.2)	3	(0.3)
Glucose;Potassium Chloride;Sodium Chloride	2	(0.4)	5	(1.0)	7	(0.7)
Glucose;Potassium Chloride;Sodium Chloride;Sodium Citrate	1	(0.2)	2	(0.4)	3	(0.3)
Glucose;Potassium Chloride;Sodium Chloride;Sodium Citrate Acid	0	(0.0)	1	(0.2)	1	(0.1)
Glucose;Potassium;Sodium Chloride	3	(0.6)	0	(0.0)	3	(0.3)
Glucose;Sodium Chloride	14	(2.8)	24	(4.8)	38	(3.8)
Helianthus Annuus Oil;Lactobacillus Reuteri;Medium-Chain Triglycerides	1	(0.2)	3	(0.6)	4	(0.4)
Hydrocortisone	15	(3.0)	17	(3.4)	32	(3.2)
Hydrocortisone Acetate	3	(0.6)	2	(0.4)	5	(0.5)
Hydrocortisone Butyrate	2	(0.4)	3	(0.6)	5	(0.5)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents	**155**	**(31.1)**	**167**	**(33.5)**	**322**	**(32.3)**
Hydrocortisone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Lactiplantibacillus Plantarum	2	(0.4)	0	(0.0)	2	(0.2)
Lactobacillus Acidophilus	3	(0.6)	2	(0.4)	5	(0.5)
Lactobacillus Nos	3	(0.6)	1	(0.2)	4	(0.4)
Lactobacillus Reuteri	44	(8.8)	33	(6.6)	77	(7.7)
Lactobacillus Rhamnosus	1	(0.2)	3	(0.6)	4	(0.4)
Miconazole	2	(0.4)	4	(0.8)	6	(0.6)
Neomycin Sulfate	0	(0.0)	2	(0.4)	2	(0.2)
Nystatin	11	(2.2)	21	(4.2)	32	(3.2)
Oral Rehydration Salt Formulations	7	(1.4)	0	(0.0)	7	(0.7)
Prednisolone	15	(3.0)	18	(3.6)	33	(3.3)
Prednisolone Sodium Phosphate	1	(0.2)	1	(0.2)	2	(0.2)
Prednisone	8	(1.6)	9	(1.8)	17	(1.7)
Probiotics Nos	2	(0.4)	1	(0.2)	3	(0.3)
Racecadotril	4	(0.8)	3	(0.6)	7	(0.7)
Saccharomyces Boulardii	2	(0.4)	1	(0.2)	3	(0.3)
Vancomycin	4	(0.8)	8	(1.6)	12	(1.2)
Vancomycin Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Antiemetics And Antinauseants	**27**	**(5.4)**	**29**	**(5.8)**	**56**	**(5.6)**
Alizapride	0	(0.0)	1	(0.2)	1	(0.1)
Calcium Carbonate;Ceratonia Siliqua Seed Powder;Ferrous Sulfate;Maltodextrin;Zinc Sulfate	2	(0.4)	0	(0.0)	2	(0.2)
Diphenhydramine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Domperidone	14	(2.8)	21	(4.2)	35	(3.5)
Hydroxyzine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Meclozine Hydrochloride;Pyridoxine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Metoclopramide	3	(0.6)	3	(0.6)	6	(0.6)
Metoclopramide Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Ondansetron	5	(1.0)	3	(0.6)	8	(0.8)
Ondansetron Hydrochloride	2	(0.4)	2	(0.4)	4	(0.4)
Antiobesity Preparations, Excl. Diet Products	**1**	**(0.2)**	**0**	**(0.0)**	**1**	**(0.1)**
Benzocaine	1	(0.2)	0	(0.0)	1	(0.1)
Appetite Stimulants	**4**	**(0.8)**	**5**	**(1.0)**	**9**	**(0.9)**

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Appetite Stimulants	**4**	**(0.8)**	**5**	**(1.0)**	**9**	**(0.9)**
Cyproheptadine	3	(0.6)	2	(0.4)	5	(0.5)
Cyproheptadine Hydrochloride	1	(0.2)	4	(0.8)	5	(0.5)
Bile And Liver Therapy	**12**	**(2.4)**	**16**	**(3.2)**	**28**	**(2.8)**
Acetylcysteine	4	(0.8)	3	(0.6)	7	(0.7)
Ademetionine	1	(0.2)	0	(0.0)	1	(0.1)
Adenosine	0	(0.0)	1	(0.2)	1	(0.1)
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)
Lactulose	4	(0.8)	5	(1.0)	9	(0.9)
Lavandula Angustifolia Oil	0	(0.0)	1	(0.2)	1	(0.1)
Ursodeoxycholic Acid	4	(0.8)	5	(1.0)	9	(0.9)
Digestives, Incl. Enzymes	**4**	**(0.8)**	**5**	**(1.0)**	**9**	**(0.9)**
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)
Biodiastase 1000;Lipase;Newlase	1	(0.2)	0	(0.0)	1	(0.1)
Lactoferrin	1	(0.2)	0	(0.0)	1	(0.1)
Matricaria Chamomilla	0	(0.0)	1	(0.2)	1	(0.1)
Phosphatase	0	(0.0)	1	(0.2)	1	(0.1)
Tilactase	2	(0.4)	2	(0.4)	4	(0.4)
Drugs For Acid Related Disorders	**88**	**(17.7)**	**89**	**(17.8)**	**177**	**(17.8)**
Althaea Officinalis;Dexpanthenol;Magnesium Alginate;Papaver Rhoeas;Simeticone;Sodium Bicarbonate;Zinc Oxide	1	(0.2)	0	(0.0)	1	(0.1)
Althaea Officinalis;Dexpanthenol;Magnesium Alginate;Papaver Rhoeas;Simeticone;Sodium Carbonate Monohydrate;Zinc Oxide	0	(0.0)	1	(0.2)	1	(0.1)
Aluminium Hydroxide;Magnesium Carbonate	2	(0.4)	0	(0.0)	2	(0.2)
Bismuth Subsalicylate	1	(0.2)	1	(0.2)	2	(0.2)
Calcium Carbonate	3	(0.6)	4	(0.8)	7	(0.7)
Calcium Carbonate;Sodium Alginate;Sodium Bicarbonate	0	(0.0)	1	(0.2)	1	(0.1)
Esomeprazole	7	(1.4)	8	(1.6)	15	(1.5)
Famotidine	5	(1.0)	7	(1.4)	12	(1.2)
Lactobacillus Reuteri	44	(8.8)	33	(6.6)	77	(7.7)
Lansoprazole	4	(0.8)	6	(1.2)	10	(1.0)
Magnesium Alginate;Simeticone	0	(0.0)	2	(0.4)	2	(0.2)
Magnesium Alginate;Sodium Alginate	3	(0.6)	0	(0.0)	3	(0.3)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Drugs For Acid Related Disorders	**88**	**(17.7)**	**89**	**(17.8)**	**177**	**(17.8)**
Magnesium Carbonate	2	(0.4)	3	(0.6)	5	(0.5)
Magnesium Hydroxide	0	(0.0)	2	(0.4)	2	(0.2)
Magnesium Oxide	0	(0.0)	1	(0.2)	1	(0.1)
Omeprazole	25	(5.0)	27	(5.4)	52	(5.2)
Pantoprazole	2	(0.4)	1	(0.2)	3	(0.3)
Pantoprazole Sodium Sesquihydrate	0	(0.0)	3	(0.6)	3	(0.3)
Polaprezinc	0	(0.0)	1	(0.2)	1	(0.1)
Potassium Bicarbonate;Sodium Alginate	2	(0.4)	0	(0.0)	2	(0.2)
Sodium Alginate	1	(0.2)	0	(0.0)	1	(0.1)
Sodium Alginate;Sodium Bicarbonate	0	(0.0)	1	(0.2)	1	(0.1)
Sodium Bicarbonate	3	(0.6)	6	(1.2)	9	(0.9)
Drugs For Constipation	**121**	**(24.3)**	**147**	**(29.5)**	**268**	**(26.9)**
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)
Bifidobacterium Lactis	4	(0.8)	6	(1.2)	10	(1.0)
Bifidobacterium Nos	0	(0.0)	1	(0.2)	1	(0.1)
Bisacodyl	1	(0.2)	0	(0.0)	1	(0.1)
Enemas	1	(0.2)	0	(0.0)	1	(0.1)
Glycerol	9	(1.8)	16	(3.2)	25	(2.5)
Glycerol;Polysorbate 80;Sodium Citrate;Sorbitol	0	(0.0)	1	(0.2)	1	(0.1)
Lactulose	4	(0.8)	5	(1.0)	9	(0.9)
Macrogol	2	(0.4)	1	(0.2)	3	(0.3)
Macrogol 3350	0	(0.0)	1	(0.2)	1	(0.1)
Macrogol 4000	2	(0.4)	1	(0.2)	3	(0.3)
Macrogol;Potassium Chloride;Sodium Bicarbonate;Sodium Chloride	2	(0.4)	0	(0.0)	2	(0.2)
Magnesium Carbonate	2	(0.4)	3	(0.6)	5	(0.5)
Magnesium Carbonate;Magnesium Phosphate;Pepsin;Phosphoric Acid Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Magnesium Hydroxide	0	(0.0)	2	(0.4)	2	(0.2)
Magnesium Oxide	0	(0.0)	1	(0.2)	1	(0.1)
Magnesium Sulfate	2	(0.4)	2	(0.4)	4	(0.4)
Mannitol	1	(0.2)	1	(0.2)	2	(0.2)
Naloxone	1	(0.2)	1	(0.2)	2	(0.2)
Paraffin Nos	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Drugs For Constipation	**121**	**(24.3)**	**147**	**(29.5)**	**268**	**(26.9)**
Paraffin, Liquid	1	(0.2)	2	(0.4)	3	(0.3)
Phosphoric Acid	0	(0.0)	1	(0.2)	1	(0.1)
Potassium Phosphate Dibasic	0	(0.0)	2	(0.4)	2	(0.2)
Probiotics Nos	2	(0.4)	1	(0.2)	3	(0.3)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Sodium Phosphate	4	(0.8)	2	(0.4)	6	(0.6)
Sodium Phosphate Dibasic;Sodium Phosphate Monobasic	1	(0.2)	1	(0.2)	2	(0.2)
Sodium Phosphate Dibasic;Sodium Phosphate Monobasic (Monohydrate)	0	(0.0)	1	(0.2)	1	(0.1)
Sodium Phosphate Monobasic	3	(0.6)	1	(0.2)	4	(0.4)
Sodium Phosphate Monobasic (Monohydrate)	1	(0.2)	0	(0.0)	1	(0.1)
Sodium Picosulfate	0	(0.0)	1	(0.2)	1	(0.1)
Soft Soap	0	(0.0)	2	(0.4)	2	(0.2)
Drugs For Functional Gastrointestinal Disorders	**42**	**(8.4)**	**49**	**(9.8)**	**91**	**(9.1)**
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)
Alizapride	0	(0.0)	1	(0.2)	1	(0.1)
Cisapride	3	(0.6)	3	(0.6)	6	(0.6)
Clebopride	1	(0.2)	0	(0.0)	1	(0.1)
Dexpanthenol	0	(0.0)	2	(0.4)	2	(0.2)
Dimeticone	9	(1.8)	4	(0.8)	13	(1.3)
Dimeticone;Papaverine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Domperidone	14	(2.8)	21	(4.2)	35	(3.5)
Foeniculum Vulgare	1	(0.2)	0	(0.0)	1	(0.1)
Lavandula Angustifolia Oil	0	(0.0)	1	(0.2)	1	(0.1)
Magnesium Alginate;Simeticone	0	(0.0)	2	(0.4)	2	(0.2)
Matricaria Chamomilla	0	(0.0)	1	(0.2)	1	(0.1)
Metoclopramide	3	(0.6)	3	(0.6)	6	(0.6)
Metoclopramide Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Simeticone	14	(2.8)	15	(3.0)	29	(2.9)
Simeticone;Trimebutine	1	(0.2)	0	(0.0)	1	(0.1)
Syzygium Aromaticum	1	(0.2)	0	(0.0)	1	(0.1)
Drugs Used In Diabetes	**2**	**(0.4)**	**1**	**(0.2)**	**3**	**(0.3)**
Glycine Max Seed Oil	1	(0.2)	0	(0.0)	1	(0.1)
Platycodon Grandiflorus	1	(0.2)	1	(0.2)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Mineral Supplements	**139**	**(27.9)**	**170**	**(34.1)**	**309**	**(31.0)**
Calcium	0	(0.0)	1	(0.2)	1	(0.1)
Calcium Carbonate	3	(0.6)	4	(0.8)	7	(0.7)
Calcium Carbonate;Colecalciferol	0	(0.0)	1	(0.2)	1	(0.1)
Calcium Carbonate;Colecalciferol;Zinc Oxide	6	(1.2)	7	(1.4)	13	(1.3)
Calcium Gluconate	3	(0.6)	6	(1.2)	9	(0.9)
Calcium Phosphate	1	(0.2)	0	(0.0)	1	(0.1)
Calcium Phosphate Dibasic	2	(0.4)	1	(0.2)	3	(0.3)
Magnesium Carbonate	2	(0.4)	3	(0.6)	5	(0.5)
Magnesium Chloride	1	(0.2)	0	(0.0)	1	(0.1)
Magnesium Hydroxide	0	(0.0)	2	(0.4)	2	(0.2)
Magnesium Oxide	0	(0.0)	1	(0.2)	1	(0.1)
Magnesium Sulfate	2	(0.4)	2	(0.4)	4	(0.4)
Minerals Nos	2	(0.4)	2	(0.4)	4	(0.4)
Potassium Chloride	7	(1.4)	12	(2.4)	19	(1.9)
Potassium Citrate	1	(0.2)	0	(0.0)	1	(0.1)
Potassium Phosphate Dibasic	0	(0.0)	2	(0.4)	2	(0.2)
Sea Water	20	(4.0)	13	(2.6)	33	(3.3)
Selenium Amino Acid Chelate;Zinc Picolinate	0	(0.0)	1	(0.2)	1	(0.1)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Sodium Phosphate	4	(0.8)	2	(0.4)	6	(0.6)
Sodium Phosphate Dibasic;Sodium Phosphate Monobasic	1	(0.2)	1	(0.2)	2	(0.2)
Sodium Phosphate Dibasic;Sodium Phosphate Monobasic (Monohydrate)	0	(0.0)	1	(0.2)	1	(0.1)
Sodium Phosphate Monobasic	3	(0.6)	1	(0.2)	4	(0.4)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Zinc Gluconate	0	(0.0)	2	(0.4)	2	(0.2)
Zinc Oxide	7	(1.4)	16	(3.2)	23	(2.3)
Zinc Sulfate	3	(0.6)	10	(2.0)	13	(1.3)
Zinc Sulfate Heptahydrate	0	(0.0)	1	(0.2)	1	(0.1)
Zinc Sulfate Monohydrate	2	(0.4)	2	(0.4)	4	(0.4)
Other Alimentary Tract And Metabolism Products	**29**	**(5.8)**	**34**	**(6.8)**	**63**	**(6.3)**
Acetylcysteine	4	(0.8)	3	(0.6)	7	(0.7)
Ademetionine	1	(0.2)	0	(0.0)	1	(0.1)
Amino Acids Nos	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Other Alimentary Tract And Metabolism Products	**29**	**(5.8)**	**34**	**(6.8)**	**63**	**(6.3)**
Carbohydrates Nos;Fats Nos;Minerals Nos;Proteins Nos;Vitamins Nos	0	(0.0)	1	(0.2)	1	(0.1)
Clostridium Butyricum	1	(0.2)	4	(0.8)	5	(0.5)
Lactobacillus Nos	3	(0.6)	1	(0.2)	4	(0.4)
Levocarnitine	1	(0.2)	0	(0.0)	1	(0.1)
Phosphorus	1	(0.2)	0	(0.0)	1	(0.1)
Polaprezinc	0	(0.0)	1	(0.2)	1	(0.1)
Probiotics Nos	2	(0.4)	1	(0.2)	3	(0.3)
Sodium Bicarbonate	3	(0.6)	6	(1.2)	9	(0.9)
Ubidecarenone	1	(0.2)	0	(0.0)	1	(0.1)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Stomatological Preparations	**226**	**(45.4)**	**244**	**(48.9)**	**470**	**(47.1)**
Acetylsalicylic Acid	11	(2.2)	11	(2.2)	22	(2.2)
Amphotericin B	1	(0.2)	1	(0.2)	2	(0.2)
Antifungals	0	(0.0)	1	(0.2)	1	(0.1)
Beclometasone	5	(1.0)	5	(1.0)	10	(1.0)
Beclometasone Dipropionate	1	(0.2)	2	(0.4)	3	(0.3)
Benzocaine	1	(0.2)	0	(0.0)	1	(0.1)
Benzocaine;Cetylpyridinium Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Benzydamine	0	(0.0)	1	(0.2)	1	(0.1)
Benzydamine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Betamethasone	6	(1.2)	3	(0.6)	9	(0.9)
Boric Acid	1	(0.2)	0	(0.0)	1	(0.1)
Carbomer	1	(0.2)	0	(0.0)	1	(0.1)
Chloramphenicol	6	(1.2)	10	(2.0)	16	(1.6)
Chlorhexidine Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Chlorhexidine;Lidocaine	1	(0.2)	0	(0.0)	1	(0.1)
Clotrimazole	10	(2.0)	18	(3.6)	28	(2.8)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)
Dexamethasone	14	(2.8)	13	(2.6)	27	(2.7)
Dexamethasone Sodium Phosphate	2	(0.4)	3	(0.6)	5	(0.5)
Diclofenac	4	(0.8)	0	(0.0)	4	(0.4)
Diclofenac Sodium	2	(0.4)	3	(0.6)	5	(0.5)
Dimeticone	9	(1.8)	4	(0.8)	13	(1.3)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Stomatological Preparations	**226**	**(45.4)**	**244**	**(48.9)**	**470**	**(47.1)**
Doxycycline	1	(0.2)	0	(0.0)	1	(0.1)
Electrolytes Nos	2	(0.4)	2	(0.4)	4	(0.4)
Epinephrine	15	(3.0)	17	(3.4)	32	(3.2)
Epinephrine Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Glycerol	9	(1.8)	16	(3.2)	25	(2.5)
Hyaluronate Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Hyaluronate Sodium;Sodium Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Hydrocortisone	15	(3.0)	17	(3.4)	32	(3.2)
Hydrocortisone Acetate	3	(0.6)	2	(0.4)	5	(0.5)
Hydrocortisone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Hydrogen Peroxide	1	(0.2)	0	(0.0)	1	(0.1)
Iron;Sodium Fluoride;Vitamins Nos	0	(0.0)	1	(0.2)	1	(0.1)
Lactobacillus Reuteri	44	(8.8)	33	(6.6)	77	(7.7)
Lidocaine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Lidocaine;Prilocaine	1	(0.2)	1	(0.2)	2	(0.2)
Macrogol	2	(0.4)	1	(0.2)	3	(0.3)
Metronidazole	0	(0.0)	4	(0.8)	4	(0.4)
Miconazole	2	(0.4)	4	(0.8)	6	(0.6)
Naproxen	1	(0.2)	0	(0.0)	1	(0.1)
Neomycin Sulfate	0	(0.0)	2	(0.4)	2	(0.2)
Nystatin	11	(2.2)	21	(4.2)	32	(3.2)
Octenidine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Other Agents For Local Oral Treatment	1	(0.2)	1	(0.2)	2	(0.2)
Oxygen	77	(15.5)	80	(16.0)	157	(15.7)
Prednisolone	15	(3.0)	18	(3.6)	33	(3.3)
Prednisolone Acetate	3	(0.6)	1	(0.2)	4	(0.4)
Sodium Bicarbonate	3	(0.6)	6	(1.2)	9	(0.9)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Syzygium Aromaticum	1	(0.2)	0	(0.0)	1	(0.1)
Tetracaine	1	(0.2)	1	(0.2)	2	(0.2)
Tetracaine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Tranexamic Acid	0	(0.0)	2	(0.4)	2	(0.2)
Triamcinolone Acetonide	0	(0.0)	3	(0.6)	3	(0.3)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Tonics	**0**	**(0.0)**	**1**	**(0.2)**	**1**	**(0.1)**
Amino Acids Nos;Minerals Nos;Vitamins Nos	0	(0.0)	1	(0.2)	1	(0.1)
Vitamins	**335**	**(67.3)**	**328**	**(65.7)**	**663**	**(66.5)**
Alfacalcidol	2	(0.4)	5	(1.0)	7	(0.7)
Amino Acids Nos;Herbal Nos;Vitamins Nos	0	(0.0)	1	(0.2)	1	(0.1)
Amino Acids Nos;Minerals Nos;Vitamins Nos	0	(0.0)	1	(0.2)	1	(0.1)
Ascorbic Acid	26	(5.2)	13	(2.6)	39	(3.9)
Ascorbic Acid (Vitamin C), Combinations	1	(0.2)	0	(0.0)	1	(0.1)
Ascorbic Acid;Biotin;Colecalciferol;Cyanocobalamin;Folic Acid;Nicotinic Acid;Pantothenic Acid;Pyridoxine Hydrochloride;Retinol;Riboflavin;Thiamine;Vitamin E Nos	0	(0.0)	2	(0.4)	2	(0.2)
Ascorbic Acid;Biotin;Colecalciferol;Nicotinamide;Pyridoxine Hydrochloride;Retinol Palmitate;Riboflavin Sodium Phosphate;Tocopheryl Acetate	1	(0.2)	1	(0.2)	2	(0.2)
Ascorbic Acid;Calcium Pantothenate;Cyanocobalamin;Ergocalciferol;Folic Acid;Nicotinamide;Pyridoxine Hydrochloride;Retinol Palmitate;Riboflavin;Thiamine Mononitrate;Tocopheryl Acetate	1	(0.2)	1	(0.2)	2	(0.2)
Ascorbic Acid;Calcium Pantothenate;Ergocalciferol;Nicotinamide;Pyridoxine Hydrochloride;Retinol;Riboflavin;Thiamine Mononitrate	2	(0.4)	4	(0.8)	6	(0.6)
Ascorbic Acid;Calcium;Calcium Pantothenate;Colecalciferol;Cyanocobalamin;Folic Acid;Iron;Nicotinamide;Phosphorus;Pyridoxine Hydrochloride;Retinol Palmitate;Riboflavin;Thiamine Hydrochloride;	0	(0.0)	1	(0.2)	1	(0.1)
Ascorbic Acid;Colecalciferol;Cyanocobalamin;Dexpanthenol;Nicotinamide; Pyridoxine Hydrochloride;Retinol;Riboflavin;Thiamine Hydrochloride	2	(0.4)	3	(0.6)	5	(0.5)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Vitamins	**335**	**(67.3)**	**328**	**(65.7)**	**663**	**(66.5)**
Ascorbic Acid;Colecalciferol;Dexpanthenol;Nicotinamide;Pyridoxine Hydrochloride;Retinol Palmitate;Riboflavin Sodium Phosphate;Thiamine Hydrochloride	1	(0.2)	1	(0.2)	2	(0.2)
Ascorbic Acid;Colecalciferol;Folic Acid;Lysine Hydrochloride;Nicotinamide;Pyridoxine Hydrochloride;Retinol;Riboflavin;Vitamin B1 Nos;Vitamin B12 Nos;Vitamin E Nos	1	(0.2)	0	(0.0)	1	(0.1)
Ascorbic Acid;Colecalciferol;Lysine Hydrochloride;Nicotinamide;Pyridoxine Hydrochloride;Retinol;Riboflavin;Taurine;Vitamin B1 Nos;Vitamin B12 Nos;Vitamin E Nos	4	(0.8)	7	(1.4)	11	(1.1)
Ascorbic Acid;Colecalciferol;Nicotinamide;Panthenol;Pyridoxine Hydrochloride;Retinol;Riboflavin;Thiamine Hydrochloride	3	(0.6)	2	(0.4)	5	(0.5)
Ascorbic Acid;Colecalciferol;Retinol	2	(0.4)	3	(0.6)	5	(0.5)
Ascorbic Acid;Cyanocobalamin;Dexpanthenol;Ferrous Gluconate;Nicotinamide;Pyridoxine Hydrochloride;Retinol Palmitate;Riboflavin;Thiamine Hydrochloride;Vitamin D Nos;Zinc Sulfate Monohydrate	7	(1.4)	8	(1.6)	15	(1.5)
Ascorbic Acid;Cyanocobalamin;Ergocalciferol;Nicotinamide;Pyridoxine;Retinol;Riboflavin;Thiamine	1	(0.2)	0	(0.0)	1	(0.1)
Ascorbic Acid;Ergocalciferol;Iron;Nicotinic Acid;Pantothenic Acid;Pyridoxine Hydrochloride;Retinol;Riboflavin;Thiamine Hydrochloride;Tocopheryl Acetate	2	(0.4)	5	(1.0)	7	(0.7)
Ascorbic Acid;Ergocalciferol;Nicotinamide;Pyridoxine Hydrochloride;Retinol Palmitate;Riboflavin;Thiamine Hydrochloride	30	(6.0)	26	(5.2)	56	(5.6)
Ascorbic Acid;Ergocalciferol;Retinol	2	(0.4)	1	(0.2)	3	(0.3)
Ascorbic Acid;Ergocalciferol;Retinol Palmitate	10	(2.0)	9	(1.8)	19	(1.9)
Ascorbic Acid;Retinol;Vitamin D Nos	22	(4.4)	15	(3.0)	37	(3.7)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Vitamins	**335**	**(67.3)**	**328**	**(65.7)**	**663**	**(66.5)**
Ascorbic Acid;Vitamin A Nos;Vitamin D Nos;Vitamin E Nos	1	(0.2)	1	(0.2)	2	(0.2)
Betacarotene;Biotin;Calcium Pantothenate;Colecalciferol;Cyanocobalamin;Folic Acid;Nicotinamide;Phytomenadione;Pyridoxine Hydrochloride;Retinol Palmitate;Riboflavin;Selenium;Sodium Ascorbate;Thiamine;	1	(0.2)	0	(0.0)	1	(0.1)
Biotin	2	(0.4)	0	(0.0)	2	(0.2)
Calcitriol	1	(0.2)	1	(0.2)	2	(0.2)
Calcium Gluconate;Cyanocobalamin;Ethanol;Ferrous Gluconate;Nicotinamide;Pyridoxine Hydrochloride;Riboflavin;Thiamine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Colecalciferol	119	(23.9)	117	(23.4)	236	(23.7)
Colecalciferol;Docosahexaenoic Acid;Helianthus Annuus Oil;Retinol;Vitamin E Nos	1	(0.2)	0	(0.0)	1	(0.1)
Colecalciferol;Lactobacillus Reuteri	1	(0.2)	2	(0.4)	3	(0.3)
Colecalciferol;Menaquinone	0	(0.0)	1	(0.2)	1	(0.1)
Dexpanthenol	0	(0.0)	2	(0.4)	2	(0.2)
Ergocalciferol	2	(0.4)	2	(0.4)	4	(0.4)
Ergocalciferol;Retinol	0	(0.0)	1	(0.2)	1	(0.1)
Ferrous Gluconate;Thiamine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Folic Acid;Iodine;Minerals Nos;Vitamins Nos	3	(0.6)	0	(0.0)	3	(0.3)
Iron;Vitamins Nos	1	(0.2)	2	(0.4)	3	(0.3)
Lysine;Taurine;Vitamins Nos	4	(0.8)	2	(0.4)	6	(0.6)
Magnesium Citrate;Potassium Citrate;Pyridoxine	0	(0.0)	1	(0.2)	1	(0.1)
Minerals Nos;Vitamins Nos	0	(0.0)	2	(0.4)	2	(0.2)
Multivitamins, Combinations	3	(0.6)	0	(0.0)	3	(0.3)
Multivitamins, Other Combinations	3	(0.6)	1	(0.2)	4	(0.4)
Multivitamins, Plain	2	(0.4)	0	(0.0)	2	(0.2)
Pyridoxine Hydrochloride	4	(0.8)	6	(1.2)	10	(1.0)
Retinol	2	(0.4)	2	(0.4)	4	(0.4)
Retinol;Tocopherol;Vitamin D Nos	0	(0.0)	2	(0.4)	2	(0.2)
Retinol;Vitamin D Nos	1	(0.2)	1	(0.2)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Alimentary Tract And Metabolism						
Vitamins	**335**	**(67.3)**	**328**	**(65.7)**	**663**	**(66.5)**
Thiamine	1	(0.2)	1	(0.2)	2	(0.2)
Tocopheryl Acetate	0	(0.0)	1	(0.2)	1	(0.1)
Vitamin A Nos	14	(2.8)	4	(0.8)	18	(1.8)
Vitamin B Complex	1	(0.2)	0	(0.0)	1	(0.1)
Vitamin D Nos	97	(19.5)	98	(19.6)	195	(19.6)
Vitamin E Nos	1	(0.2)	2	(0.4)	3	(0.3)
Vitamins Nos	60	(12.0)	62	(12.4)	122	(12.2)
Vitamins, Other Combinations	2	(0.4)	0	(0.0)	2	(0.2)
Antiinfectives For Systemic Use						
Antibacterials For Systemic Use	**138**	**(27.7)**	**167**	**(33.5)**	**305**	**(30.6)**
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)
Amikacin	6	(1.2)	10	(2.0)	16	(1.6)
Amikacin Sulfate	0	(0.0)	1	(0.2)	1	(0.1)
Amoxicillin	51	(10.2)	45	(9.0)	96	(9.6)
Amoxicillin Trihydrate	1	(0.2)	6	(1.2)	7	(0.7)
Amoxicillin Trihydrate;Clavulanate Potassium	3	(0.6)	1	(0.2)	4	(0.4)
Amoxicillin;Bromhexine	0	(0.0)	1	(0.2)	1	(0.1)
Amoxicillin;Clavulanate Potassium	14	(2.8)	16	(3.2)	30	(3.0)
Amoxicillin;Clavulanic Acid	14	(2.8)	17	(3.4)	31	(3.1)
Ampicillin	17	(3.4)	17	(3.4)	34	(3.4)
Ampicillin Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Ampicillin Sodium;Sulbactam Sodium	2	(0.4)	3	(0.6)	5	(0.5)
Ampicillin;Sulbactam	2	(0.4)	3	(0.6)	5	(0.5)
Antibiotics	2	(0.4)	0	(0.0)	2	(0.2)
Azithromycin	18	(3.6)	25	(5.0)	43	(4.3)
Azithromycin Dihydrate	2	(0.4)	1	(0.2)	3	(0.3)
Bacitracin	0	(0.0)	1	(0.2)	1	(0.1)
Benzylpenicillin	1	(0.2)	1	(0.2)	2	(0.2)
Benzylpenicillin Sodium	0	(0.0)	1	(0.2)	1	(0.1)
Cefaclor	3	(0.6)	0	(0.0)	3	(0.3)
Cefaclor Monohydrate	0	(0.0)	1	(0.2)	1	(0.1)
Cefadroxil	0	(0.0)	1	(0.2)	1	(0.1)
Cefalexin	5	(1.0)	11	(2.2)	16	(1.6)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Antiinfectives For Systemic Use						
Antibacterials For Systemic Use	**138**	**(27.7)**	**167**	**(33.5)**	**305**	**(30.6)**
Cefalotin	0	(0.0)	1	(0.2)	1	(0.1)
Cefazolin	2	(0.4)	5	(1.0)	7	(0.7)
Cefazolin Sodium	1	(0.2)	4	(0.8)	5	(0.5)
Cefdinir	2	(0.4)	2	(0.4)	4	(0.4)
Cefepime	1	(0.2)	1	(0.2)	2	(0.2)
Cefepime Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Cefixime	5	(1.0)	4	(0.8)	9	(0.9)
Cefotaxime	5	(1.0)	8	(1.6)	13	(1.3)
Cefotaxime Sodium	2	(0.4)	2	(0.4)	4	(0.4)
Cefoxitin Sodium	0	(0.0)	1	(0.2)	1	(0.1)
Cefpodoxime	0	(0.0)	1	(0.2)	1	(0.1)
Cefprozil	0	(0.0)	3	(0.6)	3	(0.3)
Ceftazidime	1	(0.2)	2	(0.4)	3	(0.3)
Ceftriaxone	16	(3.2)	20	(4.0)	36	(3.6)
Ceftriaxone Sodium	4	(0.8)	9	(1.8)	13	(1.3)
Cefuroxime	1	(0.2)	2	(0.4)	3	(0.3)
Cefuroxime Sodium	0	(0.0)	1	(0.2)	1	(0.1)
Chloramphenicol	6	(1.2)	10	(2.0)	16	(1.6)
Ciprofloxacin	2	(0.4)	4	(0.8)	6	(0.6)
Ciprofloxacin Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Clarithromycin	5	(1.0)	14	(2.8)	19	(1.9)
Clavulanic Acid	0	(0.0)	1	(0.2)	1	(0.1)
Clindamycin	2	(0.4)	1	(0.2)	3	(0.3)
Cloxacillin	0	(0.0)	1	(0.2)	1	(0.1)
Colistimethate Sodium;Erythromycin Lactobionate	0	(0.0)	1	(0.2)	1	(0.1)
Colistin	0	(0.0)	1	(0.2)	1	(0.1)
Dibekacin Sulfate	1	(0.2)	0	(0.0)	1	(0.1)
Dicloxacillin	1	(0.2)	0	(0.0)	1	(0.1)
Doxycycline	1	(0.2)	0	(0.0)	1	(0.1)
Erythromycin	1	(0.2)	2	(0.4)	3	(0.3)
Fusidic Acid	0	(0.0)	2	(0.4)	2	(0.2)
Gentamicin	5	(1.0)	12	(2.4)	17	(1.7)
Levofloxacin	3	(0.6)	2	(0.4)	5	(0.5)
Linezolid	1	(0.2)	3	(0.6)	4	(0.4)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Antiinfectives For Systemic Use						
Antibacterials For Systemic Use	**138**	**(27.7)**	**167**	**(33.5)**	**305**	**(30.6)**
Meropenem	5	(1.0)	6	(1.2)	11	(1.1)
Meropenem Trihydrate	1	(0.2)	0	(0.0)	1	(0.1)
Metronidazole	0	(0.0)	4	(0.8)	4	(0.4)
Moxifloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Moxifloxacin Hydrochloride	2	(0.4)	0	(0.0)	2	(0.2)
Neomycin Sulfate	0	(0.0)	2	(0.4)	2	(0.2)
Netilmicin Sulfate	1	(0.2)	1	(0.2)	2	(0.2)
Ofloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Oxacillin	0	(0.0)	1	(0.2)	1	(0.1)
Phenoxymethylpenicillin	0	(0.0)	1	(0.2)	1	(0.1)
Piperacillin	1	(0.2)	0	(0.0)	1	(0.1)
Piperacillin Sodium;Tazobactam Sodium	4	(0.8)	10	(2.0)	14	(1.4)
Piperacillin;Tazobactam	2	(0.4)	3	(0.6)	5	(0.5)
Platycodon Grandiflorus	1	(0.2)	1	(0.2)	2	(0.2)
Rifampicin	1	(0.2)	1	(0.2)	2	(0.2)
Sulfamethoxazole;Trimethoprim	12	(2.4)	10	(2.0)	22	(2.2)
Sultamicillin	0	(0.0)	1	(0.2)	1	(0.1)
Syzygium Aromaticum	1	(0.2)	0	(0.0)	1	(0.1)
Teicoplanin	0	(0.0)	2	(0.4)	2	(0.2)
Tobramycin	9	(1.8)	11	(2.2)	20	(2.0)
Vancomycin	4	(0.8)	8	(1.6)	12	(1.2)
Vancomycin Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Antimycobacterials	**3**	**(0.6)**	**2**	**(0.4)**	**5**	**(0.5)**
Antibiotics	2	(0.4)	0	(0.0)	2	(0.2)
Isoniazid	1	(0.2)	1	(0.2)	2	(0.2)
Pyrazinamide	1	(0.2)	0	(0.0)	1	(0.1)
Rifampicin	1	(0.2)	1	(0.2)	2	(0.2)
Antimycotics For Systemic Use	**18**	**(3.6)**	**27**	**(5.4)**	**45**	**(4.5)**
Amphotericin B	1	(0.2)	1	(0.2)	2	(0.2)
Antibiotics	2	(0.4)	0	(0.0)	2	(0.2)
Antifungals	0	(0.0)	1	(0.2)	1	(0.1)
Fluconazole	1	(0.2)	4	(0.8)	5	(0.5)
Ketoconazole	1	(0.2)	0	(0.0)	1	(0.1)
Miconazole	2	(0.4)	4	(0.8)	6	(0.6)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Antiinfectives For Systemic Use						
Antimycotics For Systemic Use	**18**	**(3.6)**	**27**	**(5.4)**	**45**	**(4.5)**
Nystatin	11	(2.2)	21	(4.2)	32	(3.2)
Antivirals For Systemic Use	**18**	**(3.6)**	**22**	**(4.4)**	**40**	**(4.0)**
Aciclovir	1	(0.2)	1	(0.2)	2	(0.2)
Amantadine	1	(0.2)	1	(0.2)	2	(0.2)
Amantadine Hydrochloride;Chlorphenamine Maleate;Paracetamol	5	(1.0)	0	(0.0)	5	(0.5)
Amantadine;Chlorphenamine;Paracetamol	2	(0.4)	6	(1.2)	8	(0.8)
Ganciclovir	1	(0.2)	1	(0.2)	2	(0.2)
Nevirapine	6	(1.2)	4	(0.8)	10	(1.0)
Oseltamivir	0	(0.0)	6	(1.2)	6	(0.6)
Oseltamivir Phosphate	0	(0.0)	2	(0.4)	2	(0.2)
Remdesivir	1	(0.2)	1	(0.2)	2	(0.2)
Ribavirin	1	(0.2)	0	(0.0)	1	(0.1)
Rimantadine	0	(0.0)	1	(0.2)	1	(0.1)
Valganciclovir	2	(0.4)	1	(0.2)	3	(0.3)
Zidovudine	2	(0.4)	1	(0.2)	3	(0.3)
Immune Sera And Immunoglobulins	**1**	**(0.2)**	**7**	**(1.4)**	**8**	**(0.8)**
Diphtheria Antitoxin Immune Sera	0	(0.0)	1	(0.2)	1	(0.1)
Nirsevimab	1	(0.2)	2	(0.4)	3	(0.3)
Palivizumab	0	(0.0)	4	(0.8)	4	(0.4)
Antineoplastic And Immunomodulating Agents						
Antineoplastic Agents	**11**	**(2.2)**	**10**	**(2.0)**	**21**	**(2.1)**
Propranolol	9	(1.8)	6	(1.2)	15	(1.5)
Propranolol Hydrochloride	3	(0.6)	4	(0.8)	7	(0.7)
Immunostimulants	**37**	**(7.4)**	**45**	**(9.0)**	**82**	**(8.2)**
Bcg Vaccine	34	(6.8)	44	(8.8)	78	(7.8)
Bcg Vaccine Live (Danish 1331)	1	(0.2)	1	(0.2)	2	(0.2)
Bifidobacterium Lactis;Lactobacillus Acidophilus	1	(0.2)	0	(0.0)	1	(0.1)
Pidotimod	1	(0.2)	0	(0.0)	1	(0.1)
Immunosuppressants	**1**	**(0.2)**	**0**	**(0.0)**	**1**	**(0.1)**
Mycophenolate Mofetil	1	(0.2)	0	(0.0)	1	(0.1)
Antiparasitic Products, Insecticides And Repellents						

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Antiparasitic Products, Insecticides And Repellents						
Antiprotozoals	**12**	**(2.4)**	**26**	**(5.2)**	**38**	**(3.8)**
Clotrimazole	10	(2.0)	18	(3.6)	28	(2.8)
Metronidazole	0	(0.0)	4	(0.8)	4	(0.4)
Miconazole	2	(0.4)	4	(0.8)	6	(0.6)
Ofloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Ectoparasiticides, Incl. Scabicides, Insecticides And Repellents	**12**	**(2.4)**	**6**	**(1.2)**	**18**	**(1.8)**
Crotamiton	0	(0.0)	1	(0.2)	1	(0.1)
Dimeticone	9	(1.8)	4	(0.8)	13	(1.3)
Lavandula Angustifolia Oil	0	(0.0)	1	(0.2)	1	(0.1)
Permethrin	2	(0.4)	0	(0.0)	2	(0.2)
Sulfur	1	(0.2)	1	(0.2)	2	(0.2)
Blood And Blood Forming Organs						
Antianemic Preparations	**285**	**(57.2)**	**267**	**(53.5)**	**552**	**(55.4)**
Ascorbic Acid;Cyanocobalamin;Ferrous Sulfate;Folic Acid;Nicotinamide;Pyridoxine Hydrochloride;Riboflavin;Thiamine Hydrochloride	1	(0.2)	1	(0.2)	2	(0.2)
Ascorbic Acid;Cyanocobalamin;Folic Acid;Iron	1	(0.2)	0	(0.0)	1	(0.1)
Ascorbic Acid;Ferric Pyrophosphate	0	(0.0)	1	(0.2)	1	(0.1)
Ascorbic Acid;Iron	1	(0.2)	0	(0.0)	1	(0.1)
Calcium Folinate	2	(0.4)	3	(0.6)	5	(0.5)
Dextriferron	1	(0.2)	0	(0.0)	1	(0.1)
Epoetin Alfa	1	(0.2)	0	(0.0)	1	(0.1)
Ferric Ammonium Citrate	15	(3.0)	10	(2.0)	25	(2.5)
Ferric Hydroxide	2	(0.4)	0	(0.0)	2	(0.2)
Ferric Hydroxide Polymaltose Complex	67	(13.5)	73	(14.6)	140	(14.0)
Ferric Hydroxide Polymaltose Complex;Folic Acid	1	(0.2)	0	(0.0)	1	(0.1)
Ferric Pyrophosphate	7	(1.4)	8	(1.6)	15	(1.5)
Ferritin	1	(0.2)	0	(0.0)	1	(0.1)
Ferroglycine Sulfate Complex	1	(0.2)	0	(0.0)	1	(0.1)
Ferrous Bisglycinate	5	(1.0)	2	(0.4)	7	(0.7)
Ferrous Fumarate	7	(1.4)	3	(0.6)	10	(1.0)
Ferrous Fumarate;Folic Acid	0	(0.0)	1	(0.2)	1	(0.1)
Ferrous Gluconate	32	(6.4)	29	(5.8)	61	(6.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Blood And Blood Forming Organs						
Antianemic Preparations	**285**	**(57.2)**	**267**	**(53.5)**	**552**	**(55.4)**
Ferrous Gluconate;Thiamine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Ferrous Glycine Sulfate	23	(4.6)	25	(5.0)	48	(4.8)
Ferrous Lactate	0	(0.0)	1	(0.2)	1	(0.1)
Ferrous Sulfate	77	(15.5)	69	(13.8)	146	(14.6)
Folic Acid	102	(20.5)	83	(16.6)	185	(18.6)
Folic Acid;Iron	1	(0.2)	1	(0.2)	2	(0.2)
Folic Acid;Iron;Mecobalamin;Zinc	1	(0.2)	1	(0.2)	2	(0.2)
Heme Iron Polypeptide	1	(0.2)	0	(0.0)	1	(0.1)
Iron	22	(4.4)	26	(5.2)	48	(4.8)
Iron Trivalent, Oral Preparations	2	(0.4)	2	(0.4)	4	(0.4)
Iron;Vitamins Nos	1	(0.2)	2	(0.4)	3	(0.3)
Lactoferrin	1	(0.2)	0	(0.0)	1	(0.1)
Saccharated Iron Oxide	3	(0.6)	2	(0.4)	5	(0.5)
Sodium Feredetate	10	(2.0)	5	(1.0)	15	(1.5)
Antihemorrhagics	**45**	**(9.0)**	**43**	**(8.6)**	**88**	**(8.8)**
Amino Acids Nos	0	(0.0)	1	(0.2)	1	(0.1)
Epinephrine	15	(3.0)	17	(3.4)	32	(3.2)
Epinephrine Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Factor I (Fibrinogen)	0	(0.0)	1	(0.2)	1	(0.1)
Menadione	2	(0.4)	1	(0.2)	3	(0.3)
Menatetrenone	9	(1.8)	10	(2.0)	19	(1.9)
Minerals Nos	2	(0.4)	2	(0.4)	4	(0.4)
Phytomenadione	13	(2.6)	11	(2.2)	24	(2.4)
Tranexamic Acid	0	(0.0)	2	(0.4)	2	(0.2)
Vitamin K Nos	7	(1.4)	3	(0.6)	10	(1.0)
Antithrombotic Agents	**19**	**(3.8)**	**20**	**(4.0)**	**39**	**(3.9)**
Acetylsalicylic Acid	11	(2.2)	11	(2.2)	22	(2.2)
Alteplase	1	(0.2)	1	(0.2)	2	(0.2)
Clopidogrel	2	(0.4)	0	(0.0)	2	(0.2)
Dalteparin	1	(0.2)	0	(0.0)	1	(0.1)
Enoxaparin	1	(0.2)	1	(0.2)	2	(0.2)
Enoxaparin Sodium	0	(0.0)	2	(0.4)	2	(0.2)
Heparin	3	(0.6)	2	(0.4)	5	(0.5)
Heparinoid	2	(0.4)	0	(0.0)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Blood And Blood Forming Organs						
Antithrombotic Agents	**19**	**(3.8)**	**20**	**(4.0)**	**39**	**(3.9)**
Iloprost	1	(0.2)	1	(0.2)	2	(0.2)
Mucopolysaccharide Polysulfuric Acid Ester	3	(0.6)	4	(0.8)	7	(0.7)
Sodium Ferulate	0	(0.0)	2	(0.4)	2	(0.2)
Tinzaparin Sodium	0	(0.0)	1	(0.2)	1	(0.1)
Warfarin	0	(0.0)	1	(0.2)	1	(0.1)
Blood Substitutes And Perfusion Solutions	**167**	**(33.5)**	**201**	**(40.3)**	**368**	**(36.9)**
Alanine;Arginine;Aspartic Acid;Calcium Chloride Dihydrate;Cysteine;Glucose Monohydrate;Glutamic Acid;Glycine;Glycine Max Seed Oil;Histidine;Isoleucine;Leucine;Lysine Monohydrate;	1	(0.2)	0	(0.0)	1	(0.1)
Albumin Human	1	(0.2)	2	(0.4)	3	(0.3)
Amino Acids Nos	0	(0.0)	1	(0.2)	1	(0.1)
Amino Acids Nos;Minerals Nos;Vitamins Nos	0	(0.0)	1	(0.2)	1	(0.1)
Blood And Related Products	1	(0.2)	0	(0.0)	1	(0.1)
Blood Plasma	0	(0.0)	1	(0.2)	1	(0.1)
Blood, Whole	0	(0.0)	1	(0.2)	1	(0.1)
Calcium Chloride Dihydrate;Glucose;Potassium Chloride;Sodium Acetate Trihydrate;Sodium Chloride	1	(0.2)	2	(0.4)	3	(0.3)
Calcium Chloride Dihydrate;Glucose;Potassium Chloride;Sodium Acetate;Sodium Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Calcium Chloride Dihydrate;Magnesium Chloride Hexahydrate;Potassium Chloride;Sodium Chloride;Sodium Lactate	0	(0.0)	1	(0.2)	1	(0.1)
Calcium Chloride;Glucose Monohydrate;Magnesium Chloride Hexahydrate;Potassium Chloride;Sodium Chloride	1	(0.2)	0	(0.0)	1	(0.1)
Calcium Chloride;Glucose;Magnesium Chloride;Potassium Chloride;Sodium Chloride;Sodium Lactate	0	(0.0)	1	(0.2)	1	(0.1)
Calcium Chloride;Glucose;Potassium Chloride;Sodium Acetate;Sodium Chloride	1	(0.2)	2	(0.4)	3	(0.3)
Calcium Chloride;Potassium Chloride;Sodium Chloride;Sodium Lactate	2	(0.4)	0	(0.0)	2	(0.2)
Calcium Gluconate	3	(0.6)	6	(1.2)	9	(0.9)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Blood And Blood Forming Organs						
Blood Substitutes And Perfusion Solutions	**167**	**(33.5)**	**201**	**(40.3)**	**368**	**(36.9)**
Calcium Gluconate Monohydrate;Glucose;Magnesium Chloride Hexahydrate;Potassium Chloride;Sodium Acetate;Sodium Chloride;Sodium Citrate Dihydrate	0	(0.0)	2	(0.4)	2	(0.2)
Calcium Gluconate;Sodium Chloride	1	(0.2)	0	(0.0)	1	(0.1)
Carbohydrates Nos;Minerals Nos	1	(0.2)	1	(0.2)	2	(0.2)
Carbohydrates Nos;Potassium Chloride;Sodium Chloride;Sodium Lactate	0	(0.0)	2	(0.4)	2	(0.2)
Chlorhexidine Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Copper Chloride;Manganese Chloride;Potassium Iodide;Sodium Fluoride;Sodium Selenate;Zinc Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Electrolytes Nos	2	(0.4)	2	(0.4)	4	(0.4)
Electrolytes Nos;Glucose	4	(0.8)	5	(1.0)	9	(0.9)
Electrolytes Nos;Sodium Lactate	0	(0.0)	1	(0.2)	1	(0.1)
Fish Oil;Glycine Max Seed Oil;Medium-Chain Triglycerides;Olea Europaea Oil	0	(0.0)	1	(0.2)	1	(0.1)
Glucose	8	(1.6)	6	(1.2)	14	(1.4)
Glucose Monohydrate;Potassium Chloride;Sodium Chloride;Sodium Citrate	1	(0.2)	0	(0.0)	1	(0.1)
Glucose Monohydrate;Sodium Chloride	0	(0.0)	2	(0.4)	2	(0.2)
Glucose;Magnesium Chloride;Potassium Acetate;Potassium Phosphate Monobasic;Sodium Acetate;Sodium Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Glucose;Potassium Chloride;Sodium Bicarbonate;Sodium Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Glucose;Potassium Chloride;Sodium Chloride	2	(0.4)	5	(1.0)	7	(0.7)
Glucose;Potassium Chloride;Sodium Chloride;Sodium Citrate	1	(0.2)	2	(0.4)	3	(0.3)
Glucose;Potassium Chloride;Sodium Chloride;Sodium Citrate Acid	0	(0.0)	1	(0.2)	1	(0.1)
Glucose;Potassium;Sodium Chloride	3	(0.6)	0	(0.0)	3	(0.3)
Glucose;Sodium Bicarbonate	1	(0.2)	0	(0.0)	1	(0.1)
Glucose;Sodium Chloride	14	(2.8)	24	(4.8)	38	(3.8)
Glucose;Sodium Chloride;Sodium Lactate	0	(0.0)	2	(0.4)	2	(0.2)
Glycerol	9	(1.8)	16	(3.2)	25	(2.5)
Glycerol;Glycine Max Oil;Phospholipids Egg	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Blood And Blood Forming Organs						
Blood Substitutes And Perfusion Solutions	**167**	**(33.5)**	**201**	**(40.3)**	**368**	**(36.9)**
Glycine Max Seed Oil	1	(0.2)	0	(0.0)	1	(0.1)
Glycine Max Seed Oil;Olea Europaea Oil	0	(0.0)	1	(0.2)	1	(0.1)
Magnesium Chloride	1	(0.2)	0	(0.0)	1	(0.1)
Magnesium Chloride;Potassium Chloride;Sodium Bicarbonate;Sodium Chloride	1	(0.2)	0	(0.0)	1	(0.1)
Magnesium Sulfate	2	(0.4)	2	(0.4)	4	(0.4)
Mannitol	1	(0.2)	1	(0.2)	2	(0.2)
Medium-Chain Triglycerides	0	(0.0)	1	(0.2)	1	(0.1)
Minerals Nos	2	(0.4)	2	(0.4)	4	(0.4)
Minerals Nos;Vitamins Nos	0	(0.0)	2	(0.4)	2	(0.2)
Neomycin Sulfate	0	(0.0)	2	(0.4)	2	(0.2)
Nutrients Nos	0	(0.0)	1	(0.2)	1	(0.1)
Phosphoric Acid	0	(0.0)	1	(0.2)	1	(0.1)
Platelets, Human Blood	1	(0.2)	1	(0.2)	2	(0.2)
Potassium Chloride	7	(1.4)	12	(2.4)	19	(1.9)
Potassium Chloride;Sodium Chloride	1	(0.2)	0	(0.0)	1	(0.1)
Potassium Phosphate Dibasic	0	(0.0)	2	(0.4)	2	(0.2)
Red Blood Cells	4	(0.8)	6	(1.2)	10	(1.0)
Red Blood Cells, Leucocyte Depleted	3	(0.6)	1	(0.2)	4	(0.4)
Sodium Bicarbonate	3	(0.6)	6	(1.2)	9	(0.9)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Sodium Phosphate	4	(0.8)	2	(0.4)	6	(0.6)
Sodium Phosphate Dibasic;Sodium Phosphate Monobasic	1	(0.2)	1	(0.2)	2	(0.2)
Sodium Phosphate Dibasic;Sodium Phosphate Monobasic (Monohydrate)	0	(0.0)	1	(0.2)	1	(0.1)
Solutions Affecting The Electrolyte Balance	0	(0.0)	1	(0.2)	1	(0.1)
Trace Elements Nos	0	(0.0)	1	(0.2)	1	(0.1)
Trometamol	0	(0.0)	1	(0.2)	1	(0.1)
Vitamins Nos	60	(12.0)	62	(12.4)	122	(12.2)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Zinc Sulfate	3	(0.6)	10	(2.0)	13	(1.3)
Zinc Sulfate Heptahydrate	0	(0.0)	1	(0.2)	1	(0.1)
Other Hematological Agents	**1**	**(0.2)**	**1**	**(0.2)**	**2**	**(0.2)**
Dornase Alfa	1	(0.2)	1	(0.2)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Cardiovascular System						
Agents Acting On The Renin-Angiotensin System	**15**	**(3.0)**	**19**	**(3.8)**	**34**	**(3.4)**
Captopril	14	(2.8)	15	(3.0)	29	(2.9)
Enalapril	1	(0.2)	5	(1.0)	6	(0.6)
Enalapril Maleate	0	(0.0)	1	(0.2)	1	(0.1)
Antihypertensives	**13**	**(2.6)**	**15**	**(3.0)**	**28**	**(2.8)**
Bosentan	0	(0.0)	2	(0.4)	2	(0.2)
Clonidine	2	(0.4)	4	(0.8)	6	(0.6)
Clonidine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Hydralazine	0	(0.0)	1	(0.2)	1	(0.1)
Magnesium Sulfate	2	(0.4)	2	(0.4)	4	(0.4)
Sildenafil	8	(1.6)	7	(1.4)	15	(1.5)
Sildenafil Citrate	1	(0.2)	1	(0.2)	2	(0.2)
Urapidil	0	(0.0)	1	(0.2)	1	(0.1)
Beta Blocking Agents	**19**	**(3.8)**	**20**	**(4.0)**	**39**	**(3.9)**
Atenolol	1	(0.2)	0	(0.0)	1	(0.1)
Carvedilol	1	(0.2)	3	(0.6)	4	(0.4)
Metoprolol	3	(0.6)	3	(0.6)	6	(0.6)
Metoprolol Tartrate	1	(0.2)	1	(0.2)	2	(0.2)
Propranolol	9	(1.8)	6	(1.2)	15	(1.5)
Propranolol Hydrochloride	3	(0.6)	4	(0.8)	7	(0.7)
Timolol	2	(0.4)	3	(0.6)	5	(0.5)
Timolol Maleate	2	(0.4)	3	(0.6)	5	(0.5)
Calcium Channel Blockers	**0**	**(0.0)**	**3**	**(0.6)**	**3**	**(0.3)**
Amlodipine	0	(0.0)	2	(0.4)	2	(0.2)
Amlodipine Besilate	0	(0.0)	1	(0.2)	1	(0.1)
Nifedipine	0	(0.0)	1	(0.2)	1	(0.1)
Cardiac Therapy	**81**	**(16.3)**	**79**	**(15.8)**	**160**	**(16.0)**
Adenosine	0	(0.0)	1	(0.2)	1	(0.1)
Amiodarone	0	(0.0)	2	(0.4)	2	(0.2)
Amiodarone Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Cafedrine Hydrochloride;Theodrenaline Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Caffeine	4	(0.8)	4	(0.8)	8	(0.8)
Digoxin	5	(1.0)	5	(1.0)	10	(1.0)
Dopamine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Epinephrine	15	(3.0)	17	(3.4)	32	(3.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Cardiovascular System						
Cardiac Therapy	**81**	**(16.3)**	**79**	**(15.8)**	**160**	**(16.0)**
Epinephrine Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Flecainide Acetate	0	(0.0)	1	(0.2)	1	(0.1)
Glyceryl Trinitrate	1	(0.2)	0	(0.0)	1	(0.1)
Ibuprofen	38	(7.6)	40	(8.0)	78	(7.8)
Ipratropium	1	(0.2)	0	(0.0)	1	(0.1)
Ipratropium Bromide	19	(3.8)	20	(4.0)	39	(3.9)
Ivabradine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Levocarnitine	1	(0.2)	0	(0.0)	1	(0.1)
Levosimendan	1	(0.2)	2	(0.4)	3	(0.3)
Lidocaine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Milrinone	2	(0.4)	6	(1.2)	8	(0.8)
Milrinone Lactate	1	(0.2)	1	(0.2)	2	(0.2)
Norepinephrine	1	(0.2)	3	(0.6)	4	(0.4)
Norepinephrine Bitartrate	1	(0.2)	0	(0.0)	1	(0.1)
Phenylephrine	3	(0.6)	4	(0.8)	7	(0.7)
Phenylephrine Hydrochloride	1	(0.2)	1	(0.2)	2	(0.2)
Phenytoin	0	(0.0)	1	(0.2)	1	(0.1)
Phenytoin Sodium	1	(0.2)	1	(0.2)	2	(0.2)
Racecadotril	4	(0.8)	3	(0.6)	7	(0.7)
Sodium Alginate	1	(0.2)	0	(0.0)	1	(0.1)
Ubidecarenone	1	(0.2)	0	(0.0)	1	(0.1)
Diuretics	**60**	**(12.0)**	**48**	**(9.6)**	**108**	**(10.8)**
Acetazolamide	0	(0.0)	1	(0.2)	1	(0.1)
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)
Chlorothiazide	4	(0.8)	0	(0.0)	4	(0.4)
Furosemide	42	(8.4)	39	(7.8)	81	(8.1)
Furosemide Sodium	1	(0.2)	1	(0.2)	2	(0.2)
Hydrochlorothiazide	13	(2.6)	15	(3.0)	28	(2.8)
Lavandula Angustifolia Oil	0	(0.0)	1	(0.2)	1	(0.1)
Spironolactone	34	(6.8)	35	(7.0)	69	(6.9)
Lipid Modifying Agents	**3**	**(0.6)**	**0**	**(0.0)**	**3**	**(0.3)**
Glycine Max Seed Oil	1	(0.2)	0	(0.0)	1	(0.1)
Lactiplantibacillus Plantarum	2	(0.4)	0	(0.0)	2	(0.2)
Peripheral Vasodilators	**0**	**(0.0)**	**2**	**(0.4)**	**2**	**(0.2)**

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Cardiovascular System						
Peripheral Vasodilators	**0**	**(0.0)**	**2**	**(0.4)**	**2**	**(0.2)**
Bosentan	0	(0.0)	2	(0.4)	2	(0.2)
Vasoprotectives	**88**	**(17.7)**	**107**	**(21.4)**	**195**	**(19.6)**
Antibiotics	2	(0.4)	0	(0.0)	2	(0.2)
Beclometasone	5	(1.0)	5	(1.0)	10	(1.0)
Beclometasone Dipropionate	1	(0.2)	2	(0.4)	3	(0.3)
Benzocaine	1	(0.2)	0	(0.0)	1	(0.1)
Betamethasone	6	(1.2)	3	(0.6)	9	(0.9)
Betamethasone Dipropionate	0	(0.0)	2	(0.4)	2	(0.2)
Betamethasone Valerate	0	(0.0)	2	(0.4)	2	(0.2)
Carbomer	1	(0.2)	0	(0.0)	1	(0.1)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroids	1	(0.2)	0	(0.0)	1	(0.1)
Dexamethasone	14	(2.8)	13	(2.6)	27	(2.7)
Dexamethasone Sodium Phosphate	2	(0.4)	3	(0.6)	5	(0.5)
Escin	0	(0.0)	1	(0.2)	1	(0.1)
Fluorometholone	2	(0.4)	1	(0.2)	3	(0.3)
Glucose Monohydrate;Sodium Chloride	0	(0.0)	2	(0.4)	2	(0.2)
Glucose;Sodium Chloride	14	(2.8)	24	(4.8)	38	(3.8)
Glyceryl Trinitrate	1	(0.2)	0	(0.0)	1	(0.1)
Hamamelis Virginiana Extract	0	(0.0)	1	(0.2)	1	(0.1)
Heparin	3	(0.6)	2	(0.4)	5	(0.5)
Heparinoid	2	(0.4)	0	(0.0)	2	(0.2)
Hyaluronate Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Hydrocortisone	15	(3.0)	17	(3.4)	32	(3.2)
Hydrocortisone Acetate	3	(0.6)	2	(0.4)	5	(0.5)
Hydrocortisone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Lidocaine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Mucopolysaccharide Polysulfuric Acid Ester	3	(0.6)	4	(0.8)	7	(0.7)
Nifedipine	0	(0.0)	1	(0.2)	1	(0.1)
Phenylephrine	3	(0.6)	4	(0.8)	7	(0.7)
Phenylephrine Hydrochloride	1	(0.2)	1	(0.2)	2	(0.2)
Prednisolone	15	(3.0)	18	(3.6)	33	(3.3)
Prednisolone Acetate	3	(0.6)	1	(0.2)	4	(0.4)
Prednisolone Sodium Phosphate	1	(0.2)	1	(0.2)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Cardiovascular System						
Vasoprotectives	**88**	**(17.7)**	**107**	**(21.4)**	**195**	**(19.6)**
Prednisolone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Prednisolone Steaglate	0	(0.0)	1	(0.2)	1	(0.1)
Prednisolone Valeroacetate	0	(0.0)	2	(0.4)	2	(0.2)
Sodium Alginate	1	(0.2)	0	(0.0)	1	(0.1)
Talc	0	(0.0)	1	(0.2)	1	(0.1)
Tetracaine	1	(0.2)	1	(0.2)	2	(0.2)
Tetracaine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Triamcinolone Acetonide	0	(0.0)	3	(0.6)	3	(0.3)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Zinc Sulfate	3	(0.6)	10	(2.0)	13	(1.3)
Dermatologicals						
Anti-Acne Preparations	**81**	**(16.3)**	**86**	**(17.2)**	**167**	**(16.8)**
Azithromycin	18	(3.6)	25	(5.0)	43	(4.3)
Chloramphenicol	6	(1.2)	10	(2.0)	16	(1.6)
Chlorhexidine Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Clindamycin	2	(0.4)	1	(0.2)	3	(0.3)
Dimeticone	9	(1.8)	4	(0.8)	13	(1.3)
Doxycycline	1	(0.2)	0	(0.0)	1	(0.1)
Erythromycin	1	(0.2)	2	(0.4)	3	(0.3)
Ibuprofen	38	(7.6)	40	(8.0)	78	(7.8)
Lactoferrin	1	(0.2)	0	(0.0)	1	(0.1)
Retinol	2	(0.4)	2	(0.4)	4	(0.4)
Sulfacetamide	1	(0.2)	0	(0.0)	1	(0.1)
Sulfur	1	(0.2)	1	(0.2)	2	(0.2)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Zinc Gluconate	0	(0.0)	2	(0.4)	2	(0.2)
Antibiotics And Chemotherapeutics For Dermatological Use	**39**	**(7.8)**	**64**	**(12.8)**	**103**	**(10.3)**
Aciclovir	1	(0.2)	1	(0.2)	2	(0.2)
Amikacin	6	(1.2)	10	(2.0)	16	(1.6)
Amikacin Sulfate	0	(0.0)	1	(0.2)	1	(0.1)
Antibiotics	2	(0.4)	0	(0.0)	2	(0.2)
Bacitracin	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Dermatologicals						
Antibiotics And Chemotherapeutics For Dermatological Use	**39**	**(7.8)**	**64**	**(12.8)**	**103**	**(10.3)**
Benzylpenicillin	1	(0.2)	1	(0.2)	2	(0.2)
Chloramphenicol	6	(1.2)	10	(2.0)	16	(1.6)
Ciprofloxacin	2	(0.4)	4	(0.8)	6	(0.6)
Ciprofloxacin Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Clarithromycin	5	(1.0)	14	(2.8)	19	(1.9)
Clotrimazole;Zinc Oxide	0	(0.0)	1	(0.2)	1	(0.1)
Doxycycline	1	(0.2)	0	(0.0)	1	(0.1)
Erythromycin	1	(0.2)	2	(0.4)	3	(0.3)
Fusidic Acid	0	(0.0)	2	(0.4)	2	(0.2)
Ganciclovir	1	(0.2)	1	(0.2)	2	(0.2)
Gentamicin	5	(1.0)	12	(2.4)	17	(1.7)
Lactoferrin	1	(0.2)	0	(0.0)	1	(0.1)
Levofloxacin	3	(0.6)	2	(0.4)	5	(0.5)
Metronidazole	0	(0.0)	4	(0.8)	4	(0.4)
Moxifloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Mupirocin	4	(0.8)	5	(1.0)	9	(0.9)
Neomycin Sulfate	0	(0.0)	2	(0.4)	2	(0.2)
Neomycin Sulfate;Tyrothricin	0	(0.0)	1	(0.2)	1	(0.1)
Ofloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Ribavirin	1	(0.2)	0	(0.0)	1	(0.1)
Rifampicin	1	(0.2)	1	(0.2)	2	(0.2)
Sulfadiazine Silver	0	(0.0)	1	(0.2)	1	(0.1)
Antifungals For Dermatological Use	**28**	**(5.6)**	**42**	**(8.4)**	**70**	**(7.0)**
Amphotericin B	1	(0.2)	1	(0.2)	2	(0.2)
Antibiotics	2	(0.4)	0	(0.0)	2	(0.2)
Antifungals	0	(0.0)	1	(0.2)	1	(0.1)
Clotrimazole	10	(2.0)	18	(3.6)	28	(2.8)
Clotrimazole;Zinc Oxide	0	(0.0)	1	(0.2)	1	(0.1)
Fluconazole	1	(0.2)	4	(0.8)	5	(0.5)
Hydrocortisone;Miconazole Nitrate	1	(0.2)	0	(0.0)	1	(0.1)
Ketoconazole	1	(0.2)	0	(0.0)	1	(0.1)
Miconazole	2	(0.4)	4	(0.8)	6	(0.6)
Miconazole Nitrate;Zinc Oxide	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Dermatologicals						
Antifungals For Dermatological Use	**28**	**(5.6)**	**42**	**(8.4)**	**70**	**(7.0)**
Nystatin	11	(2.2)	21	(4.2)	32	(3.2)
Nystatin;Zinc Oxide	0	(0.0)	2	(0.4)	2	(0.2)
Antipruritics, Incl. Antihistamines, Anesthetics, Etc.	**48**	**(9.6)**	**52**	**(10.4)**	**100**	**(10.0)**
Benzocaine	1	(0.2)	0	(0.0)	1	(0.1)
Calamine	1	(0.2)	3	(0.6)	4	(0.4)
Camphor;Eucalyptus Globulus Oil;Juniperus Virginiana Wood Oil;Menthol	0	(0.0)	1	(0.2)	1	(0.1)
Camphor;Eucalyptus Globulus Oil;Menthol	0	(0.0)	1	(0.2)	1	(0.1)
Cetirizine	5	(1.0)	7	(1.4)	12	(1.2)
Cetirizine Hydrochloride	4	(0.8)	2	(0.4)	6	(0.6)
Chlorhexidine;Lidocaine	1	(0.2)	0	(0.0)	1	(0.1)
Chlorphenamine	3	(0.6)	6	(1.2)	9	(0.9)
Chlorphenamine Maleate	3	(0.6)	0	(0.0)	3	(0.3)
Crotamiton	0	(0.0)	1	(0.2)	1	(0.1)
Cyproheptadine	3	(0.6)	2	(0.4)	5	(0.5)
Cyproheptadine Hydrochloride	1	(0.2)	4	(0.8)	5	(0.5)
Desloratadine	7	(1.4)	2	(0.4)	9	(0.9)
Dimetindene	0	(0.0)	1	(0.2)	1	(0.1)
Dimetindene Maleate	2	(0.4)	4	(0.8)	6	(0.6)
Diphenhydramine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Emedastine Fumarate	0	(0.0)	1	(0.2)	1	(0.1)
Fexofenadine	3	(0.6)	1	(0.2)	4	(0.4)
Fexofenadine Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Hydroxyzine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Ketotifen	1	(0.2)	0	(0.0)	1	(0.1)
Levocetirizine	4	(0.8)	2	(0.4)	6	(0.6)
Lidocaine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Lidocaine;Prilocaine	1	(0.2)	1	(0.2)	2	(0.2)
Loratadine	8	(1.6)	10	(2.0)	18	(1.8)
Oxybuprocaine	3	(0.6)	1	(0.2)	4	(0.4)
Tetracaine	1	(0.2)	1	(0.2)	2	(0.2)
Tetracaine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Antipsoriatics	**1**	**(0.2)**	**1**	**(0.2)**	**2**	**(0.2)**
Calcitriol	1	(0.2)	1	(0.2)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Dermatologicals						
Antiseptics And Disinfectants	**4**	**(0.8)**	**4**	**(0.8)**	**8**	**(0.8)**
Aluminium Acetate	0	(0.0)	1	(0.2)	1	(0.1)
Benzalkonium;Paraffin Nos;Triclosan	0	(0.0)	1	(0.2)	1	(0.1)
Boric Acid	1	(0.2)	0	(0.0)	1	(0.1)
Boric Acid;Sodium Borate	1	(0.2)	0	(0.0)	1	(0.1)
Chlorhexidine Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Eosine	1	(0.2)	0	(0.0)	1	(0.1)
Hydrogen Peroxide	1	(0.2)	0	(0.0)	1	(0.1)
Octenidine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroids, Dermatological Preparations	**103**	**(20.7)**	**112**	**(22.4)**	**215**	**(21.6)**
Beclometasone	5	(1.0)	5	(1.0)	10	(1.0)
Beclometasone Dipropionate	1	(0.2)	2	(0.4)	3	(0.3)
Betamethasone	6	(1.2)	3	(0.6)	9	(0.9)
Betamethasone Dipropionate	0	(0.0)	2	(0.4)	2	(0.2)
Betamethasone Valerate	0	(0.0)	2	(0.4)	2	(0.2)
Betamethasone Valerate;Fusidic Acid	2	(0.4)	0	(0.0)	2	(0.2)
Budesonide	31	(6.2)	22	(4.4)	53	(5.3)
Clobetasone	1	(0.2)	0	(0.0)	1	(0.1)
Clobetasone Butyrate	1	(0.2)	2	(0.4)	3	(0.3)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroids	1	(0.2)	0	(0.0)	1	(0.1)
Desonide	0	(0.0)	3	(0.6)	3	(0.3)
Dexamethasone	14	(2.8)	13	(2.6)	27	(2.7)
Dexamethasone Sodium Phosphate	2	(0.4)	3	(0.6)	5	(0.5)
Fluorometholone	2	(0.4)	1	(0.2)	3	(0.3)
Fluticasone	14	(2.8)	11	(2.2)	25	(2.5)
Fluticasone Propionate	16	(3.2)	15	(3.0)	31	(3.1)
Gentamicin Sulfate;Nystatin;Triamcinolone Acetonide	0	(0.0)	1	(0.2)	1	(0.1)
Gramicidin;Neomycin;Nystatin;Triamcinolone	3	(0.6)	5	(1.0)	8	(0.8)
Hydrocortisone	15	(3.0)	17	(3.4)	32	(3.2)
Hydrocortisone Acetate	3	(0.6)	2	(0.4)	5	(0.5)
Hydrocortisone Acetate;Urea	0	(0.0)	1	(0.2)	1	(0.1)
Hydrocortisone Butyrate	2	(0.4)	3	(0.6)	5	(0.5)
Hydrocortisone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Hydrocortisone;Natamycin;Neomycin	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Dermatologicals						
Corticosteroids, Dermatological Preparations	**103**	**(20.7)**	**112**	**(22.4)**	**215**	**(21.6)**
Methylprednisolone	5	(1.0)	7	(1.4)	12	(1.2)
Methylprednisolone Aceponate	1	(0.2)	1	(0.2)	2	(0.2)
Methylprednisolone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Mometasone Furoate	0	(0.0)	1	(0.2)	1	(0.1)
Prednisolone	15	(3.0)	18	(3.6)	33	(3.3)
Prednisolone Acetate	3	(0.6)	1	(0.2)	4	(0.4)
Prednisolone Sodium Phosphate	1	(0.2)	1	(0.2)	2	(0.2)
Prednisolone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Prednisolone Steaglate	0	(0.0)	1	(0.2)	1	(0.1)
Prednisolone Valeroacetate	0	(0.0)	2	(0.4)	2	(0.2)
Prednisone	8	(1.6)	9	(1.8)	17	(1.7)
Triamcinolone Acetonide	0	(0.0)	3	(0.6)	3	(0.3)
Emollients And Protectives	**59**	**(11.8)**	**87**	**(17.4)**	**146**	**(14.6)**
Avena Sativa	0	(0.0)	1	(0.2)	1	(0.1)
Benzyl Alcohol;Benzyl Benzoate;Benzyl Cinnamate;Wool Fat;Zinc Oxide	1	(0.2)	0	(0.0)	1	(0.1)
Boric Acid	1	(0.2)	0	(0.0)	1	(0.1)
Calamine;Dexpanthenol;Hyaluronic Acid;Zinc Oxide	0	(0.0)	1	(0.2)	1	(0.1)
Calendula Officinalis Flower;Matricaria Chamomilla Flower	1	(0.2)	0	(0.0)	1	(0.1)
Ceramide;Urea	0	(0.0)	1	(0.2)	1	(0.1)
Cetomacrogol;Glycerol	1	(0.2)	0	(0.0)	1	(0.1)
Copper Sulfate;Sucralfate;Zinc Oxide;Zinc Sulfate	0	(0.0)	1	(0.2)	1	(0.1)
Dimeticone	9	(1.8)	4	(0.8)	13	(1.3)
Emollients And Protectives	7	(1.4)	7	(1.4)	14	(1.4)
Emulsifying Wax;Paraffin, Liquid;White Soft Paraffin	2	(0.4)	0	(0.0)	2	(0.2)
Ergocalciferol;Retinol	0	(0.0)	1	(0.2)	1	(0.1)
Glycerol	9	(1.8)	16	(3.2)	25	(2.5)
Glycine Max Seed Oil	1	(0.2)	0	(0.0)	1	(0.1)
Heparinoid	2	(0.4)	0	(0.0)	2	(0.2)
Light Liquid Paraffin;White Soft Paraffin	1	(0.2)	0	(0.0)	1	(0.1)
Mineral Wax;Paraffin, Liquid;Petrolatum;Wool Alcohols	0	(0.0)	1	(0.2)	1	(0.1)
Mucopolysaccharide Polysulfuric Acid Ester	3	(0.6)	4	(0.8)	7	(0.7)
Olea Europaea Oil	1	(0.2)	1	(0.2)	2	(0.2)
Omega-6 Fatty Acids	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Dermatologicals						
Emollients And Protectives	**59**	**(11.8)**	**87**	**(17.4)**	**146**	**(14.6)**
Other Emollients And Protectives	1	(0.2)	2	(0.4)	3	(0.3)
Paraffin Nos	0	(0.0)	1	(0.2)	1	(0.1)
Paraffin Soft	1	(0.2)	2	(0.4)	3	(0.3)
Paraffin Soft;Paraffin, Liquid	1	(0.2)	0	(0.0)	1	(0.1)
Paraffin Soft;Paraffin, Liquid;Zinc Oxide	0	(0.0)	2	(0.4)	2	(0.2)
Paraffin, Liquid	1	(0.2)	2	(0.4)	3	(0.3)
Paraffin, Liquid;White Soft Paraffin	1	(0.2)	0	(0.0)	1	(0.1)
Retinol;Tocopherol;Vitamin D Nos	0	(0.0)	2	(0.4)	2	(0.2)
Retinol;Vitamin D Nos	1	(0.2)	1	(0.2)	2	(0.2)
Ricinus Communis Oil;Zinc Oxide	2	(0.4)	11	(2.2)	13	(1.3)
Ricinus Communis;Zinc	0	(0.0)	1	(0.2)	1	(0.1)
Soft Soap	0	(0.0)	2	(0.4)	2	(0.2)
Tocopheryl Acetate	0	(0.0)	1	(0.2)	1	(0.1)
Tocopheryl Acetate;Zinc Oxide	0	(0.0)	1	(0.2)	1	(0.1)
Vitamin E Nos	1	(0.2)	2	(0.4)	3	(0.3)
White Soft Paraffin	4	(0.8)	12	(2.4)	16	(1.6)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Zinc Oxide	7	(1.4)	16	(3.2)	23	(2.3)
Zinc Sulfate	3	(0.6)	10	(2.0)	13	(1.3)
Zinc Sulfate Heptahydrate	0	(0.0)	1	(0.2)	1	(0.1)
Medicated Dressings	**97**	**(19.5)**	**133**	**(26.7)**	**230**	**(23.1)**
Chlorhexidine Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Fusidic Acid	0	(0.0)	2	(0.4)	2	(0.2)
Paraffin Nos	0	(0.0)	1	(0.2)	1	(0.1)
Paraffin Soft	1	(0.2)	2	(0.4)	3	(0.3)
Sodium Alginate	1	(0.2)	0	(0.0)	1	(0.1)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Zinc Oxide	7	(1.4)	16	(3.2)	23	(2.3)
Other Dermatological Preparations	**170**	**(34.1)**	**181**	**(36.3)**	**351**	**(35.2)**
Acetylcysteine	4	(0.8)	3	(0.6)	7	(0.7)
Ascorbic Acid	26	(5.2)	13	(2.6)	39	(3.9)
Caffeine	4	(0.8)	4	(0.8)	8	(0.8)
Calcium Gluconate	3	(0.6)	6	(1.2)	9	(0.9)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Dermatologicals						
Other Dermatological Preparations	**170**	**(34.1)**	**181**	**(36.3)**	**351**	**(35.2)**
Cromoglicate Sodium	0	(0.0)	2	(0.4)	2	(0.2)
Dexpanthenol	0	(0.0)	2	(0.4)	2	(0.2)
Diclofenac	4	(0.8)	0	(0.0)	4	(0.4)
Diclofenac Sodium	2	(0.4)	3	(0.6)	5	(0.5)
Guaiazulene	1	(0.2)	1	(0.2)	2	(0.2)
Hyaluronate Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Hydrogen Peroxide	1	(0.2)	0	(0.0)	1	(0.1)
Ibuprofen	38	(7.6)	40	(8.0)	78	(7.8)
Lactoferrin	1	(0.2)	0	(0.0)	1	(0.1)
Magnesium Sulfate	2	(0.4)	2	(0.4)	4	(0.4)
Other Dermatologicals	1	(0.2)	2	(0.4)	3	(0.3)
Oxygen	77	(15.5)	80	(16.0)	157	(15.7)
Oxymetazoline	8	(1.6)	14	(2.8)	22	(2.2)
Oxymetazoline Hydrochloride	32	(6.4)	47	(9.4)	79	(7.9)
Phytomenadione	13	(2.6)	11	(2.2)	24	(2.4)
Pimecrolimus	1	(0.2)	1	(0.2)	2	(0.2)
Pyridoxine Hydrochloride	4	(0.8)	6	(1.2)	10	(1.0)
Retinol;Vitamin D Nos	1	(0.2)	1	(0.2)	2	(0.2)
Sodium Bicarbonate	3	(0.6)	6	(1.2)	9	(0.9)
Sucrose	4	(0.8)	8	(1.6)	12	(1.2)
Sulfacetamide	1	(0.2)	0	(0.0)	1	(0.1)
Sulfur	1	(0.2)	1	(0.2)	2	(0.2)
Talc	0	(0.0)	1	(0.2)	1	(0.1)
Tranexamic Acid	0	(0.0)	2	(0.4)	2	(0.2)
Ubidecarenone	1	(0.2)	0	(0.0)	1	(0.1)
Preparations For Treatment Of Wounds And Ulcers	**98**	**(19.7)**	**123**	**(24.6)**	**221**	**(22.2)**
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)
Dexpanthenol	0	(0.0)	2	(0.4)	2	(0.2)
Dimeticone	9	(1.8)	4	(0.8)	13	(1.3)
Hamamelis Virginiana Extract	0	(0.0)	1	(0.2)	1	(0.1)
Hyaluronate Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Matricaria Chamomilla	0	(0.0)	1	(0.2)	1	(0.1)
Menadione	2	(0.4)	1	(0.2)	3	(0.3)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Dermatologicals						
Preparations For Treatment Of Wounds And Ulcers	**98**	**(19.7)**	**123**	**(24.6)**	**221**	**(22.2)**
Tocopheryl Acetate	0	(0.0)	1	(0.2)	1	(0.1)
OTHER	**2**	**(0.4)**	**2**	**(0.4)**	**4**	**(0.4)**
Diosmectite	2	(0.4)	2	(0.4)	4	(0.4)
Genito Urinary System And Sex Hormones						
Gynecological Antiinfectives And Antiseptics	**70**	**(14.1)**	**73**	**(14.6)**	**143**	**(14.3)**
Amphotericin B	1	(0.2)	1	(0.2)	2	(0.2)
Antibiotics	2	(0.4)	0	(0.0)	2	(0.2)
Antifungals	0	(0.0)	1	(0.2)	1	(0.1)
Ascorbic Acid	26	(5.2)	13	(2.6)	39	(3.9)
Boric Acid	1	(0.2)	0	(0.0)	1	(0.1)
Chloramphenicol	6	(1.2)	10	(2.0)	16	(1.6)
Chlorhexidine Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Ciprofloxacin	2	(0.4)	4	(0.8)	6	(0.6)
Ciprofloxacin Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Clindamycin	2	(0.4)	1	(0.2)	3	(0.3)
Clotrimazole	10	(2.0)	18	(3.6)	28	(2.8)
Ketoconazole	1	(0.2)	0	(0.0)	1	(0.1)
Lactiplantibacillus Plantarum	2	(0.4)	0	(0.0)	2	(0.2)
Lactobacillus Acidophilus	3	(0.6)	2	(0.4)	5	(0.5)
Lactobacillus Nos	3	(0.6)	1	(0.2)	4	(0.4)
Lactobacillus Rhamnosus	1	(0.2)	3	(0.6)	4	(0.4)
Metronidazole	0	(0.0)	4	(0.8)	4	(0.4)
Miconazole	2	(0.4)	4	(0.8)	6	(0.6)
Nystatin	11	(2.2)	21	(4.2)	32	(3.2)
Ofloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Probiotics Nos	2	(0.4)	1	(0.2)	3	(0.3)
Other Gynecologicals	**130**	**(26.1)**	**146**	**(29.3)**	**276**	**(27.7)**
Benzydamine	0	(0.0)	1	(0.2)	1	(0.1)
Benzydamine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Bifidobacterium Bifidum;Lactobacillus Acidophilus	3	(0.6)	7	(1.4)	10	(1.0)
Carbomer	1	(0.2)	0	(0.0)	1	(0.1)
Clonidine	2	(0.4)	4	(0.8)	6	(0.6)
Clonidine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Genito Urinary System And Sex Hormones						
Other Gynecologicals	**130**	**(26.1)**	**146**	**(29.3)**	**276**	**(27.7)**
Fenoterol Hydrobromide	0	(0.0)	1	(0.2)	1	(0.1)
Glycerol	9	(1.8)	16	(3.2)	25	(2.5)
Hyaluronate Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Ibuprofen	38	(7.6)	40	(8.0)	78	(7.8)
Naproxen	1	(0.2)	0	(0.0)	1	(0.1)
Nifedipine	0	(0.0)	1	(0.2)	1	(0.1)
Salbutamol	75	(15.1)	74	(14.8)	149	(14.9)
Salbutamol Sulfate	9	(1.8)	18	(3.6)	27	(2.7)
Sildenafil	8	(1.6)	7	(1.4)	15	(1.5)
Sildenafil Citrate	1	(0.2)	1	(0.2)	2	(0.2)
Sodium Bicarbonate	3	(0.6)	6	(1.2)	9	(0.9)
Terbutaline	1	(0.2)	0	(0.0)	1	(0.1)
Terbutaline Sulfate	0	(0.0)	1	(0.2)	1	(0.1)
Sex Hormones And Modulators Of The Genital System	**1**	**(0.2)**	**1**	**(0.2)**	**2**	**(0.2)**
Glycine Max Seed Oil	1	(0.2)	0	(0.0)	1	(0.1)
Testosterone	0	(0.0)	1	(0.2)	1	(0.1)
Urologicals	**44**	**(8.8)**	**38**	**(7.6)**	**82**	**(8.2)**
Budesonide	31	(6.2)	22	(4.4)	53	(5.3)
Hyaluronate Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Magnesium Citrate;Potassium Citrate;Pyridoxine	0	(0.0)	1	(0.2)	1	(0.1)
Magnesium Hydroxide	0	(0.0)	2	(0.4)	2	(0.2)
Potassium Citrate	1	(0.2)	0	(0.0)	1	(0.1)
Sildenafil	8	(1.6)	7	(1.4)	15	(1.5)
Sildenafil Citrate	1	(0.2)	1	(0.2)	2	(0.2)
Sodium Bicarbonate	3	(0.6)	6	(1.2)	9	(0.9)
Sodium Phosphate	4	(0.8)	2	(0.4)	6	(0.6)
Sodium Phosphate Monobasic	3	(0.6)	1	(0.2)	4	(0.4)
Trometamol	0	(0.0)	1	(0.2)	1	(0.1)
Urapidil	0	(0.0)	1	(0.2)	1	(0.1)
Musculo-Skeletal System						
Antiinflammatory And Antirheumatic Products	**50**	**(10.0)**	**49**	**(9.8)**	**99**	**(9.9)**
Ademetionine	1	(0.2)	0	(0.0)	1	(0.1)
Benzydamine	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Musculo-Skeletal System						
Antiinflammatory And Antirheumatic Products	**50**	**(10.0)**	**49**	**(9.8)**	**99**	**(9.9)**
Benzydamine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Chlorphenamine Maleate;Ibuprofen	1	(0.2)	0	(0.0)	1	(0.1)
Diclofenac	4	(0.8)	0	(0.0)	4	(0.4)
Diclofenac Resinate	2	(0.4)	2	(0.4)	4	(0.4)
Diclofenac Sodium	2	(0.4)	3	(0.6)	5	(0.5)
Guaiazulene	1	(0.2)	1	(0.2)	2	(0.2)
Heparinoid	2	(0.4)	0	(0.0)	2	(0.2)
Ibuprofen	38	(7.6)	40	(8.0)	78	(7.8)
Ketorolac	0	(0.0)	1	(0.2)	1	(0.1)
Matricaria Chamomilla	0	(0.0)	1	(0.2)	1	(0.1)
Mefenamic Acid	0	(0.0)	1	(0.2)	1	(0.1)
Mucopolysaccharide Polysulfuric Acid Ester	3	(0.6)	4	(0.8)	7	(0.7)
Naproxen	1	(0.2)	0	(0.0)	1	(0.1)
Propionic Acid Derivatives	2	(0.4)	1	(0.2)	3	(0.3)
Drugs For Treatment Of Bone Diseases	**16**	**(3.2)**	**13**	**(2.6)**	**29**	**(2.9)**
Menatetrenone	9	(1.8)	10	(2.0)	19	(1.9)
Vitamin K Nos	7	(1.4)	3	(0.6)	10	(1.0)
Muscle Relaxants	**8**	**(1.6)**	**8**	**(1.6)**	**16**	**(1.6)**
Atracurium Besilate	1	(0.2)	0	(0.0)	1	(0.1)
Baclofen	0	(0.0)	1	(0.2)	1	(0.1)
Cisatracurium	1	(0.2)	2	(0.4)	3	(0.3)
Cisatracurium Besilate	1	(0.2)	0	(0.0)	1	(0.1)
Diazepam	3	(0.6)	3	(0.6)	6	(0.6)
Rocuronium	3	(0.6)	1	(0.2)	4	(0.4)
Rocuronium Bromide	2	(0.4)	1	(0.2)	3	(0.3)
Vecuronium	1	(0.2)	0	(0.0)	1	(0.1)
Vecuronium Bromide	0	(0.0)	1	(0.2)	1	(0.1)
Other Drugs For Disorders Of The Musculo-Skeletal System	**1**	**(0.2)**	**0**	**(0.0)**	**1**	**(0.1)**
Hyaluronate Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Topical Products For Joint And Muscular Pain	**161**	**(32.3)**	**148**	**(29.7)**	**309**	**(31.0)**
Acetylsalicylic Acid	11	(2.2)	11	(2.2)	22	(2.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Musculo-Skeletal System						
Topical Products For Joint And Muscular Pain	**161**	**(32.3)**	**148**	**(29.7)**	**309**	**(31.0)**
Amber (Fossilized Tree Resin);Camphor;Eucalyptus Globulus Oil;Menthol;Methyl Salicylate;Pinus Pinaster Oil;Syzygium Aromaticum Oil	1	(0.2)	0	(0.0)	1	(0.1)
Benzydamine	0	(0.0)	1	(0.2)	1	(0.1)
Benzydamine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Camphor;Eucalyptus Globulus Oil;Menthol	0	(0.0)	1	(0.2)	1	(0.1)
Diclofenac	4	(0.8)	0	(0.0)	4	(0.4)
Diclofenac Resinate	2	(0.4)	2	(0.4)	4	(0.4)
Diclofenac Sodium	2	(0.4)	3	(0.6)	5	(0.5)
Folic Acid	102	(20.5)	83	(16.6)	185	(18.6)
Heparinoid	2	(0.4)	0	(0.0)	2	(0.2)
Ibuprofen	38	(7.6)	40	(8.0)	78	(7.8)
Ketorolac	0	(0.0)	1	(0.2)	1	(0.1)
Lavandula Angustifolia Oil	0	(0.0)	1	(0.2)	1	(0.1)
Magnesium Chloride	1	(0.2)	0	(0.0)	1	(0.1)
Mucopolysaccharide Polysulfuric Acid Ester	3	(0.6)	4	(0.8)	7	(0.7)
Naproxen	1	(0.2)	0	(0.0)	1	(0.1)
Prednisolone	15	(3.0)	18	(3.6)	33	(3.3)
Nervous System						
Analgesics	**174**	**(34.9)**	**233**	**(46.7)**	**407**	**(40.8)**
Acetylsalicylic Acid	11	(2.2)	11	(2.2)	22	(2.2)
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)
Aminophenazone	0	(0.0)	1	(0.2)	1	(0.1)
Aminophenazone;Phenobarbital	0	(0.0)	2	(0.4)	2	(0.2)
Anilides	1	(0.2)	0	(0.0)	1	(0.1)
Caffeine;Chlorphenamine Maleate;Paracetamol;Phenylpropanolamine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Carbamazepine	1	(0.2)	0	(0.0)	1	(0.1)
Chlorphenamine;Paracetamol	1	(0.2)	0	(0.0)	1	(0.1)
Clonidine	2	(0.4)	4	(0.8)	6	(0.6)
Clonidine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Codeine Phosphate;Ibuprofen	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Nervous System						
Analgesics	**174**	**(34.9)**	**233**	**(46.7)**	**407**	**(40.8)**
Fentanyl	5	(1.0)	6	(1.2)	11	(1.1)
Fentanyl Citrate	1	(0.2)	1	(0.2)	2	(0.2)
Glucose;Morphine	0	(0.0)	1	(0.2)	1	(0.1)
Guaifenesin;Paracetamol;Phenylephrine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Ibuprofen;Paracetamol	1	(0.2)	2	(0.4)	3	(0.3)
Metamizole	5	(1.0)	9	(1.8)	14	(1.4)
Metamizole Magnesium	0	(0.0)	1	(0.2)	1	(0.1)
Metamizole Sodium	12	(2.4)	9	(1.8)	21	(2.1)
Metamizole Sodium Monohydrate	0	(0.0)	1	(0.2)	1	(0.1)
Methadone	1	(0.2)	0	(0.0)	1	(0.1)
Metoprolol	3	(0.6)	3	(0.6)	6	(0.6)
Metoprolol Tartrate	1	(0.2)	1	(0.2)	2	(0.2)
Morphine	6	(1.2)	6	(1.2)	12	(1.2)
Morphine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Nalbuphine	0	(0.0)	1	(0.2)	1	(0.1)
Nalbuphine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Paracetamol	151	(30.3)	209	(41.9)	360	(36.1)
Phenytoin	0	(0.0)	1	(0.2)	1	(0.1)
Phenytoin Sodium	1	(0.2)	1	(0.2)	2	(0.2)
Piritramide	1	(0.2)	2	(0.4)	3	(0.3)
Platycodon Grandiflorus	1	(0.2)	1	(0.2)	2	(0.2)
Propranolol	9	(1.8)	6	(1.2)	15	(1.5)
Propranolol Hydrochloride	3	(0.6)	4	(0.8)	7	(0.7)
Sufentanil	0	(0.0)	2	(0.4)	2	(0.2)
Timolol	2	(0.4)	3	(0.6)	5	(0.5)
Timolol Maleate	2	(0.4)	3	(0.6)	5	(0.5)
Tramadol	0	(0.0)	1	(0.2)	1	(0.1)
Valproic Acid	0	(0.0)	1	(0.2)	1	(0.1)
Anesthetics	**16**	**(3.2)**	**16**	**(3.2)**	**32**	**(3.2)**
Benzocaine	1	(0.2)	0	(0.0)	1	(0.1)
Benzocaine;Cetylpyridinium Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Bupivacaine	1	(0.2)	1	(0.2)	2	(0.2)
Chlorhexidine;Lidocaine	1	(0.2)	0	(0.0)	1	(0.1)
Fentanyl	5	(1.0)	6	(1.2)	11	(1.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Nervous System						
Anesthetics	**16**	**(3.2)**	**16**	**(3.2)**	**32**	**(3.2)**
Fentanyl Citrate	1	(0.2)	1	(0.2)	2	(0.2)
Ketamine	3	(0.6)	2	(0.4)	5	(0.5)
Ketamine Hydrochloride	0	(0.0)	2	(0.4)	2	(0.2)
Levobupivacaine	1	(0.2)	0	(0.0)	1	(0.1)
Lidocaine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Lidocaine;Prilocaine	1	(0.2)	1	(0.2)	2	(0.2)
Oxybuprocaine	3	(0.6)	1	(0.2)	4	(0.4)
Propofol	1	(0.2)	6	(1.2)	7	(0.7)
Remifentanil	0	(0.0)	2	(0.4)	2	(0.2)
Ropivacaine Hydrochloride	0	(0.0)	2	(0.4)	2	(0.2)
Sevoflurane	0	(0.0)	2	(0.4)	2	(0.2)
Sufentanil	0	(0.0)	2	(0.4)	2	(0.2)
Syzygium Aromaticum	1	(0.2)	0	(0.0)	1	(0.1)
Tetracaine	1	(0.2)	1	(0.2)	2	(0.2)
Tetracaine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Anti-Parkinson Drugs	**2**	**(0.4)**	**2**	**(0.4)**	**4**	**(0.4)**
Amantadine	1	(0.2)	1	(0.2)	2	(0.2)
Diphenhydramine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Hydrogen Peroxide	1	(0.2)	0	(0.0)	1	(0.1)
Antiepileptics	**17**	**(3.4)**	**21**	**(4.2)**	**38**	**(3.8)**
Acetazolamide	0	(0.0)	1	(0.2)	1	(0.1)
Carbamazepine	1	(0.2)	0	(0.0)	1	(0.1)
Diazepam	3	(0.6)	3	(0.6)	6	(0.6)
Levetiracetam	5	(1.0)	6	(1.2)	11	(1.1)
Lorazepam	1	(0.2)	2	(0.4)	3	(0.3)
Magnesium Sulfate	2	(0.4)	2	(0.4)	4	(0.4)
Midazolam	6	(1.2)	5	(1.0)	11	(1.1)
Midazolam Hydrochloride	0	(0.0)	2	(0.4)	2	(0.2)
Phenobarbital	3	(0.6)	7	(1.4)	10	(1.0)
Phenytoin	0	(0.0)	1	(0.2)	1	(0.1)
Phenytoin Sodium	1	(0.2)	1	(0.2)	2	(0.2)
Valproic Acid	0	(0.0)	1	(0.2)	1	(0.1)
Other Nervous System Drugs	**16**	**(3.2)**	**15**	**(3.0)**	**31**	**(3.1)**
Baclofen	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Nervous System						
Other Nervous System Drugs	**16**	**(3.2)**	**15**	**(3.0)**	**31**	**(3.1)**
Clonidine	2	(0.4)	4	(0.8)	6	(0.6)
Clonidine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Diphenhydramine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Meclozine Hydrochloride;Pyridoxine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Methadone	1	(0.2)	0	(0.0)	1	(0.1)
Naloxone	1	(0.2)	1	(0.2)	2	(0.2)
Propranolol	9	(1.8)	6	(1.2)	15	(1.5)
Propranolol Hydrochloride	3	(0.6)	4	(0.8)	7	(0.7)
Psychoanaleptics	**8**	**(1.6)**	**12**	**(2.4)**	**20**	**(2.0)**
Ademetionine	1	(0.2)	0	(0.0)	1	(0.1)
Avena Sativa	0	(0.0)	1	(0.2)	1	(0.1)
Caffeine	4	(0.8)	4	(0.8)	8	(0.8)
Caffeine Citrate	1	(0.2)	3	(0.6)	4	(0.4)
Clonidine	2	(0.4)	4	(0.8)	6	(0.6)
Clonidine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Psycholeptics	**38**	**(7.6)**	**56**	**(11.2)**	**94**	**(9.4)**
Aloe Vera;Cocos Nucifera Oil;Eucalyptus Spp.;Lavandula Angustifolia;Salvia Rosmarinus	10	(2.0)	19	(3.8)	29	(2.9)
Aloe Vera;Eucalyptus Globulus Oil;Lavandula Spp. Oil;Salvia Rosmarinus Oil	0	(0.0)	1	(0.2)	1	(0.1)
Calendula Officinalis Flower;Matricaria Chamomilla Flower	1	(0.2)	0	(0.0)	1	(0.1)
Carbamazepine	1	(0.2)	0	(0.0)	1	(0.1)
Chloral Hydrate	6	(1.2)	9	(1.8)	15	(1.5)
Dexmedetomidine	2	(0.4)	2	(0.4)	4	(0.4)
Dexmedetomidine Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Diazepam	3	(0.6)	3	(0.6)	6	(0.6)
Diphenhydramine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Hydroxyzine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Lavandula Angustifolia Oil	0	(0.0)	1	(0.2)	1	(0.1)
Levomepromazine	0	(0.0)	2	(0.4)	2	(0.2)
Lorazepam	1	(0.2)	2	(0.4)	3	(0.3)
Matricaria Chamomilla	0	(0.0)	1	(0.2)	1	(0.1)
Melatonin	0	(0.0)	3	(0.6)	3	(0.3)
Midazolam	6	(1.2)	5	(1.0)	11	(1.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Nervous System						
Psycholeptics	**38**	**(7.6)**	**56**	**(11.2)**	**94**	**(9.4)**
Midazolam Hydrochloride	0	(0.0)	2	(0.4)	2	(0.2)
Phenobarbital	3	(0.6)	7	(1.4)	10	(1.0)
Platycodon Grandiflorus	1	(0.2)	1	(0.2)	2	(0.2)
Propranolol	9	(1.8)	6	(1.2)	15	(1.5)
Propranolol Hydrochloride	3	(0.6)	4	(0.8)	7	(0.7)
Quetiapine	0	(0.0)	1	(0.2)	1	(0.1)
Triclofos Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Valproic Acid	0	(0.0)	1	(0.2)	1	(0.1)
Respiratory System						
Antihistamines For Systemic Use	**42**	**(8.4)**	**46**	**(9.2)**	**88**	**(8.8)**
Bisulepin Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Cetirizine	5	(1.0)	7	(1.4)	12	(1.2)
Cetirizine Hydrochloride	4	(0.8)	2	(0.4)	6	(0.6)
Chlorphenamine	3	(0.6)	6	(1.2)	9	(0.9)
Chlorphenamine Maleate	3	(0.6)	0	(0.0)	3	(0.3)
Cyproheptadine	3	(0.6)	2	(0.4)	5	(0.5)
Cyproheptadine Hydrochloride	1	(0.2)	4	(0.8)	5	(0.5)
Desloratadine	7	(1.4)	2	(0.4)	9	(0.9)
Dimetindene	0	(0.0)	1	(0.2)	1	(0.1)
Dimetindene Maleate	2	(0.4)	4	(0.8)	6	(0.6)
Diphenhydramine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Emedastine Fumarate	0	(0.0)	1	(0.2)	1	(0.1)
Fexofenadine	3	(0.6)	1	(0.2)	4	(0.4)
Fexofenadine Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Hydroxyzine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Ketotifen	1	(0.2)	0	(0.0)	1	(0.1)
Levocetirizine	4	(0.8)	2	(0.4)	6	(0.6)
Loratadine	8	(1.6)	10	(2.0)	18	(1.8)
Meclozine Hydrochloride;Pyridoxine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Triprolidine Hydrochloride	0	(0.0)	2	(0.4)	2	(0.2)
Cough And Cold Preparations	**130**	**(26.1)**	**171**	**(34.3)**	**301**	**(30.2)**
Acetylcysteine	4	(0.8)	3	(0.6)	7	(0.7)
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Respiratory System						
Cough And Cold Preparations	**130**	**(26.1)**	**171**	**(34.3)**	**301**	**(30.2)**
Agave Tequilana;Zinc Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Amber (Fossilized Tree Resin);Camphor;Eucalyptus Globulus Oil;Menthol;Methyl Salicylate;Pinus Pinaster Oil;Syzygium Aromaticum Oil	1	(0.2)	0	(0.0)	1	(0.1)
Ambroxol	12	(2.4)	13	(2.6)	25	(2.5)
Ambroxol Hydrochloride	4	(0.8)	4	(0.8)	8	(0.8)
Ambroxol;Dextromethorphan	1	(0.2)	0	(0.0)	1	(0.1)
Ambroxol;Loratadine	0	(0.0)	1	(0.2)	1	(0.1)
Ambroxol;Salbutamol	3	(0.6)	3	(0.6)	6	(0.6)
Bromhexine	2	(0.4)	4	(0.8)	6	(0.6)
Bromhexine Hydrochloride	0	(0.0)	4	(0.8)	4	(0.4)
Bromhexine Hydrochloride;Orciprenaline Sulfate	16	(3.2)	20	(4.0)	36	(3.6)
Butamirate	0	(0.0)	1	(0.2)	1	(0.1)
Butamirate Citrate	1	(0.2)	3	(0.6)	4	(0.4)
Butamirate Citrate;Guaifenesin	0	(0.0)	2	(0.4)	2	(0.2)
Camphor;Eucalyptus Globulus Oil;Juniperus Virginiana Wood Oil;Menthol;Myristica Fragrans Oil;Pinus Nigra Oil;Thymol	3	(0.6)	7	(1.4)	10	(1.0)
Camphor;Eucalyptus Globulus Oil;Menthol	0	(0.0)	1	(0.2)	1	(0.1)
Carbocisteine	5	(1.0)	9	(1.8)	14	(1.4)
Carbocisteine Lysine	1	(0.2)	0	(0.0)	1	(0.1)
Chlorphenamine Maleate;Dextromethorphan;Phenylephrine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Chlorphenamine Maleate;Glycyrrhizic Acid;Platycodon Grandiflorus;Polygala Spp.	1	(0.2)	0	(0.0)	1	(0.1)
Chlorphenamine Maleate;Guaifenesin;Methylephedrine Hydrochloride-Dl	2	(0.4)	5	(1.0)	7	(0.7)
Cineole;Guaifenesin;Pentoxyverine;Terpin;Terpineol	0	(0.0)	1	(0.2)	1	(0.1)
Codeine Phosphate;Drimia Maritima;Euphorbia Hirta;Guarea Guidonia;Senega Officinalis	1	(0.2)	0	(0.0)	1	(0.1)
Cough And Cold Preparations	1	(0.2)	1	(0.2)	2	(0.2)
Dextromethorphan Hydrobromide	0	(0.0)	1	(0.2)	1	(0.1)
Dextromethorphan;Guaifenesin;Phenylephrine	0	(0.0)	1	(0.2)	1	(0.1)
Dornase Alfa	1	(0.2)	1	(0.2)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Respiratory System						
Cough And Cold Preparations	**130**	**(26.1)**	**171**	**(34.3)**	**301**	**(30.2)**
Electrolytes Nos	2	(0.4)	2	(0.4)	4	(0.4)
Emser Salt	1	(0.2)	0	(0.0)	1	(0.1)
Erdosteine	1	(0.2)	0	(0.0)	1	(0.1)
Foeniculum Vulgare	1	(0.2)	0	(0.0)	1	(0.1)
Gelsemium Sempervirens Extract;Grindelia Hirsutula;Melaleuca Viridiflora Oil	1	(0.2)	0	(0.0)	1	(0.1)
Glycerol	9	(1.8)	16	(3.2)	25	(2.5)
Guaifenesin	2	(0.4)	6	(1.2)	8	(0.8)
Hedera Helix	4	(0.8)	0	(0.0)	4	(0.4)
Hedera Helix Leaf	1	(0.2)	2	(0.4)	3	(0.3)
Hedera Helix Leaf Extract	1	(0.2)	0	(0.0)	1	(0.1)
Hyaluronate Sodium;Sodium Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Levodropropizine	0	(0.0)	1	(0.2)	1	(0.1)
Mannitol	1	(0.2)	1	(0.2)	2	(0.2)
Pholcodine	1	(0.2)	0	(0.0)	1	(0.1)
Platycodon Grandiflorus	1	(0.2)	1	(0.2)	2	(0.2)
Sobrerol	1	(0.2)	2	(0.4)	3	(0.3)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Zinc Gluconate	0	(0.0)	2	(0.4)	2	(0.2)
Drugs For Obstructive Airway Diseases	**120**	**(24.1)**	**132**	**(26.5)**	**252**	**(25.3)**
Ambroxol Hydrochloride;Clenbuterol Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Ambroxol Hydrochloride;Theophylline	0	(0.0)	1	(0.2)	1	(0.1)
Ambroxol;Salbutamol	3	(0.6)	3	(0.6)	6	(0.6)
Ambroxol;Theophylline	0	(0.0)	1	(0.2)	1	(0.1)
Aminophenazone;Buphenine Hydrochloride;Diphenylpyraline Hydrochloride	2	(0.4)	1	(0.2)	3	(0.3)
Aminophenazone;Buphenine;Diphenylpyraline	6	(1.2)	2	(0.4)	8	(0.8)
Beclometasone	5	(1.0)	5	(1.0)	10	(1.0)
Beclometasone Dipropionate	1	(0.2)	2	(0.4)	3	(0.3)
Betamethasone	6	(1.2)	3	(0.6)	9	(0.9)
Betamethasone Dipropionate	0	(0.0)	2	(0.4)	2	(0.2)
Betamethasone Valerate	0	(0.0)	2	(0.4)	2	(0.2)
Budesonide	31	(6.2)	22	(4.4)	53	(5.3)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Respiratory System						
Drugs For Obstructive Airway Diseases	**120**	**(24.1)**	**132**	**(26.5)**	**252**	**(25.3)**
Budesonide;Formoterol	0	(0.0)	1	(0.2)	1	(0.1)
Budesonide;Formoterol Fumarate	1	(0.2)	0	(0.0)	1	(0.1)
Choline Theophyllinate	1	(0.2)	0	(0.0)	1	(0.1)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)
Cromoglicate Sodium	0	(0.0)	2	(0.4)	2	(0.2)
Dexamethasone	14	(2.8)	13	(2.6)	27	(2.7)
Dexamethasone Sodium Phosphate	2	(0.4)	3	(0.6)	5	(0.5)
Epinephrine	15	(3.0)	17	(3.4)	32	(3.2)
Epinephrine Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Fenoterol Hydrobromide	0	(0.0)	1	(0.2)	1	(0.1)
Fenoterol Hydrobromide;Ipratropium Bromide	2	(0.4)	2	(0.4)	4	(0.4)
Fenoterol;Ipratropium Bromide	1	(0.2)	0	(0.0)	1	(0.1)
Fluticasone	14	(2.8)	11	(2.2)	25	(2.5)
Fluticasone Furoate	1	(0.2)	0	(0.0)	1	(0.1)
Fluticasone Propionate	16	(3.2)	15	(3.0)	31	(3.1)
Fluticasone Propionate;Salmeterol Xinafoate	1	(0.2)	1	(0.2)	2	(0.2)
Fluticasone;Salmeterol	2	(0.4)	0	(0.0)	2	(0.2)
Formoterol	0	(0.0)	1	(0.2)	1	(0.1)
Ipratropium	1	(0.2)	0	(0.0)	1	(0.1)
Ipratropium Bromide	19	(3.8)	20	(4.0)	39	(3.9)
Ipratropium Bromide;Salbutamol	4	(0.8)	2	(0.4)	6	(0.6)
Ipratropium Bromide;Salbutamol Sulfate	2	(0.4)	2	(0.4)	4	(0.4)
Mometasone Furoate	0	(0.0)	1	(0.2)	1	(0.1)
Montelukast	1	(0.2)	7	(1.4)	8	(0.8)
Montelukast Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Pranlukast	1	(0.2)	3	(0.6)	4	(0.4)
Procaterol	1	(0.2)	2	(0.4)	3	(0.3)
Procaterol Hydrochloride	3	(0.6)	6	(1.2)	9	(0.9)
Racepinefrine	1	(0.2)	0	(0.0)	1	(0.1)
Salbutamol	75	(15.1)	74	(14.8)	149	(14.9)
Salbutamol Sulfate	9	(1.8)	18	(3.6)	27	(2.7)
Salmeterol	0	(0.0)	2	(0.4)	2	(0.2)
Terbutaline	1	(0.2)	0	(0.0)	1	(0.1)
Terbutaline Sulfate	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Respiratory System						
Drugs For Obstructive Airway Diseases	**120**	**(24.1)**	**132**	**(26.5)**	**252**	**(25.3)**
Theophylline	1	(0.2)	1	(0.2)	2	(0.2)
Triamcinolone Acetonide	0	(0.0)	3	(0.6)	3	(0.3)
Tulobuterol	0	(0.0)	2	(0.4)	2	(0.2)
Nasal Preparations	**184**	**(36.9)**	**214**	**(42.9)**	**398**	**(39.9)**
Acetylcysteine	4	(0.8)	3	(0.6)	7	(0.7)
Beclometasone	5	(1.0)	5	(1.0)	10	(1.0)
Beclometasone Dipropionate	1	(0.2)	2	(0.4)	3	(0.3)
Betamethasone	6	(1.2)	3	(0.6)	9	(0.9)
Betamethasone Dipropionate	0	(0.0)	2	(0.4)	2	(0.2)
Betamethasone Valerate	0	(0.0)	2	(0.4)	2	(0.2)
Budesonide	31	(6.2)	22	(4.4)	53	(5.3)
Chlorphenamine Maleate;Phenylephrine Hydrochloride;Phenylpropanolamine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroids	1	(0.2)	0	(0.0)	1	(0.1)
Cromoglicate Sodium	0	(0.0)	2	(0.4)	2	(0.2)
Dexamethasone	14	(2.8)	13	(2.6)	27	(2.7)
Dexamethasone Sodium Phosphate	2	(0.4)	3	(0.6)	5	(0.5)
Dexpanthenol	0	(0.0)	2	(0.4)	2	(0.2)
Emser Salt	1	(0.2)	0	(0.0)	1	(0.1)
Epinephrine	15	(3.0)	17	(3.4)	32	(3.2)
Epinephrine Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Fluticasone	14	(2.8)	11	(2.2)	25	(2.5)
Fluticasone Furoate	1	(0.2)	0	(0.0)	1	(0.1)
Fluticasone Propionate	16	(3.2)	15	(3.0)	31	(3.1)
Hyaluronate Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Hyaluronate Sodium;Sodium Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Hypromellose	0	(0.0)	1	(0.2)	1	(0.1)
Ipratropium	1	(0.2)	0	(0.0)	1	(0.1)
Ipratropium Bromide	19	(3.8)	20	(4.0)	39	(3.9)
Ketotifen	1	(0.2)	0	(0.0)	1	(0.1)
Loratadine;Phenylephrine	1	(0.2)	1	(0.2)	2	(0.2)
Matricaria Chamomilla	0	(0.0)	1	(0.2)	1	(0.1)
Mometasone Furoate	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Respiratory System						
Nasal Preparations	**184**	**(36.9)**	**214**	**(42.9)**	**398**	**(39.9)**
Mupirocin	4	(0.8)	5	(1.0)	9	(0.9)
Octenidine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Oxymetazoline	8	(1.6)	14	(2.8)	22	(2.2)
Oxymetazoline Hydrochloride	32	(6.4)	47	(9.4)	79	(7.9)
Phenylephrine	3	(0.6)	4	(0.8)	7	(0.7)
Phenylephrine Hydrochloride	1	(0.2)	1	(0.2)	2	(0.2)
Potassium Chloride;Sodium Chloride	1	(0.2)	0	(0.0)	1	(0.1)
Prednisolone	15	(3.0)	18	(3.6)	33	(3.3)
Prednisolone Acetate	3	(0.6)	1	(0.2)	4	(0.4)
Pseudoephedrine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Retinol	2	(0.4)	2	(0.4)	4	(0.4)
Ribavirin	1	(0.2)	0	(0.0)	1	(0.1)
Sea Water	20	(4.0)	13	(2.6)	33	(3.3)
Sodium Bicarbonate	3	(0.6)	6	(1.2)	9	(0.9)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Triamcinolone Acetonide	0	(0.0)	3	(0.6)	3	(0.3)
Xylometazoline Hydrochloride	2	(0.4)	5	(1.0)	7	(0.7)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Zinc Gluconate	0	(0.0)	2	(0.4)	2	(0.2)
Other Respiratory System Products	**28**	**(5.6)**	**30**	**(6.0)**	**58**	**(5.8)**
Acetazolamide	0	(0.0)	1	(0.2)	1	(0.1)
Ambroxol	12	(2.4)	13	(2.6)	25	(2.5)
Ambroxol Hydrochloride	4	(0.8)	4	(0.8)	8	(0.8)
Beractant	0	(0.0)	1	(0.2)	1	(0.1)
Caffeine	4	(0.8)	4	(0.8)	8	(0.8)
Caffeine Citrate	1	(0.2)	3	(0.6)	4	(0.4)
Dimeticone	9	(1.8)	4	(0.8)	13	(1.3)
Throat Preparations	**56**	**(11.2)**	**62**	**(12.4)**	**118**	**(11.8)**
Ambroxol	12	(2.4)	13	(2.6)	25	(2.5)
Ambroxol Hydrochloride	4	(0.8)	4	(0.8)	8	(0.8)
Antibiotics	2	(0.4)	0	(0.0)	2	(0.2)
Bacitracin	0	(0.0)	1	(0.2)	1	(0.1)
Benzocaine	1	(0.2)	0	(0.0)	1	(0.1)
Benzocaine;Cetylpyridinium Chloride	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Respiratory System						
Throat Preparations	**56**	**(11.2)**	**62**	**(12.4)**	**118**	**(11.8)**
Benzydamine	0	(0.0)	1	(0.2)	1	(0.1)
Benzydamine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Chlorhexidine Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Chlorhexidine;Lidocaine	1	(0.2)	0	(0.0)	1	(0.1)
Diclofenac	4	(0.8)	0	(0.0)	4	(0.4)
Diclofenac Sodium	2	(0.4)	3	(0.6)	5	(0.5)
Emser Salt	1	(0.2)	0	(0.0)	1	(0.1)
Ibuprofen	38	(7.6)	40	(8.0)	78	(7.8)
Lidocaine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Neomycin Sulfate	0	(0.0)	2	(0.4)	2	(0.2)
Neomycin Sulfate;Tyrothricin	0	(0.0)	1	(0.2)	1	(0.1)
Octenidine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Tetracaine	1	(0.2)	1	(0.2)	2	(0.2)
Tetracaine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Tranexamic Acid	0	(0.0)	2	(0.4)	2	(0.2)
Sensory Organs						
Ophthalmological And Otological Preparations	**53**	**(10.6)**	**67**	**(13.4)**	**120**	**(12.0)**
Betamethasone	6	(1.2)	3	(0.6)	9	(0.9)
Chloramphenicol	6	(1.2)	10	(2.0)	16	(1.6)
Chlorhexidine Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Ciprofloxacin	2	(0.4)	4	(0.8)	6	(0.6)
Ciprofloxacin Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroids	1	(0.2)	0	(0.0)	1	(0.1)
Dexamethasone	14	(2.8)	13	(2.6)	27	(2.7)
Dexamethasone Sodium Phosphate	2	(0.4)	3	(0.6)	5	(0.5)
Dexamethasone Sodium Phosphate;Moxifloxacin Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Dexamethasone;Tobramycin	2	(0.4)	1	(0.2)	3	(0.3)
Gentamicin	5	(1.0)	12	(2.4)	17	(1.7)
Levofloxacin	3	(0.6)	2	(0.4)	5	(0.5)
Moxifloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Moxifloxacin Hydrochloride	2	(0.4)	0	(0.0)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Sensory Organs						
Ophthalmological And Otological Preparations	**53**	**(10.6)**	**67**	**(13.4)**	**120**	**(12.0)**
Neomycin Sulfate	0	(0.0)	2	(0.4)	2	(0.2)
Ofloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Prednisolone	15	(3.0)	18	(3.6)	33	(3.3)
Prednisolone Acetate	3	(0.6)	1	(0.2)	4	(0.4)
Prednisolone Sodium Phosphate	1	(0.2)	1	(0.2)	2	(0.2)
Prednisolone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Prednisolone Steaglate	0	(0.0)	1	(0.2)	1	(0.1)
Prednisolone Valeroacetate	0	(0.0)	2	(0.4)	2	(0.2)
Ophthalmologicals	**233**	**(46.8)**	**260**	**(52.1)**	**493**	**(49.4)**
Acetazolamide	0	(0.0)	1	(0.2)	1	(0.1)
Acetylcysteine	4	(0.8)	3	(0.6)	7	(0.7)
Aciclovir	1	(0.2)	1	(0.2)	2	(0.2)
Adenosine	0	(0.0)	1	(0.2)	1	(0.1)
Albumin Human	1	(0.2)	2	(0.4)	3	(0.3)
Alkonium Bromide;Boric Acid;Sodium Borate Decahydrate	1	(0.2)	0	(0.0)	1	(0.1)
Alkonium Bromide;Boric Acid;Sodium Borate;Sodium Edetate	0	(0.0)	1	(0.2)	1	(0.1)
Alteplase	1	(0.2)	1	(0.2)	2	(0.2)
Amikacin	6	(1.2)	10	(2.0)	16	(1.6)
Amikacin Sulfate	0	(0.0)	1	(0.2)	1	(0.1)
Amino Acids Nos	0	(0.0)	1	(0.2)	1	(0.1)
Amphotericin B	1	(0.2)	1	(0.2)	2	(0.2)
Ampicillin	17	(3.4)	17	(3.4)	34	(3.4)
Ampicillin Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Antibiotics	2	(0.4)	0	(0.0)	2	(0.2)
Ascorbic Acid	26	(5.2)	13	(2.6)	39	(3.9)
Azithromycin	18	(3.6)	25	(5.0)	43	(4.3)
Azithromycin Dihydrate	2	(0.4)	1	(0.2)	3	(0.3)
Bacitracin	0	(0.0)	1	(0.2)	1	(0.1)
Benzylpenicillin	1	(0.2)	1	(0.2)	2	(0.2)
Benzylpenicillin Sodium	0	(0.0)	1	(0.2)	1	(0.1)
Betamethasone	6	(1.2)	3	(0.6)	9	(0.9)
Betamethasone Dipropionate	0	(0.0)	2	(0.4)	2	(0.2)
Betamethasone Valerate	0	(0.0)	2	(0.4)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Sensory Organs						
Ophthalmologicals	**233**	**(46.8)**	**260**	**(52.1)**	**493**	**(49.4)**
Boric Acid	1	(0.2)	0	(0.0)	1	(0.1)
Boric Acid;Sodium Borate	1	(0.2)	0	(0.0)	1	(0.1)
Bupivacaine	1	(0.2)	1	(0.2)	2	(0.2)
Carbomer	1	(0.2)	0	(0.0)	1	(0.1)
Cefazolin	2	(0.4)	5	(1.0)	7	(0.7)
Cefuroxime	1	(0.2)	2	(0.4)	3	(0.3)
Cefuroxime Sodium	0	(0.0)	1	(0.2)	1	(0.1)
Cetirizine	5	(1.0)	7	(1.4)	12	(1.2)
Cetirizine Hydrochloride	4	(0.8)	2	(0.4)	6	(0.6)
Chloramphenicol	6	(1.2)	10	(2.0)	16	(1.6)
Chlorhexidine Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Ciprofloxacin	2	(0.4)	4	(0.8)	6	(0.6)
Ciprofloxacin Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Clindamycin	2	(0.4)	1	(0.2)	3	(0.3)
Clobetasone	1	(0.2)	0	(0.0)	1	(0.1)
Clobetasone Butyrate	1	(0.2)	2	(0.4)	3	(0.3)
Clonidine	2	(0.4)	4	(0.8)	6	(0.6)
Clonidine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Clotrimazole	10	(2.0)	18	(3.6)	28	(2.8)
Colistimethate Sodium;Erythromycin Lactobionate	0	(0.0)	1	(0.2)	1	(0.1)
Colistin	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroids	1	(0.2)	0	(0.0)	1	(0.1)
Cromoglicate Sodium	0	(0.0)	2	(0.4)	2	(0.2)
Cyclopentolate	3	(0.6)	2	(0.4)	5	(0.5)
Cyclopentolate Hydrochloride;Phenylephrine Hydrochloride	3	(0.6)	2	(0.4)	5	(0.5)
Desloratadine	7	(1.4)	2	(0.4)	9	(0.9)
Desonide	0	(0.0)	3	(0.6)	3	(0.3)
Dexamethasone	14	(2.8)	13	(2.6)	27	(2.7)
Dexamethasone Sodium Phosphate	2	(0.4)	3	(0.6)	5	(0.5)
Dexamethasone Sodium Phosphate;Moxifloxacin Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Dexamethasone;Tobramycin	2	(0.4)	1	(0.2)	3	(0.3)
Dexpanthenol	0	(0.0)	2	(0.4)	2	(0.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Sensory Organs						
Ophthalmologicals	**233**	**(46.8)**	**260**	**(52.1)**	**493**	**(49.4)**
Dextran 70;Hypromellose	2	(0.4)	0	(0.0)	2	(0.2)
Dibekacin Sulfate	1	(0.2)	0	(0.0)	1	(0.1)
Diclofenac	4	(0.8)	0	(0.0)	4	(0.4)
Diclofenac Resinate	2	(0.4)	2	(0.4)	4	(0.4)
Diclofenac Sodium	2	(0.4)	3	(0.6)	5	(0.5)
Dimeticone	9	(1.8)	4	(0.8)	13	(1.3)
Diphenhydramine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Emedastine Fumarate	0	(0.0)	1	(0.2)	1	(0.1)
Epinephrine	15	(3.0)	17	(3.4)	32	(3.2)
Epinephrine Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Erythromycin	1	(0.2)	2	(0.4)	3	(0.3)
Fluconazole	1	(0.2)	4	(0.8)	5	(0.5)
Fluorescein	0	(0.0)	1	(0.2)	1	(0.1)
Fluorometholone	2	(0.4)	1	(0.2)	3	(0.3)
Fusidic Acid	0	(0.0)	2	(0.4)	2	(0.2)
Ganciclovir	1	(0.2)	1	(0.2)	2	(0.2)
Gentamicin	5	(1.0)	12	(2.4)	17	(1.7)
Glucose;Potassium Chloride;Sodium Chloride	2	(0.4)	5	(1.0)	7	(0.7)
Glucose;Potassium;Sodium Chloride	3	(0.6)	0	(0.0)	3	(0.3)
Glycerol	9	(1.8)	16	(3.2)	25	(2.5)
Guaiazulene	1	(0.2)	1	(0.2)	2	(0.2)
Hamamelis Virginiana Extract	0	(0.0)	1	(0.2)	1	(0.1)
Heparin	3	(0.6)	2	(0.4)	5	(0.5)
Heparinoid	2	(0.4)	0	(0.0)	2	(0.2)
Hyaluronate Sodium	1	(0.2)	0	(0.0)	1	(0.1)
Hyaluronate Sodium;Sodium Chloride	0	(0.0)	1	(0.2)	1	(0.1)
Hydrocortisone	15	(3.0)	17	(3.4)	32	(3.2)
Hydrocortisone Acetate	3	(0.6)	2	(0.4)	5	(0.5)
Hydrocortisone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Hydrogen Peroxide	1	(0.2)	0	(0.0)	1	(0.1)
Hypromellose	0	(0.0)	1	(0.2)	1	(0.1)
Ketorolac	0	(0.0)	1	(0.2)	1	(0.1)
Ketotifen	1	(0.2)	0	(0.0)	1	(0.1)
Levofloxacin	3	(0.6)	2	(0.4)	5	(0.5)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Sensory Organs						
Ophthalmologicals	**233**	**(46.8)**	**260**	**(52.1)**	**493**	**(49.4)**
Lidocaine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Light Liquid Paraffin;White Soft Paraffin	1	(0.2)	0	(0.0)	1	(0.1)
Macrogol	2	(0.4)	1	(0.2)	3	(0.3)
Macrogol 4000	2	(0.4)	1	(0.2)	3	(0.3)
Matricaria Chamomilla	0	(0.0)	1	(0.2)	1	(0.1)
Methylprednisolone	5	(1.0)	7	(1.4)	12	(1.2)
Methylprednisolone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Moxifloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Moxifloxacin Hydrochloride	2	(0.4)	0	(0.0)	2	(0.2)
Mucopolysaccharide Polysulfuric Acid Ester	3	(0.6)	4	(0.8)	7	(0.7)
Naproxen	1	(0.2)	0	(0.0)	1	(0.1)
Neomycin Sulfate	0	(0.0)	2	(0.4)	2	(0.2)
Neomycin Sulfate;Tyrothricin	0	(0.0)	1	(0.2)	1	(0.1)
Netilmicin Sulfate	1	(0.2)	1	(0.2)	2	(0.2)
Ofloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Ophthalmologicals	1	(0.2)	0	(0.0)	1	(0.1)
Oxybuprocaine	3	(0.6)	1	(0.2)	4	(0.4)
Oxymetazoline	8	(1.6)	14	(2.8)	22	(2.2)
Oxymetazoline Hydrochloride	32	(6.4)	47	(9.4)	79	(7.9)
Paraffin Nos	0	(0.0)	1	(0.2)	1	(0.1)
Paraffin Soft	1	(0.2)	2	(0.4)	3	(0.3)
Paraffin, Liquid	1	(0.2)	2	(0.4)	3	(0.3)
Paraffin, Liquid;White Soft Paraffin	1	(0.2)	0	(0.0)	1	(0.1)
Phenylephrine	3	(0.6)	4	(0.8)	7	(0.7)
Phenylephrine Hydrochloride	1	(0.2)	1	(0.2)	2	(0.2)
Phenylephrine Hydrochloride;Tropicamide	2	(0.4)	1	(0.2)	3	(0.3)
Phosphoric Acid	0	(0.0)	1	(0.2)	1	(0.1)
Picloxydine Dihydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Potassium Chloride	7	(1.4)	12	(2.4)	19	(1.9)
Potassium Chloride;Sodium Chloride	1	(0.2)	0	(0.0)	1	(0.1)
Prednisolone	15	(3.0)	18	(3.6)	33	(3.3)
Prednisolone Acetate	3	(0.6)	1	(0.2)	4	(0.4)
Prednisolone Sodium Phosphate	1	(0.2)	1	(0.2)	2	(0.2)
Prednisolone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Sensory Organs						
Ophthalmologicals	**233**	**(46.8)**	**260**	**(52.1)**	**493**	**(49.4)**
Prednisolone Steaglate	0	(0.0)	1	(0.2)	1	(0.1)
Prednisolone Valeroacetate	0	(0.0)	2	(0.4)	2	(0.2)
Prednisone	8	(1.6)	9	(1.8)	17	(1.7)
Proxymetacaine	1	(0.2)	0	(0.0)	1	(0.1)
Proxymetacaine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Retinol	2	(0.4)	2	(0.4)	4	(0.4)
Ribavirin	1	(0.2)	0	(0.0)	1	(0.1)
Rifampicin	1	(0.2)	1	(0.2)	2	(0.2)
Sea Water	20	(4.0)	13	(2.6)	33	(3.3)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Sodium Phosphate	4	(0.8)	2	(0.4)	6	(0.6)
Sodium Phosphate Dibasic;Sodium Phosphate Monobasic	1	(0.2)	1	(0.2)	2	(0.2)
Sodium Phosphate Dibasic;Sodium Phosphate Monobasic (Monohydrate)	0	(0.0)	1	(0.2)	1	(0.1)
Sulfacetamide	1	(0.2)	0	(0.0)	1	(0.1)
Sulfadiazine Silver	0	(0.0)	1	(0.2)	1	(0.1)
Tetracaine	1	(0.2)	1	(0.2)	2	(0.2)
Tetracaine Hydrochloride	0	(0.0)	1	(0.2)	1	(0.1)
Timolol	2	(0.4)	3	(0.6)	5	(0.5)
Timolol Maleate	2	(0.4)	3	(0.6)	5	(0.5)
Tobramycin	9	(1.8)	11	(2.2)	20	(2.0)
Tocofersolan;Ubidecarenone	0	(0.0)	1	(0.2)	1	(0.1)
Tocopheryl Acetate	0	(0.0)	1	(0.2)	1	(0.1)
Triamcinolone Acetonide	0	(0.0)	3	(0.6)	3	(0.3)
Tropicamide	1	(0.2)	4	(0.8)	5	(0.5)
Ubidecarenone	1	(0.2)	0	(0.0)	1	(0.1)
Vancomycin	4	(0.8)	8	(1.6)	12	(1.2)
Vancomycin Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Xylometazoline Hydrochloride	2	(0.4)	5	(1.0)	7	(0.7)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Zinc Sulfate	3	(0.6)	10	(2.0)	13	(1.3)
Zinc Sulfate Heptahydrate	0	(0.0)	1	(0.2)	1	(0.1)
Otologicals	**166**	**(33.3)**	**191**	**(38.3)**	**357**	**(35.8)**
Benzocaine	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Sensory Organs						
Otologicals	**166**	**(33.3)**	**191**	**(38.3)**	**357**	**(35.8)**
Betamethasone	6	(1.2)	3	(0.6)	9	(0.9)
Betamethasone Dipropionate	0	(0.0)	2	(0.4)	2	(0.2)
Betamethasone Valerate	0	(0.0)	2	(0.4)	2	(0.2)
Boric Acid	1	(0.2)	0	(0.0)	1	(0.1)
Calendula Officinalis Flower;Matricaria Chamomilla Flower	1	(0.2)	0	(0.0)	1	(0.1)
Chloramphenicol	6	(1.2)	10	(2.0)	16	(1.6)
Chlorhexidine Gluconate	0	(0.0)	1	(0.2)	1	(0.1)
Ciprofloxacin	2	(0.4)	4	(0.8)	6	(0.6)
Ciprofloxacin Hydrochloride	1	(0.2)	2	(0.4)	3	(0.3)
Clotrimazole	10	(2.0)	18	(3.6)	28	(2.8)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroids	1	(0.2)	0	(0.0)	1	(0.1)
Dexamethasone	14	(2.8)	13	(2.6)	27	(2.7)
Dexamethasone Sodium Phosphate	2	(0.4)	3	(0.6)	5	(0.5)
Dexamethasone;Tobramycin	2	(0.4)	1	(0.2)	3	(0.3)
Gentamicin	5	(1.0)	12	(2.4)	17	(1.7)
Glycerol	9	(1.8)	16	(3.2)	25	(2.5)
Gramicidin;Neomycin;Nystatin;Triamcinolone	3	(0.6)	5	(1.0)	8	(0.8)
Hydrocortisone	15	(3.0)	17	(3.4)	32	(3.2)
Hydrocortisone Acetate	3	(0.6)	2	(0.4)	5	(0.5)
Hydrocortisone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Hydrogen Peroxide	1	(0.2)	0	(0.0)	1	(0.1)
Levofloxacin	3	(0.6)	2	(0.4)	5	(0.5)
Lidocaine Hydrochloride	1	(0.2)	0	(0.0)	1	(0.1)
Miconazole	2	(0.4)	4	(0.8)	6	(0.6)
Neomycin Sulfate	0	(0.0)	2	(0.4)	2	(0.2)
Ofloxacin	0	(0.0)	1	(0.2)	1	(0.1)
Olea Europaea Oil	1	(0.2)	1	(0.2)	2	(0.2)
Paraffin, Liquid	1	(0.2)	2	(0.4)	3	(0.3)
Prednisolone	15	(3.0)	18	(3.6)	33	(3.3)
Prednisolone Acetate	3	(0.6)	1	(0.2)	4	(0.4)
Prednisolone Sodium Phosphate	1	(0.2)	1	(0.2)	2	(0.2)
Prednisolone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Prednisolone Steaglate	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Sensory Organs						
Otologicals	**166**	**(33.3)**	**191**	**(38.3)**	**357**	**(35.8)**
Prednisolone Valeroacetate	0	(0.0)	2	(0.4)	2	(0.2)
Sea Water	20	(4.0)	13	(2.6)	33	(3.3)
Sodium Bicarbonate	3	(0.6)	6	(1.2)	9	(0.9)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Triamcinolone Acetonide	0	(0.0)	3	(0.6)	3	(0.3)
Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins						
Corticosteroids For Systemic Use	**60**	**(12.0)**	**75**	**(15.0)**	**135**	**(13.5)**
Betamethasone	6	(1.2)	3	(0.6)	9	(0.9)
Betamethasone Dipropionate	0	(0.0)	2	(0.4)	2	(0.2)
Betamethasone Valerate	0	(0.0)	2	(0.4)	2	(0.2)
Betamethasone;Loratadine	1	(0.2)	1	(0.2)	2	(0.2)
Corticosteroid Nos	0	(0.0)	1	(0.2)	1	(0.1)
Corticosteroids	1	(0.2)	0	(0.0)	1	(0.1)
Deflazacort	0	(0.0)	1	(0.2)	1	(0.1)
Dexamethasone	14	(2.8)	13	(2.6)	27	(2.7)
Dexamethasone Sodium Phosphate	2	(0.4)	3	(0.6)	5	(0.5)
Hydrocortisone	15	(3.0)	17	(3.4)	32	(3.2)
Hydrocortisone Acetate	3	(0.6)	2	(0.4)	5	(0.5)
Hydrocortisone Butyrate	2	(0.4)	3	(0.6)	5	(0.5)
Hydrocortisone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Ketoconazole	1	(0.2)	0	(0.0)	1	(0.1)
Methylprednisolone	5	(1.0)	7	(1.4)	12	(1.2)
Methylprednisolone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Prednisolone	15	(3.0)	18	(3.6)	33	(3.3)
Prednisolone Acetate	3	(0.6)	1	(0.2)	4	(0.4)
Prednisolone Sodium Phosphate	1	(0.2)	1	(0.2)	2	(0.2)
Prednisolone Sodium Succinate	1	(0.2)	2	(0.4)	3	(0.3)
Prednisolone Steaglate	0	(0.0)	1	(0.2)	1	(0.1)
Prednisolone Valeroacetate	0	(0.0)	2	(0.4)	2	(0.2)
Prednisone	8	(1.6)	9	(1.8)	17	(1.7)
Triamcinolone Acetonide	0	(0.0)	3	(0.6)	3	(0.3)
Pituitary And Hypothalamic Hormones And Analogues	**0**	**(0.0)**	**1**	**(0.2)**	**1**	**(0.1)**
Somatostatin	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins						
Thyroid Therapy	**20**	**(4.0)**	**22**	**(4.4)**	**42**	**(4.2)**
Levothyroxine	2	(0.4)	5	(1.0)	7	(0.7)
Levothyroxine Sodium	8	(1.6)	6	(1.2)	14	(1.4)
Liothyronine	0	(0.0)	1	(0.2)	1	(0.1)
Propranolol	9	(1.8)	6	(1.2)	15	(1.5)
Propranolol Hydrochloride	3	(0.6)	4	(0.8)	7	(0.7)
Various						
All Other Non-Therapeutic Products	**118**	**(23.7)**	**134**	**(26.9)**	**252**	**(25.3)**
Ascorbic Acid	26	(5.2)	13	(2.6)	39	(3.9)
Glucose	8	(1.6)	6	(1.2)	14	(1.4)
Hypromellose	0	(0.0)	1	(0.2)	1	(0.1)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Sucrose	4	(0.8)	8	(1.6)	12	(1.2)
Water For Injection	0	(0.0)	1	(0.2)	1	(0.1)
All Other Therapeutic Products	**137**	**(27.5)**	**133**	**(26.7)**	**270**	**(27.1)**
Acetylcysteine	4	(0.8)	3	(0.6)	7	(0.7)
Adenosine	0	(0.0)	1	(0.2)	1	(0.1)
Ascorbic Acid	26	(5.2)	13	(2.6)	39	(3.9)
Calcium Carbonate	3	(0.6)	4	(0.8)	7	(0.7)
Calcium Folinate	2	(0.4)	3	(0.6)	5	(0.5)
Calcium Polystyrene Sulfonate	1	(0.2)	1	(0.2)	2	(0.2)
Iron	22	(4.4)	26	(5.2)	48	(4.8)
Lactobacillus Rhamnosus	1	(0.2)	3	(0.6)	4	(0.4)
Lactoferrin	1	(0.2)	0	(0.0)	1	(0.1)
Lactose	0	(0.0)	1	(0.2)	1	(0.1)
Naloxone	1	(0.2)	1	(0.2)	2	(0.2)
Other Therapeutic Products	5	(1.0)	9	(1.8)	14	(1.4)
Oxygen	77	(15.5)	80	(16.0)	157	(15.7)
Phosphoric Acid	0	(0.0)	1	(0.2)	1	(0.1)
Protamine Sulfate	1	(0.2)	0	(0.0)	1	(0.1)
Rasburicase	0	(0.0)	1	(0.2)	1	(0.1)
Sodium Phosphate	4	(0.8)	2	(0.4)	6	(0.6)
Sodium Phosphate Monobasic	3	(0.6)	1	(0.2)	4	(0.4)
Sodium Polystyrene Sulfonate	0	(0.0)	1	(0.2)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Various						
All Other Therapeutic Products	**137**	**(27.5)**	**133**	**(26.7)**	**270**	**(27.1)**
Sucrose	4	(0.8)	8	(1.6)	12	(1.2)
Sugammadex	2	(0.4)	0	(0.0)	2	(0.2)
Water	1	(0.2)	0	(0.0)	1	(0.1)
Contrast Media	**16**	**(3.2)**	**10**	**(2.0)**	**26**	**(2.6)**
Barium Sulfate	1	(0.2)	0	(0.0)	1	(0.1)
Ferric Ammonium Citrate	15	(3.0)	10	(2.0)	25	(2.5)
Diagnostic Agents	**114**	**(22.9)**	**92**	**(18.4)**	**206**	**(20.7)**
Caffeine	4	(0.8)	4	(0.8)	8	(0.8)
Fluorescein	0	(0.0)	1	(0.2)	1	(0.1)
Folic Acid	102	(20.5)	83	(16.6)	185	(18.6)
Glucose	8	(1.6)	6	(1.2)	14	(1.4)
Magnesium Sulfate	2	(0.4)	2	(0.4)	4	(0.4)
Mannitol	1	(0.2)	1	(0.2)	2	(0.2)
General Nutrients	**15**	**(3.0)**	**21**	**(4.2)**	**36**	**(3.6)**
Amino Acids Nos	0	(0.0)	1	(0.2)	1	(0.1)
Amino Acids Nos;Minerals Nos;Vitamins Nos	0	(0.0)	1	(0.2)	1	(0.1)
Carbohydrates Nos;Carotenoids Nos;Choline;Fats Nos;Fibre Nos;Inositol;Levocarnitine;Minerals Nos;Nucleotides Nos;Proteins Nos;Taurine;Vitamins Nos	1	(0.2)	0	(0.0)	1	(0.1)
Carbohydrates Nos;Fats Nos;Fibre Nos;Proteins Nos;Sodium	0	(0.0)	1	(0.2)	1	(0.1)
Carbohydrates Nos;Fats Nos;Minerals Nos;Proteins Nos;Vitamins Nos	0	(0.0)	1	(0.2)	1	(0.1)
Fat/Carbohydrates/Proteins/Minerals/Vitamins, Combinations	0	(0.0)	2	(0.4)	2	(0.2)
General Nutrients	1	(0.2)	0	(0.0)	1	(0.1)
Glucose	8	(1.6)	6	(1.2)	14	(1.4)
Infant Formulas	1	(0.2)	1	(0.2)	2	(0.2)
Medium-Chain Triglycerides	0	(0.0)	1	(0.2)	1	(0.1)
Nutrients Nos	0	(0.0)	1	(0.2)	1	(0.1)
Other Combinations Of Nutrients	0	(0.0)	1	(0.2)	1	(0.1)
Sucrose	4	(0.8)	8	(1.6)	12	(1.2)
Trace Elements Nos	0	(0.0)	1	(0.2)	1	(0.1)
Homeopathic Preparation	**157**	**(31.5)**	**180**	**(36.1)**	**337**	**(33.8)**
Ascorbic Acid	26	(5.2)	13	(2.6)	39	(3.9)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Various						
Homeopathic Preparation	**157**	**(31.5)**	**180**	**(36.1)**	**337**	**(33.8)**
Boric Acid	1	(0.2)	0	(0.0)	1	(0.1)
Bryonia Alba;Calcium Sulfide;Euphrasia Officinalis;Phosphorus;Pulsatilla Pratensis;Rumex Crispus;Silicon Dioxide	0	(0.0)	1	(0.2)	1	(0.1)
Bryonia Alba;Euphrasia Officinalis;Phosphorus;Pulsatilla Spp.;Rumex Crispus;Silicon Dioxide;Sodium Chloride;Sulfurated Potash	2	(0.4)	2	(0.4)	4	(0.4)
Bryonia Spp.;Cephaelis Spp.;Drosera Rotundifolia;Homeopathics Nos;Phosphorus;Potassium Hydroxide;Rumex Crispus	1	(0.2)	2	(0.4)	3	(0.3)
Calcium Carbonate	3	(0.6)	4	(0.8)	7	(0.7)
Calcium Phosphate	1	(0.2)	0	(0.0)	1	(0.1)
Epinephrine	15	(3.0)	17	(3.4)	32	(3.2)
Ferric Hydroxide	2	(0.4)	0	(0.0)	2	(0.2)
Foeniculum Vulgare	1	(0.2)	0	(0.0)	1	(0.1)
Homeopathic Preparation	0	(0.0)	1	(0.2)	1	(0.1)
Iron	22	(4.4)	26	(5.2)	48	(4.8)
Matricaria Chamomilla	0	(0.0)	1	(0.2)	1	(0.1)
Minerals Nos	2	(0.4)	2	(0.4)	4	(0.4)
Paraffin, Liquid	1	(0.2)	2	(0.4)	3	(0.3)
Phosphoric Acid	0	(0.0)	1	(0.2)	1	(0.1)
Phosphorus	1	(0.2)	0	(0.0)	1	(0.1)
Potassium Chloride	7	(1.4)	12	(2.4)	19	(1.9)
Potassium Phosphate Dibasic	0	(0.0)	2	(0.4)	2	(0.2)
Sodium Chloride	88	(17.7)	114	(22.8)	202	(20.3)
Sodium Phosphate	4	(0.8)	2	(0.4)	6	(0.6)
Sulfur	1	(0.2)	1	(0.2)	2	(0.2)
Syzygium Aromaticum	1	(0.2)	0	(0.0)	1	(0.1)
Ubidecarenone	1	(0.2)	0	(0.0)	1	(0.1)
Zinc	13	(2.6)	17	(3.4)	30	(3.0)
Zinc Gluconate	0	(0.0)	2	(0.4)	2	(0.2)
Zinc Oxide	7	(1.4)	16	(3.2)	23	(2.3)
Investigational Drug	**0**	**(0.0)**	**3**	**(0.6)**	**3**	**(0.3)**
Actein	0	(0.0)	3	(0.6)	3	(0.3)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Various						
Unspecified Herbal And Traditional Medicine	**26**	**(5.2)**	**30**	**(6.0)**	**56**	**(5.6)**
Agave Americana	0	(0.0)	1	(0.2)	1	(0.1)
Aloe Vera;Cocos Nucifera Oil;Eucalyptus Spp.;Lavandula Angustifolia;Salvia Rosmarinus	10	(2.0)	19	(3.8)	29	(2.9)
Aloe Vera;Eucalyptus Globulus Oil;Lavandula Spp. Oil;Salvia Rosmarinus Oil	0	(0.0)	1	(0.2)	1	(0.1)
Avena Sativa	0	(0.0)	1	(0.2)	1	(0.1)
Calcium Carbonate;Ceratonia Siliqua Seed Powder;Ferrous Sulfate;Maltodextrin;Zinc Sulfate	2	(0.4)	0	(0.0)	2	(0.2)
Calendula Officinalis Flower;Matricaria Chamomilla Flower	1	(0.2)	0	(0.0)	1	(0.1)
Camphor;Eucalyptus Globulus Oil;Menthol	0	(0.0)	1	(0.2)	1	(0.1)
Foeniculum Vulgare	1	(0.2)	0	(0.0)	1	(0.1)
Gelsemium Sempervirens Extract;Grindelia Hirsutula;Melaleuca Viridiflora Oil	1	(0.2)	0	(0.0)	1	(0.1)
Glycine Max Seed Oil	1	(0.2)	0	(0.0)	1	(0.1)
Glycine Max Seed Oil;Olea Europaea Oil	0	(0.0)	1	(0.2)	1	(0.1)
Hamamelis Virginiana Extract	0	(0.0)	1	(0.2)	1	(0.1)
Hedera Helix	4	(0.8)	0	(0.0)	4	(0.4)
Hedera Helix Leaf	1	(0.2)	2	(0.4)	3	(0.3)
Hedera Helix Leaf Extract	1	(0.2)	0	(0.0)	1	(0.1)
Herbal Oil Nos	1	(0.2)	0	(0.0)	1	(0.1)
Lavandula Angustifolia Oil	0	(0.0)	1	(0.2)	1	(0.1)
Matricaria Chamomilla	0	(0.0)	1	(0.2)	1	(0.1)
Olea Europaea Oil	1	(0.2)	1	(0.2)	2	(0.2)
Platycodon Grandiflorus	1	(0.2)	1	(0.2)	2	(0.2)
Syzygium Aromaticum	1	(0.2)	0	(0.0)	1	(0.1)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Various						
Unspecified Herbal And Traditional Medicine	**26**	**(5.2)**	**30**	**(6.0)**	**56**	**(5.6)**
Unspecified Herbal And Traditional Medicine	1	(0.2)	1	(0.2)	2	(0.2)

Every participant is counted a single time for each applicable specific concomitant medication. A participant with multiple concomitant medications within a medication category is counted a single time for that category. Each specific concomitant medication is listed under all relevant medication classes based on the medication's generic name, regardless of route of administration or reason for use A medication that is not mapped to a second level therapeutic subgroup is classified under Other

WHO-DD GLOBALB 3Sep25 was used in the reporting of this study

Concomitant medications taken during Season 1 are included. Any medications initiated at or after the administration of study treatment in RSV Season 2 are not included

RSV: Respiratory Syncytial Virus; WHO-DD: World Health Organization Drug Dictionary

Tabelle 4G-5: Koadministrationen der Studienpopulation – RCT mit dem zu bewertenden Arzneimittel

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Participants in population	498		499		997	
with one or more concomitant vaccinations	336	(67.5)	353	(70.7)	689	(69.1)
with no concomitant vaccination	162	(32.5)	146	(29.3)	308	(30.9)
Antiinfectives For Systemic Use						
Vaccines	**336**	**(67.5)**	**353**	**(70.7)**	**689**	**(69.1)**
Bacteria Nos	0	(0.0)	2	(0.4)	2	(0.2)
Bacterial And Viral Vaccines, Combined	1	(0.2)	1	(0.2)	2	(0.2)
Bcg Vaccine	33	(6.6)	42	(8.4)	75	(7.5)
Bcg Vaccine Live (Danish 1331)	1	(0.2)	1	(0.2)	2	(0.2)
Bcg Vaccine Live Intradermal	0	(0.0)	1	(0.2)	1	(0.1)
Covid-19 Vaccine Mrna	1	(0.2)	1	(0.2)	2	(0.2)
Diphtheria Vaccine	2	(0.4)	3	(0.6)	5	(0.5)
Diphtheria Vaccine Toxoid;Hepatitis B Vaccine Rhbsag (Yeast);Hib Vaccine Conj (Menigococcal Protein);Pertussis Vaccine Acellular 5-Component;Polio Vaccine Inact 3v (Vero);Tetanus Vaccine Toxoid	17	(3.4)	25	(5.0)	42	(4.2)
Diphtheria Vaccine Toxoid;Hepatitis B Vaccine Rhbsag (Yeast);Hib Vaccine Conj;Pertussis Vaccine Acellular 3-Component;Polio Vaccine Inact 3v (Vero);Tetanus Vaccine Toxoid	21	(4.2)	27	(5.4)	48	(4.8)
Diphtheria Vaccine Toxoid;Hepatitis B Vaccine Rhbsag (Yeast);Pertussis Vaccine Acellular 3-Component;Polio Vaccine Inact 3v (Vero);Tetanus Vaccine Toxoid	2	(0.4)	1	(0.2)	3	(0.3)
Diphtheria Vaccine Toxoid;Hepatitis B Vaccine Rhbsag;Hib Vaccine Conj (Tet Tox);Pertussis Vaccine Acellular 2-Component;Polio Vaccine Inact 3v (Vero);Tetanus Vaccine Toxoid	56	(11.2)	66	(13.2)	122	(12.2)
Diphtheria Vaccine Toxoid;Hepatitis B Vaccine;Hib Vaccine;Pertussis Vaccine;Tetanus Vaccine Toxoid	19	(3.8)	21	(4.2)	40	(4.0)
Diphtheria Vaccine Toxoid;Hib Vaccine Conj (Tet Tox);Pertussis Vaccine Acellular 2-Component;Polio Vaccine Inact 3v (Vero);Tetanus Vaccine Toxoid	38	(7.6)	33	(6.6)	71	(7.1)
Diphtheria Vaccine Toxoid;Hib Vaccine Conj (Tet Tox);Pertussis Vaccine Acellular 5-Component;Polio Vaccine Inact 3v (Mrc 5);Tetanus Vaccine Toxoid	3	(0.6)	3	(0.6)	6	(0.6)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Antiinfectives For Systemic Use						
Vaccines	**336**	**(67.5)**	**353**	**(70.7)**	**689**	**(69.1)**
Diphtheria Vaccine Toxoid;Hib Vaccine Conj;Pertussis Vaccine Acellular 3-Component;Polio Vaccine Inact 3v (Vero);Tetanus Vaccine Toxoid	11	(2.2)	7	(1.4)	18	(1.8)
Diphtheria Vaccine Toxoid;Pertussis Vaccine Acellular 3-Component;Tetanus Vaccine Toxoid	2	(0.4)	3	(0.6)	5	(0.5)
Diphtheria Vaccine Toxoid;Pertussis Vaccine Acellular;Polio Vaccine Inact 3v (Vero);Tetanus Vaccine Toxoid	2	(0.4)	2	(0.4)	4	(0.4)
Diphtheria Vaccine Toxoid;Pertussis Vaccine Acellular;Polio Vaccine Inact;Tetanus Vaccine Toxoid	4	(0.8)	3	(0.6)	7	(0.7)
Diphtheria Vaccine Toxoid;Pertussis Vaccine Acellular;Tetanus Vaccine Toxoid	1	(0.2)	3	(0.6)	4	(0.4)
Diphtheria Vaccine Toxoid;Pertussis Vaccine;Polio Vaccine Inact 3v (Vero);Tetanus Vaccine Toxoid	1	(0.2)	2	(0.4)	3	(0.3)
Diphtheria Vaccine Toxoid;Pertussis Vaccine;Tetanus Vaccine Toxoid	2	(0.4)	1	(0.2)	3	(0.3)
Diphtheria Vaccine;Hepatitis B Vaccine;Hib Vaccine;Pertussis Vaccine Acellular;Polio Vaccine Inact;Tetanus Vaccine	34	(6.8)	38	(7.6)	72	(7.2)
Diphtheria Vaccine;Hepatitis B Vaccine;Hib Vaccine;Pertussis Vaccine Acellular;Polio Vaccine;Tetanus Vaccine	7	(1.4)	9	(1.8)	16	(1.6)
Diphtheria Vaccine;Hepatitis B Vaccine;Hib Vaccine;Pertussis Vaccine;Polio Vaccine Inact;Tetanus Vaccine	5	(1.0)	4	(0.8)	9	(0.9)
Diphtheria Vaccine;Hepatitis B Vaccine;Hib Vaccine;Pertussis Vaccine;Polio Vaccine;Tetanus Vaccine	17	(3.4)	21	(4.2)	38	(3.8)
Diphtheria Vaccine;Hepatitis B Vaccine;Hib Vaccine;Pertussis Vaccine;Tetanus Vaccine	12	(2.4)	19	(3.8)	31	(3.1)
Diphtheria Vaccine;Hepatitis B Vaccine;Pertussis Vaccine Acellular;Polio Vaccine Inact;Tetanus Vaccine	1	(0.2)	1	(0.2)	2	(0.2)
Diphtheria Vaccine;Hepatitis B Vaccine;Pertussis Vaccine Acellular;Polio Vaccine;Tetanus Vaccine	0	(0.0)	1	(0.2)	1	(0.1)
Diphtheria Vaccine;Hib Vaccine;Pertussis Vaccine Acellular;Polio Vaccine Inact;Tetanus Vaccine	12	(2.4)	14	(2.8)	26	(2.6)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Antiinfectives For Systemic Use						
Vaccines	**336**	**(67.5)**	**353**	**(70.7)**	**689**	**(69.1)**
Diphtheria Vaccine;Hib Vaccine;Pertussis Vaccine;Polio Vaccine;Tetanus Vaccine	6	(1.2)	5	(1.0)	11	(1.1)
Diphtheria Vaccine;Pertussis Vaccine;Tetanus Vaccine	7	(1.4)	1	(0.2)	8	(0.8)
Hemophilus Influenzae B Vaccines	1	(0.2)	0	(0.0)	1	(0.1)
Hepatitis A Vaccine	8	(1.6)	9	(1.8)	17	(1.7)
Hepatitis A Vaccine Inact	0	(0.0)	1	(0.2)	1	(0.1)
Hepatitis B Vaccine	20	(4.0)	34	(6.8)	54	(5.4)
Hepatitis B Vaccine Rhbsag	1	(0.2)	0	(0.0)	1	(0.1)
Hepatitis B Vaccine Rhbsag (Yeast)	15	(3.0)	21	(4.2)	36	(3.6)
Hib Vaccine	10	(2.0)	6	(1.2)	16	(1.6)
Hib Vaccine Conj	1	(0.2)	0	(0.0)	1	(0.1)
Hib Vaccine Conj (Ompc)	2	(0.4)	0	(0.0)	2	(0.2)
Hib Vaccine Conj (Tet Tox)	8	(1.6)	16	(3.2)	24	(2.4)
Hib Vaccine Conj (Tet Tox);Meningococcal Vaccine C Conj (Tet Tox)	0	(0.0)	2	(0.4)	2	(0.2)
Influenza Vaccine	44	(8.8)	43	(8.6)	87	(8.7)
Influenza Vaccine Inact	0	(0.0)	1	(0.2)	1	(0.1)
Influenza Vaccine Inact Sag 3v	1	(0.2)	4	(0.8)	5	(0.5)
Influenza Vaccine Inact Split 3v	0	(0.0)	4	(0.8)	4	(0.4)
Influenza Vaccine Inact Split 4v	4	(0.8)	5	(1.0)	9	(0.9)
Japanese Encephalitis Vaccine	2	(0.4)	1	(0.2)	3	(0.3)
Japanese Encephalitis Vaccine Inact	0	(0.0)	2	(0.4)	2	(0.2)
Japanese Encephalitis Vaccine Live R (Vero)	2	(0.4)	3	(0.6)	5	(0.5)
Measles Vaccine	36	(7.2)	43	(8.6)	79	(7.9)
Measles Vaccine Live (Cam 70)	1	(0.2)	0	(0.0)	1	(0.1)
Measles Vaccine Live (Enders-Edmonston);Mumps Vaccine Live (Jeryl Lynn);Rubella Vaccine Live (Wistar Ra 27/3)	1	(0.2)	6	(1.2)	7	(0.7)
Measles Vaccine Live (Schwartz);Mumps Vaccine Live (Rit 4385);Rubella Vaccine Live (Wistar Ra 27/3)	6	(1.2)	4	(0.8)	10	(1.0)
Measles Vaccine Live;Mumps Vaccine Live;Rubella Vaccine Live	4	(0.8)	7	(1.4)	11	(1.1)
Measles Vaccine;Mumps Vaccine;Rubella Vaccine	22	(4.4)	34	(6.8)	56	(5.6)
Meningococcal Vaccine	3	(0.6)	1	(0.2)	4	(0.4)
Meningococcal Vaccine A/C/Y/W	3	(0.6)	4	(0.8)	7	(0.7)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Antiinfectives For Systemic Use						
Vaccines	**336**	**(67.5)**	**353**	**(70.7)**	**689**	**(69.1)**
Meningococcal Vaccine A/C/Y/W Conj	2	(0.4)	4	(0.8)	6	(0.6)
Meningococcal Vaccine A/C/Y/W Conj (Tet Tox)	3	(0.6)	3	(0.6)	6	(0.6)
Meningococcal Vaccine A/C/Y/W Polysacch	1	(0.2)	0	(0.0)	1	(0.1)
Meningococcal Vaccine B	13	(2.6)	11	(2.2)	24	(2.4)
Meningococcal Vaccine B Rfhbp/Nada/Nhba Omv	44	(8.8)	47	(9.4)	91	(9.1)
Meningococcal Vaccine C	7	(1.4)	3	(0.6)	10	(1.0)
Meningococcal Vaccine C Conj	1	(0.2)	2	(0.4)	3	(0.3)
Meningococcal Vaccine C Conj (Tet Tox)	34	(6.8)	29	(5.8)	63	(6.3)
Pertussis Vaccine	2	(0.4)	3	(0.6)	5	(0.5)
Pneumococcal Vaccine	67	(13.5)	70	(14.0)	137	(13.7)
Pneumococcal Vaccine 10v	1	(0.2)	1	(0.2)	2	(0.2)
Pneumococcal Vaccine 13v	6	(1.2)	7	(1.4)	13	(1.3)
Pneumococcal Vaccine Conj	59	(11.8)	71	(14.2)	130	(13.0)
Pneumococcal Vaccine Conj 10v	7	(1.4)	4	(0.8)	11	(1.1)
Pneumococcal Vaccine Conj 13v (Crm197)	105	(21.1)	122	(24.4)	227	(22.8)
Pneumococcal Vaccine Conj 15v (Crm197)	9	(1.8)	8	(1.6)	17	(1.7)
Pneumococcal Vaccine Conj 20v (Crm197)	0	(0.0)	1	(0.2)	1	(0.1)
Pneumococcal Vaccine Conj 7v (Crm197)	33	(6.6)	28	(5.6)	61	(6.1)
Polio Vaccine	39	(7.8)	37	(7.4)	76	(7.6)
Polio Vaccine Inact	4	(0.8)	7	(1.4)	11	(1.1)
Polio Vaccine Live Oral	10	(2.0)	24	(4.8)	34	(3.4)
Rotavirus Vaccine	113	(22.7)	113	(22.6)	226	(22.7)
Rotavirus Vaccine Live 1v	1	(0.2)	3	(0.6)	4	(0.4)
Rotavirus Vaccine Live Oral 1v	54	(10.8)	53	(10.6)	107	(10.7)
Rotavirus Vaccine Live Reassort Oral 5v	29	(5.8)	28	(5.6)	57	(5.7)
Tetanus Vaccine	2	(0.4)	3	(0.6)	5	(0.5)
Tetanus Vaccine Toxoid	0	(0.0)	1	(0.2)	1	(0.1)
Tozinameran	0	(0.0)	2	(0.4)	2	(0.2)
Vaccines	0	(0.0)	1	(0.2)	1	(0.1)
Varicella Zoster Vaccine	10	(2.0)	10	(2.0)	20	(2.0)
Varicella Zoster Vaccine Live (Oka/Merck)	6	(1.2)	6	(1.2)	12	(1.2)

	Clesrovimab		Palivizumab		Total	
	n	(%)	n	(%)	n	(%)
Antiinfectives For Systemic Use						
Vaccines	**336**	**(67.5)**	**353**	**(70.7)**	**689**	**(69.1)**
Yellow Fever Vaccine	1	(0.2)	1	(0.2)	2	(0.2)

Every participant is counted a single time for each applicable specific concomitant vaccination. A participant with multiple concomitant vaccinations within a vaccination category is counted a single time for that category. Each specific concomitant vaccination is listed under all relevant vaccination classes based on the vaccination's generic name, regardless of route of administration or reason for use

The oral medication 'Vioment tab' (encoded to 'BACTERIA NOS') is included in this table as it is categorized as a Vaccine based on the WHO-DD

Concomitant vaccination taken during Season 1 are included. Any vaccination initiated at or after the administration of study treatment in RSV Season 2 are not included

RSV: Respiratory Syncytial Virus; WHO-DD: World Health Organization Drug Dictionary

Anhang 4-G2: Ergebnisse der Subgruppen mit nicht signifikantem Interaktionstest ($p \geq 0,05$)

Im Folgenden werden ergänzend zu Abschnitt 4.3.1.3.2.2 die Ergebnisse der Subgruppenanalysen, für die ein nicht signifikanter Interaktionstest ($p \geq 0,05$) vorliegt, dargestellt.

Anhang 4-G2.1: Mortalität

Ergebnisse zum Endpunkt Unerwünschte Ereignisse, die zum Tod führen, werden im Abschnitt Nebenwirkungen dargestellt.

Anhang 4-G2.2: Morbidität

Tabelle 4G-6: Subgruppenanalysen mit nicht signifikantem Interaktionstest (p ≥ 0,05) für den Endpunkt RSV-assoziierte MALRI (Tag 1 bis 150) – RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	**Clesrovimab**				**Palivizumab**				**Clesrovimab vs Palivizumab**		**p-Value for interaction test[g]**
RSV-associated Outpatient and Inpatient MALRI	**N[b]**	**Participants with Event**	**Total Follow-up Time in Months[c]**	**Incidence Rate Over 5 Months[d]**	**N[b]**	**Participants with Event**	**Total Follow-up Time in Months[c]**	**Incidence Rate Over 5 Months[d]**	**Observed Efficacy (%) Estimate (95% CI)[e]**	**p-Value[f]**	
Sex											
Female	244	7	1165.1	0.030	242	5	1177.3	0.021	-41.5 (-345.9, 55.1)	0.554	0.344
Male	251	8	1209.9	0.033	243	11	1159.0	0.047	30.3 (-73.9, 72.1)	0.439	
Age Group											
<6 Months	452	13	2182.2	0.030	416	11	2017.5	0.027	-9.3 (-144.0, 51.1)	0.829	0.580
≥6 Months	43	2	192.8	0.052	69	5	318.8	0.078	33.9 (-250.0, 87.5)	0.627	
Participant Condition											
CHD	52	4	231.7	0.086	51	4	239.2	0.084	-3.2 (-331.8, 75.3)	0.692	0.739
CLD	137	4	663.3	0.030	138	5	661.2	0.038	20.2 (-196.9, 79.8)	0.996	
Neither CLD nor CHD <29 Weeks Gestational Age	41	0	197.6	0.000	38	2	184.5	0.054	100.0 (-224.2, 100.0)	0.466	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	7	1282.3	0.027	258	5	1251.3	0.020	-36.6 (-341.5, 59.4)	0.412	
Region											
Northern Hemisphere	348	11	1678.0	0.033	338	10	1629.1	0.031	-6.8 (-151.7, 54.7)	0.881	0.557

Study: MK-1654-007[a]	Clesrovimab				Palivizumab				Clesrovimab vs Palivizumab		p-Value for interaction test[g]
RSV-associated Outpatient and Inpatient MALRI	N[b]	Participants with Event	Total Follow-up Time in Months[c]	Incidence Rate Over 5 Months[d]	N[b]	Participants with Event	Total Follow-up Time in Months[c]	Incidence Rate Over 5 Months[d]	Observed Efficacy (%) Estimate (95% CI)[e]	p-Value[f]	
Southern Hemisphere	147	4	696.9	0.029	147	6	707.2	0.042	32.4 (-141.3, 81.0)	0.547	

a: Database Cutoff Date: 01AUG2025

b: Number of participants in the full analysis set population

c: One month is defined as 30 days for the total follow-up time calculation

d: Five months is defined as 150 days

e: Estimate and 95% CI of efficacy were estimated from the modified Poisson regression with robust variance method with the use of only the term of treatment group assignment. Due to convergence issue and/or non-estimable CI using the modified Poisson method for the participant condition subgroup, estimate of efficacy was based on the exact binomial method proposed by Chan and Bohidar, and estimate of 95% CI was based on Blaker's exact CI

f: Two-sided p-value using Wald test. For the participant condition subgroup, two-sided p-value using an exact binomial method proposed by Chan and Bohidar

g: Two-sided p-value based on the modified Poisson regression with treatment and subgroup as covariates, and treatment-by-subgroup interaction (p-value of likelihood ratio test for interaction term). For the participant condition subgroup, Cochran's Q (chi-squared) two-sided p-value for heterogeneity test

CHD: Congenital Heart Disease; CI: Confidence Interval; CLD: Chronic Lung Disease; MALRI: Medically Attended Lower Respiratory Infection; RSV: Respiratory Syncytial Virus

Tabelle 4G-7: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt RSV-assoziierte Hospitalisierungen (Tag 1 bis 150) – RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	Clesrovimab				Palivizumab				Clesrovimab vs Palivizumab		p-Value for interaction test[g]
RSV-associated Hospitalization	N[b]	Participants with Event	Total Follow-up Time in Months[c]	Incidence Rate Over 5 Months[d]	N[b]	Participants with Event	Total Follow-up Time in Months[c]	Incidence Rate Over 5 Months[d]	Observed Efficacy (%) Estimate (95% CI)[e]	p-Value[f]	
Sex											
Female	244	2	1174.5	0.009	242	1	1191.6	0.004	-102.9 (-2133.4, 81.6)	0.563	0.282
Male	251	3	1224.0	0.012	243	7	1173.0	0.030	58.9 (-59.3, 89.4)	0.198	
Age Group											
<6 Months	452	4	2202.7	0.009	416	6	2032.4	0.015	38.5 (-118.1, 82.6)	0.452	0.825
≥6 Months	43	1	195.8	0.026	69	2	332.1	0.030	15.2 (-855.2, 92.5)	0.894	
Participant Condition											
CHD	52	2	236.8	0.042	51	3	241.9	0.062	n.c.	n.c.	n.c.
CLD	137	2	667.9	0.015	138	3	669.2	0.022	n.c.	n.c.	

Neither CLD nor CHD <29 Weeks Gestational Age	41	0	197.6	0.000	38	1	188.1	0.027	n.c.	n.c.	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	1	1296.2	0.004	258	1	1265.4	0.004	n.c.	n.c.	
Region											
Northern Hemisphere	348	4	1693.6	0.012	338	5	1645.5	0.015	n.c.	n.c.	n.c.
Southern Hemisphere	147	1	704.9	0.007	147	3	719.1	0.021	n.c.	n.c.	

a: Database Cutoff Date: 01AUG2025

b: Number of participants in the full analysis set population

c: One month is defined as 30 days for the total follow-up time calculation

d: Five months is defined as 150 days

e: Estimate and 95% CI of efficacy were estimated from the modified Poisson regression with robust variance method with the use only of the term of treatment group assignment

f: Two-sided p-value using Wald test

g: Two-sided p-value based on the modified Poisson regression with treatment and subgroup as covariates, and treatment-by-subgroup interaction (p-value of likelihood ratio test for interaction term)

CHD: Congenital Heart Disease; CI: Confidence Interval; CLD: Chronic Lung Disease; n.c.: not calculated (at least 10 participants per subgroup category and at least 10 participants with events in one of the subgroup categories necessary); RSV: Respiratory Syncytial Virus

Anhang 4-G2.3: Nebenwirkungen

Unerwünschte Ereignisse Gesamtraten

Tabelle 4G-8: Subgruppenanalysen mit nicht signifikantem Interaktionstest (p ≥ 0,05) für den Endpunkt Unerwünschte Ereignisse gesamt – RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events	N[b]	Participants with Event n (%)	N[b]	Participants with Event n (%)	Relative Risk [95 %-CI][c]	p-Value[d]	p-Value for Interaction Test[e]
Age Group							
<6 Months	454	336 (74.0)	429	333 (77.6)	0.95 [0.88; 1.03]	0.211	0.830
≥6 Months	43	38 (88.4)	70	64 (91.4)	0.97 [0.85; 1.10]	0.596	
Participant Condition							
CHD	54	44 (81.5)	52	44 (84.6)	0.96 [0.81; 1.14]	0.669	0.514
CLD	137	105 (76.6)	142	117 (82.4)	0.93 [0.83; 1.05]	0.234	
Neither CLD nor CHD <29 Weeks Gestational Age	41	29 (70.7)	38	33 (86.8)	0.81 [0.65; 1.03]	0.084	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	196 (74.0)	267	203 (76.0)	0.97 [0.88; 1.07]	0.582	
Region							
Northern Hemisphere	351	249 (70.9)	352	268 (76.1)	0.93 [0.85; 1.02]	0.119	0.831
Southern Hemisphere	146	125 (85.6)	147	129 (87.8)	0.98 [0.89; 1.07]	0.591	

a: Database Cutoff Date: 01AUG2025

b: Number of participants: all-participants-as-treated population

c: Based on 2x2 contingency table, using Wald confidence interval. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

d: Based on Mantel-Haenszel Chi-Squared test. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

e: Based on Breslow-Day test with subgroup as stratification factor. In case no participant or all participants with event in both treatment groups for a subgroup category, it is excluded from interaction test (if only one subgroup category remaining, report ‘n.a.’). In case no participant with event in at least one treatment group across all subgroup categories, report 'n.a.'

Reported adverse events include nonserious adverse events that occurred from Day 1 through the day prior to Dose 2, and 14 days after each subsequent dose, and serious adverse events that occurred through the duration of participation in RSV Season 1

CHD: Congenital Heart Disease; CI: Confidence Interval; CLD: Chronic Lung Disease; n.a.: not applicable (when estimation not possible); RSV: Respiratory Syncytial Virus

Tabelle 4G-9: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt Schwerwiegende unerwünschte Ereignisse– RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	**Clesrovimab**		**Palivizumab**		**Clesrovimab vs. Palivizumab**		
Serious Adverse Events	**N**[b]	**Participants with Event n (%)**	**N**[b]	**Participants with Event n (%)**	**Relative Risk [95 %-CI]**[c]	**p-Value**[d]	**p-Value for Interaction Test**[e]
Sex							
Female	246	62 (25.2)	251	57 (22.7)	1.11 [0.81; 1.52]	0.515	0.057
Male	251	60 (23.9)	248	80 (32.3)	0.74 [0.56; 0.99]	0.038	
Age Group							
<6 Months	454	113 (24.9)	429	120 (28.0)	0.89 [0.71; 1.11]	0.299	0.946
≥6 Months	43	9 (20.9)	70	17 (24.3)	0.86 [0.42; 1.76]	0.682	
Participant Condition							
CHD	54	21 (38.9)	52	23 (44.2)	0.88 [0.56; 1.38]	0.579	0.951
CLD	137	41 (29.9)	142	50 (35.2)	0.85 [0.61; 1.19]	0.347	
Neither CLD nor CHD <29 Weeks Gestational Age	41	8 (19.5)	38	7 (18.4)	1.06 [0.42; 2.64]	0.902	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	52 (19.6)	267	57 (21.3)	0.92 [0.66; 1.29]	0.622	
Region							
Northern Hemisphere	351	78 (22.2)	352	99 (28.1)	0.79 [0.61; 1.02]	0.072	0.092
Southern Hemisphere	146	44 (30.1)	147	38 (25.9)	1.17 [0.81; 1.69]	0.415	

a: Database Cutoff Date: 01AUG2025

b: Number of participants: all-participants-as-treated population

c: Based on 2x2 contingency table, using Wald confidence interval. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

d: Based on Mantel-Haenszel Chi-Squared test. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

e: Based on Breslow-Day test with subgroup as stratification factor. In case no participant or all participants with event in both treatment groups for a subgroup category, it is excluded from interaction test (if only one subgroup category remaining, report ‘n.a.’). In case no participant with event in at least one treatment group across all subgroup categories, report 'n.a.'

Reported serious adverse events include events that occurred through the duration of participation in RSV Season 1

CHD: Congenital Heart Disease; CI: Confidence Interval; CLD: Chronic Lung Disease; n.a.: not applicable (when estimation not possible); RSV: Respiratory Syncytial Virus

Tabelle 4G-10: Subgruppenanalysen mit nicht signifikantem Interaktionstest (p ≥ 0,05) für den Endpunkt Schwere unerwünschte Ereignisse (CTCAE-Grad 3-5) – RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	**Clesrovimab**		**Palivizumab**		**Clesrovimab vs. Palivizumab**		
Severe Adverse Events (CTCAE Grade 3-5)	**N[b]**	**Participants with Event n (%)**	**N[b]**	**Participants with Event n (%)**	**Relative Risk [95 %-CI][c]**	**p-Value[d]**	**p-Value for Interaction Test[e]**
Age Group							
<6 Months	454	86 (18.9)	429	100 (23.3)	0.81 [0.63; 1.05]	0.112	0.881
≥6 Months	43	8 (18.6)	70	17 (24.3)	0.77 [0.36; 1.62]	0.482	
Participant Condition							
CHD	54	15 (27.8)	52	21 (40.4)	0.69 [0.40; 1.18]	0.173	0.749
CLD	137	30 (21.9)	142	42 (29.6)	0.74 [0.49; 1.11]	0.143	
Neither CLD nor CHD <29 Weeks Gestational Age	41	7 (17.1)	38	7 (18.4)	0.93 [0.36; 2.40]	0.876	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	42 (15.8)	267	47 (17.6)	0.90 [0.62; 1.32]	0.588	

a: Database Cutoff Date: 01AUG2025

b: Number of participants: all-participants-as-treated population

c: Based on 2x2 contingency table, using Wald confidence interval. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

d: Based on Mantel-Haenszel Chi-Squared test. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

e: Based on Breslow-Day test with subgroup as stratification factor. In case no participant or all participants with event in both treatment groups for a subgroup category, it is excluded from interaction test (if only one subgroup category remaining, report 'n.a.'). In case no participant with event in at least one treatment group across all subgroup categories, report 'n.a.'

Reported adverse events include nonserious adverse events that occurred from Day 1 through the day prior to Dose 2, and 14 days after each subsequent dose, and serious adverse events that occurred through the duration of participation in RSV Season 1

CHD: Congenital Heart Disease; CI: Confidence Interval; CLD: Chronic Lung Disease; CTCAE: Common Terminology Criteria for Adverse Events; n.a.: not applicable (when estimation not possible); RSV: Respiratory Syncytial Virus

Tabelle 4G-11: Subgruppenanalysen mit nicht signifikantem Interaktionstest (p ≥ 0,05) für den Endpunkt Unerwünschte Ereignisse, die zum Tod führen – RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events Leading to Death	**N[b]**	**Participants with Event n (%)**	**N[b]**	**Participants with Event n (%)**	**Relative Risk [95 %-CI][c]**	**p-Value[d]**	**p-Value for Interaction Test[e]**
Sex							
Female	246	5 (2.0)	251	2 (0.8)	n.c. [n.c.; n.c.]	n.c.	n.c.
Male	251	3 (1.2)	248	2 (0.8)	n.c. [n.c.; n.c.]	n.c.	
Age Group							
<6 Months	454	6 (1.3)	429	4 (0.9)	1.42 [0.40; 4.99]	0.585	n.a.
≥6 Months	43	2 (4.7)	70	0 (0.0)	n.a. [n.a.; n.a.]	n.a.	
Participant Condition							
CHD	54	5 (9.3)	52	2 (3.8)	n.c. [n.c.; n.c.]	n.c.	n.c.
CLD	137	0 (0.0)	142	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	
Neither CLD nor CHD <29 Weeks Gestational Age	41	0 (0.0)	38	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	3 (1.1)	267	2 (0.7)	n.c. [n.c.; n.c.]	n.c.	
Region							
Northern Hemisphere	351	4 (1.1)	352	3 (0.9)	n.c. [n.c.; n.c.]	n.c.	n.c.
Southern Hemisphere	146	4 (2.7)	147	1 (0.7)	n.c. [n.c.; n.c.]	n.c.	

a: Database Cutoff Date: 01AUG2025

b: Number of participants: all-participants-as-treated population

c: Based on 2x2 contingency table, using Wald confidence interval. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

d: Based on Mantel-Haenszel Chi-Squared test. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

e: Based on Breslow-Day test with subgroup as stratification factor. In case no participant or all participants with event in both treatment groups for a subgroup category, it is excluded from interaction test (if only one subgroup category remaining, report 'n.a.'). In case no participant with event in at least one treatment group across all subgroup categories, report 'n.a.'

Reported serious adverse events include events that occurred through the duration of participation in RSV Season 1

CHD: Congenital Heart Disease; CI: Confidence Interval; CLD: Chronic Lung Disease; n.a.: not applicable (when estimation not possible); n.c.: not calculated (at least 10 participants per subgroup and at least 10 events in one of the subgroups necessary); RSV: Respiratory Syncytial Virus

Tabelle 4G-12: Subgruppenanalysen mit nicht signifikantem Interaktionstest (p ≥ 0,05) für den Endpunkt Therapieabbruch wegen unerwünschter Ereignisse – RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events Leading to Treatment Discontinuation	**N[b]**	**Participants with Event n (%)**	**N[b]**	**Participants with Event n (%)**	**Relative Risk [95 %-CI][c]**	**p-Value[d]**	**p-Value for Interaction Test[e]**
Sex							
Female	246	0 (0.0)	251	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	n.c.
Male	251	0 (0.0)	248	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	
Age Group							
<6 Months	454	0 (0.0)	429	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	n.c.
≥6 Months	43	0 (0.0)	70	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	
Participant Condition							
CHD	54	0 (0.0)	52	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	n.c.
CLD	137	0 (0.0)	142	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	
Neither CLD nor CHD <29 Weeks Gestational Age	41	0 (0.0)	38	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	0 (0.0)	267	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	
Region							
Northern Hemisphere	351	0 (0.0)	352	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	n.c.
Southern Hemisphere	146	0 (0.0)	147	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	

a: Database Cutoff Date: 01AUG2025

b: Number of participants: all-participants-as-treated population

c: Based on 2x2 contingency table, using Wald confidence interval. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

d: Based on Mantel-Haenszel Chi-Squared test. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

e: Based on Breslow-Day test with subgroup as stratification factor. In case no participant or all participants with event in both treatment groups for a subgroup category, it is excluded from interaction test (if only one subgroup category remaining, report 'n.a.'). In case no participant with event in at least one treatment group across all subgroup categories, report 'n.a.'

Reported adverse events include nonserious adverse events that occurred from Day 1 through the day prior to Dose 2, and 14 days after each subsequent dose, and serious adverse events that occurred through the duration of participation in RSV Season 1

CHD: Congenital Heart Disease; CI: Confidence Interval; CLD: Chronic Lung Disease; n.a.: not applicable (when estimation not possible); n.c.: not calculated (at least 10 participants per subgroup and at least 10 events in one of the subgroups necessary); RSV: Respiratory Syncytial Virus

Unerwünschte Ereignisse (gegliedert nach SOC und PT)

Hinweis: Für die Endpunkte Schwerwiegende unerwünschte Ereignisse (SOC und PT) und Schwere unerwünschte Ereignisse (CTCAE-Grad 3-5) (SOC) liegen keine Ergebnisse vor.

Tabelle 4G-13: Subgruppenanalysen mit nicht signifikantem Interaktionstest ($p \geq 0,05$) für den Endpunkt Unerwünschte Ereignisse gesamt (SOC) – RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events	**N[b]**	**Participants with Event n (%)**	**N[b]**	**Participants with Event n (%)**	**Relative Risk [95 %-CI][c]**	**p-Value[d]**	**p-Value for Interaction Test[e]**
SOC[f]: Infections and infestations							
Sex							
Female	246	84 (34.1)	251	115 (45.8)	0.75 [0.60; 0.93]	0.008	0.142
Male	251	94 (37.5)	248	146 (58.9)	0.64 [0.53; 0.77]	<0.001	
Age Group							
<6 Months	454	159 (35.0)	429	212 (49.4)	0.71 [0.61; 0.83]	<0.001	0.253
≥6 Months	43	19 (44.2)	70	49 (70.0)	0.63 [0.44; 0.91]	0.007	
Participant Condition							
CHD	54	23 (42.6)	52	32 (61.5)	0.69 [0.47; 1.01]	0.052	0.835
CLD	137	60 (43.8)	142	81 (57.0)	0.77 [0.61; 0.97]	0.027	
Neither CLD nor CHD <29 Weeks Gestational Age	41	15 (36.6)	38	23 (60.5)	0.60 [0.37; 0.97]	0.034	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	80 (30.2)	267	125 (46.8)	0.64 [0.52; 0.81]	<0.001	
Region							
Northern Hemisphere	351	93 (26.5)	352	159 (45.2)	0.59 [0.48; 0.72]	<0.001	0.247
Southern Hemisphere	146	85 (58.2)	147	102 (69.4)	0.84 [0.70; 1.00]	0.047	
SOC[f]: Investigations							
Sex							
Female	246	19 (7.7)	251	30 (12.0)	0.65 [0.37; 1.12]	0.114	0.642
Male	251	15 (6.0)	248	28 (11.3)	0.53 [0.29; 0.97]	0.035	
Age Group							
<6 Months	454	31 (6.8)	429	50 (11.7)	0.59 [0.38; 0.90]	0.013	0.952
≥6 Months	43	3 (7.0)	70	8 (11.4)	0.61 [0.17; 2.18]	0.440	
Participant Condition							
CHD	54	5 (9.3)	52	6 (11.5)	0.80 [0.26; 2.47]	0.702	0.545
CLD	137	6 (4.4)	142	17 (12.0)	0.37 [0.15; 0.90]	0.021	
Neither CLD nor CHD <29 Weeks Gestational Age	41	2 (4.9)	38	5 (13.2)	0.37 [0.08; 1.80]	0.199	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	21 (7.9)	267	30 (11.2)	0.71 [0.41; 1.20]	0.195	
Region							
Northern Hemisphere	351	31 (8.8)	352	53 (15.1)	0.59 [0.39; 0.89]	0.011	0.912
Southern Hemisphere	146	3 (2.1)	147	5 (3.4)	0.60 [0.15; 2.48]	0.480	

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events	**N[b]**	**Participants with Event n (%)**	**N[b]**	**Participants with Event n (%)**	**Relative Risk [95 %-CI][c]**	**p-Value[d]**	**p-Value for Interaction Test[e]**
SOC[f]: Respiratory, thoracic and mediastinal disorders							
Sex							
Female	246	29 (11.8)	251	41 (16.3)	0.72 [0.46; 1.12]	0.146	0.943
Male	251	37 (14.7)	248	49 (19.8)	0.75 [0.51; 1.10]	0.138	
Age Group							
<6 Months	454	59 (13.0)	429	77 (17.9)	0.72 [0.53; 0.99]	0.042	0.685
≥6 Months	43	7 (16.3)	70	13 (18.6)	0.88 [0.38; 2.02]	0.758	
Participant Condition							
CHD	54	11 (20.4)	52	10 (19.2)	1.06 [0.49; 2.28]	0.884	0.070
CLD	137	24 (17.5)	142	26 (18.3)	0.96 [0.58; 1.58]	0.863	
Neither CLD nor CHD <29 Weeks Gestational Age	41	5 (12.2)	38	2 (5.3)	2.32 [0.48; 11.24]	0.282	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	26 (9.8)	267	52 (19.5)	0.50 [0.32; 0.78]	0.002	
Region							
Northern Hemisphere	351	48 (13.7)	352	70 (19.9)	0.69 [0.49; 0.96]	0.028	0.405
Southern Hemisphere	146	18 (12.3)	147	20 (13.6)	0.91 [0.50; 1.64]	0.745	
SOC[f]: Skin and subcutaneous tissue disorders							
Sex							
Female	246	26 (10.6)	251	36 (14.3)	0.74 [0.46; 1.18]	0.204	0.764
Male	251	22 (8.8)	248	33 (13.3)	0.66 [0.40; 1.10]	0.106	
Age Group							
<6 Months	454	46 (10.1)	429	62 (14.5)	0.70 [0.49; 1.00]	0.050[g]	0.621
≥6 Months	43	2 (4.7)	70	7 (10.0)	0.47 [0.10; 2.14]	0.310	
Participant Condition							
CHD	54	5 (9.3)	52	6 (11.5)	0.80 [0.26; 2.47]	0.702	0.520
CLD	137	16 (11.7)	142	16 (11.3)	1.04 [0.54; 1.99]	0.914	
Neither CLD nor CHD <29 Weeks Gestational Age	41	3 (7.3)	38	5 (13.2)	0.56 [0.14; 2.17]	0.393	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	24 (9.1)	267	42 (15.7)	0.58 [0.36; 0.92]	0.020	
Region							
Northern Hemisphere	351	33 (9.4)	352	47 (13.4)	0.70 [0.46; 1.07]	0.099	0.936

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events	**N[b]**	**Participants with Event n (%)**	**N[b]**	**Participants with Event n (%)**	**Relative Risk [95 %-CI][c]**	**p-Value[d]**	**p-Value for Interaction Test[e]**
Southern Hemisphere	146	15 (10.3)	147	22 (15.0)	0.69 [0.37; 1.27]	0.227	

a: Database Cutoff Date: 01AUG2025

b: Number of participants: all-participants-as-treated population

c: Based on 2x2 contingency table, using Wald confidence interval. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

d: Based on Mantel-Haenszel Chi-Squared test. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

e: Based on Breslow-Day test with subgroup as stratification factor. In case no participant or all participants with event in both treatment groups for a subgroup category, it is excluded from interaction test (if only one subgroup category remaining, report ‘n.a.’). In case no participant with event in at least one treatment group across all subgroup categories, report 'n.a.'

f: A system organ class appears on this report only if its incidence ≥10% or (incidence ≥1% and in at least 10 participants) in one or more treatment groups and p-value of main treatment effect is smaller than 0.05, and the interaction p-value is greater than or equal to 0.05 or not calculated

Reported adverse events include nonserious adverse events that occurred from Day 1 through the day prior to Dose 2, and 14 days after each subsequent dose, and serious adverse events that occurred through the duration of participation in RSV Season 1

g: Unrounded p-value > 0.050

CHD: Congenital Heart Disease; CI: Confidence Interval; CLD: Chronic Lung Disease; n.a.: not applicable (when estimation not possible); RSV: Respiratory Syncytial Virus; SOC: System Organ Class

Tabelle 4G-14: Subgruppenanalysen mit nicht signifikantem Interaktionstest (p ≥ 0,05) für den Endpunkt Unerwünschte Ereignisse gesamt (PT) – RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events	N[b]	Participants with Event n (%)	N[b]	Participants with Event n (%)	Relative Risk [95 %-CI][c]	p-Value[d]	p-Value for Interaction Test[e]
SOC: General disorders and administration site conditions - PT[f]: Pyrexia							
Sex							
Female	246	1 (0.4)	251	8 (3.2)	n.c. [n.c.; n.c.]	n.c.	n.c.
Male	251	3 (1.2)	248	4 (1.6)	n.c. [n.c.; n.c.]	n.c.	
Age Group							
<6 Months	454	4 (0.9)	429	10 (2.3)	0.38 [0.12; 1.20]	0.085	n.a.
≥6 Months	43	0 (0.0)	70	2 (2.9)	n.a. [n.a.; n.a.]	n.a.	
Participant Condition							
CHD	54	0 (0.0)	52	3 (5.8)	n.c. [n.c.; n.c.]	n.c.	n.c.
CLD	137	2 (1.5)	142	2 (1.4)	n.c. [n.c.; n.c.]	n.c.	
Neither CLD nor CHD <29 Weeks Gestational Age	41	0 (0.0)	38	0 (0.0)	n.c. [n.c.; n.c.]	n.c.	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	2 (0.8)	267	7 (2.6)	n.c. [n.c.; n.c.]	n.c.	
Region							
Northern Hemisphere	351	3 (0.9)	352	10 (2.8)	0.30 [0.08; 1.08]	0.051	0.704
Southern Hemisphere	146	1 (0.7)	147	2 (1.4)	0.50 [0.05; 5.49]	0.566	
SOC: Infections and infestations - PT[f]: Conjunctivitis							
Sex							
Female	246	2 (0.8)	251	5 (2.0)	0.41 [0.08; 2.08]	0.265	0.655
Male	251	2 (0.8)	248	8 (3.2)	0.25 [0.05; 1.15]	0.053	
Age Group							
<6 Months	454	4 (0.9)	429	13 (3.0)	0.29 [0.10; 0.88]	0.020	n.a.
≥6 Months	43	0 (0.0)	70	0 (0.0)	n.a. [n.a.; n.a.]	n.a.	
Participant Condition							
CHD	54	0 (0.0)	52	1 (1.9)	n.a. [n.a.; n.a.]	n.a.	0.170
CLD	137	2 (1.5)	142	2 (1.4)	1.04 [0.15; 7.26]	0.971	
Neither CLD nor CHD <29 Weeks Gestational Age	41	0 (0.0)	38	0 (0.0)	n.a. [n.a.; n.a.]	n.a.	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	2 (0.8)	267	10 (3.7)	0.20 [0.04; 0.91]	0.020	
Region							
Northern Hemisphere	351	3 (0.9)	352	9 (2.6)	0.33 [0.09; 1.22]	0.082	0.826
Southern Hemisphere	146	1 (0.7)	147	4 (2.7)	0.25 [0.03; 2.23]	0.179	

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events	**N[b]**	**Participants with Event n (%)**	**N[b]**	**Participants with Event n (%)**	**Relative Risk [95 %-CI][c]**	**p-Value[d]**	**p-Value for Interaction Test[e]**
SOC: Infections and infestations - PT[f]: Nasopharyngitis							
Sex							
Female	246	7 (2.8)	251	15 (6.0)	0.48 [0.20; 1.15]	0.090	0.503
Male	251	6 (2.4)	248	19 (7.7)	0.31 [0.13; 0.77]	0.007	
Age Group							
<6 Months	454	12 (2.6)	429	26 (6.1)	0.44 [0.22; 0.85]	0.012	0.458
≥6 Months	43	1 (2.3)	70	8 (11.4)	0.20 [0.03; 1.57]	0.084	
Participant Condition							
CHD	54	3 (5.6)	52	9 (17.3)	0.32 [0.09; 1.12]	0.057	0.367
CLD	137	7 (5.1)	142	11 (7.7)	0.66 [0.26; 1.65]	0.371	
Neither CLD nor CHD <29 Weeks Gestational Age	41	0 (0.0)	38	1 (2.6)	n.a. [n.a.; n.a.]	n.a.	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	3 (1.1)	267	13 (4.9)	0.23 [0.07; 0.81]	0.012	
Region							
Northern Hemisphere	351	8 (2.3)	352	27 (7.7)	0.30 [0.14; 0.64]	0.001	0.194
Southern Hemisphere	146	5 (3.4)	147	7 (4.8)	0.72 [0.23; 2.21]	0.564	
SOC: Infections and infestations - PT[f]: Upper respiratory tract infection							
Sex							
Female	246	27 (11.0)	251	46 (18.3)	0.60 [0.39; 0.93]	0.021	0.457
Male	251	36 (14.3)	248	47 (19.0)	0.76 [0.51; 1.13]	0.167	
Age Group							
<6 Months	454	54 (11.9)	429	71 (16.6)	0.72 [0.52; 1.00]	0.047	0.740
≥6 Months	43	9 (20.9)	70	22 (31.4)	0.67 [0.34; 1.31]	0.227	
Participant Condition							
CHD	54	5 (9.3)	52	10 (19.2)	0.48 [0.18; 1.31]	0.143	0.880
CLD	137	15 (10.9)	142	20 (14.1)	0.78 [0.42; 1.46]	0.430	
Neither CLD nor CHD <29 Weeks Gestational Age	41	9 (22.0)	38	12 (31.6)	0.70 [0.33; 1.46]	0.336	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	34 (12.8)	267	51 (19.1)	0.67 [0.45; 1.00]	0.049	
Region							
Northern Hemisphere	351	17 (4.8)	352	25 (7.1)	0.68 [0.37; 1.24]	0.207	0.587
Southern Hemisphere	146	46 (31.5)	147	68 (46.3)	0.68 [0.51; 0.92]	0.010	

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events	**N[b]**	**Participants with Event n (%)**	**N[b]**	**Participants with Event n (%)**	**Relative Risk [95 %-CI][c]**	**p-Value[d]**	**p-Value for Interaction Test[e]**
SOC: Investigations - PT[f]: Body temperature increased							
Sex							
Female	246	18 (7.3)	251	27 (10.8)	0.68 [0.38; 1.20]	0.182	0.671
Male	251	13 (5.2)	248	23 (9.3)	0.56 [0.29; 1.08]	0.077	
Age Group							
<6 Months	454	28 (6.2)	429	43 (10.0)	0.62 [0.39; 0.97]	0.035	0.860
≥6 Months	43	3 (7.0)	70	7 (10.0)	0.70 [0.19; 2.56]	0.584	
Participant Condition							
CHD	54	5 (9.3)	52	5 (9.6)	0.96 [0.30; 3.13]	0.950	0.601
CLD	137	4 (2.9)	142	12 (8.5)	0.35 [0.11; 1.05]	0.047	
Neither CLD nor CHD <29 Weeks Gestational Age	41	2 (4.9)	38	4 (10.5)	0.46 [0.09; 2.39]	0.347	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	20 (7.5)	267	29 (10.9)	0.69 [0.40; 1.20]	0.187	
Region							
Northern Hemisphere	351	28 (8.0)	352	45 (12.8)	0.62 [0.40; 0.98]	0.037	0.992
Southern Hemisphere	146	3 (2.1)	147	5 (3.4)	0.60 [0.15; 2.48]	0.480	
SOC: Respiratory, thoracic and mediastinal disorders - PT[f]: Cough							
Sex							
Female	246	4 (1.6)	251	11 (4.4)	0.37 [0.12; 1.15]	0.073	0.809
Male	251	5 (2.0)	248	11 (4.4)	0.45 [0.16; 1.27]	0.122	
Age Group							
<6 Months	454	6 (1.3)	429	18 (4.2)	0.31 [0.13; 0.79]	0.009	0.117
≥6 Months	43	3 (7.0)	70	4 (5.7)	1.22 [0.29; 5.19]	0.788	
Participant Condition							
CHD	54	1 (1.9)	52	2 (3.8)	0.48 [0.05; 5.15]	0.538	0.825
CLD	137	4 (2.9)	142	8 (5.6)	0.52 [0.16; 1.68]	0.265	
Neither CLD nor CHD <29 Weeks Gestational Age	41	1 (2.4)	38	1 (2.6)	0.93 [0.06; 14.30]	0.957	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	3 (1.1)	267	11 (4.1)	0.27 [0.08; 0.97]	0.032	
Region							
Northern Hemisphere	351	7 (2.0)	352	21 (6.0)	0.33 [0.14; 0.78]	0.007	0.122
Southern Hemisphere	146	2 (1.4)	147	1 (0.7)	2.01 [0.18; 21.97]	0.558	

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events	**N[b]**	**Participants with Event n (%)**	**N[b]**	**Participants with Event n (%)**	**Relative Risk [95 %-CI][c]**	**p-Value[d]**	**p-Value for Interaction Test[e]**
SOC: Respiratory, thoracic and mediastinal disorders - PT[f]: Rhinorrhoea							
Sex							
Female	246	6 (2.4)	251	13 (5.2)	0.47 [0.18; 1.22]	0.112	0.803
Male	251	9 (3.6)	248	16 (6.5)	0.56 [0.25; 1.23]	0.143	
Age Group							
<6 Months	454	14 (3.1)	429	27 (6.3)	0.49 [0.26; 0.92]	0.024	0.674
≥6 Months	43	1 (2.3)	70	2 (2.9)	0.81 [0.08; 8.71]	0.865	
Participant Condition							
CHD	54	3 (5.6)	52	4 (7.7)	0.72 [0.17; 3.07]	0.659	0.745
CLD	137	2 (1.5)	142	4 (2.8)	0.52 [0.10; 2.78]	0.436	
Neither CLD nor CHD <29 Weeks Gestational Age	41	2 (4.9)	38	0 (0.0)	n.a. [n.a.; n.a.]	n.a.	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	8 (3.0)	267	21 (7.9)	0.38 [0.17; 0.85]	0.014	
Region							
Northern Hemisphere	351	15 (4.3)	352	27 (7.7)	0.56 [0.30; 1.03]	0.058	n.a.
Southern Hemisphere	146	0 (0.0)	147	2 (1.4)	n.a. [n.a.; n.a.]	n.a.	
SOC: Skin and subcutaneous tissue disorders - PT[f]: Dermatitis diaper							
Sex							
Female	246	4 (1.6)	251	13 (5.2)	0.31 [0.10; 0.95]	0.029	0.946
Male	251	3 (1.2)	248	9 (3.6)	0.33 [0.09; 1.20]	0.076	
Age Group							
<6 Months	454	6 (1.3)	429	20 (4.7)	0.28 [0.11; 0.70]	0.003	0.398
≥6 Months	43	1 (2.3)	70	2 (2.9)	0.81 [0.08; 8.71]	0.865	
Participant Condition							
CHD	54	0 (0.0)	52	1 (1.9)	n.a. [n.a.; n.a.]	n.a.	0.108
CLD	137	3 (2.2)	142	2 (1.4)	1.55 [0.26; 9.16]	0.623	
Neither CLD nor CHD <29 Weeks Gestational Age	41	1 (2.4)	38	3 (7.9)	0.31 [0.03; 2.84]	0.272	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	3 (1.1)	267	16 (6.0)	0.19 [0.06; 0.64]	0.003	
Region							
Northern Hemisphere	351	3 (0.9)	352	11 (3.1)	0.27 [0.08; 0.97]	0.031	0.765

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Adverse Events	**N[b]**	**Participants with Event n (%)**	**N[b]**	**Participants with Event n (%)**	**Relative Risk [95 %-CI][c]**	**p-Value[d]**	**p-Value for Interaction Test[e]**
Southern Hemisphere	146	4 (2.7)	147	11 (7.5)	0.37 [0.12; 1.12]	0.066	

a: Database Cutoff Date: 01AUG2025

b: Number of participants: all-participants-as-treated population

c: Based on 2x2 contingency table, using Wald confidence interval. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

d: Based on Mantel-Haenszel Chi-Squared test. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

e: Based on Breslow-Day test with subgroup as stratification factor. In case no participant or all participants with event in both treatment groups for a subgroup category, it is excluded from interaction test (if only one subgroup category remaining, report ‘n.a.’). In case no participant with event in at least one treatment group across all subgroup categories, report 'n.a.'

f: A specific adverse event appears on this report only if its incidence ≥10% or (incidence ≥1% and in at least 10 participants) in one or more treatment groups and p-value of main treatment effect is smaller than 0.05, and the interaction p-value is greater than or equal to 0.05 or not calculated

Reported adverse events include nonserious adverse events that occurred from Day 1 through the day prior to Dose 2, and 14 days after each subsequent dose, and serious adverse events that occurred through the duration of participation in RSV Season 1

CHD: Congenital Heart Disease; CI: Confidence Interval; CLD: Chronic Lung Disease; n.a.: not applicable (when estimation not possible); n.c.: not calculated (at least 10 participants per subgroup and at least 10 events in one of the subgroups necessary); PT: Preferred Term; RSV: Respiratory Syncytial Virus; SOC: System Organ Class

Tabelle 4G-15: Subgruppenanalysen mit nicht signifikantem Interaktionstest (p ≥ 0,05) für den Endpunkt Unerwünschte Ereignisse gesamt (PT) – RCT mit dem zu bewertenden Arzneimittel

Study: MK-1654-007[a]	Clesrovimab		Palivizumab		Clesrovimab vs. Palivizumab		
Severe Adverse Events (CTCAE Grade 3-5)	N[b]	Participants with Event n (%)	N[b]	Participants with Event n (%)	Relative Risk [95 %-CI][c]	p-Value[d]	p-Value for Interaction Test[e]
SOC[f]: Infections and infestations							
Sex							
Female	246	36 (14.6)	251	38 (15.1)	0.97 [0.63; 1.47]	0.874	0.066
Male	251	28 (11.2)	248	50 (20.2)	0.55 [0.36; 0.85]	0.006	
Age Group							
<6 Months	454	59 (13.0)	429	74 (17.2)	0.75 [0.55; 1.03]	0.078	0.602
≥6 Months	43	5 (11.6)	70	14 (20.0)	0.58 [0.23; 1.50]	0.250	
Participant Condition							
CHD	54	10 (18.5)	52	15 (28.8)	0.64 [0.32; 1.30]	0.213	0.825
CLD	137	23 (16.8)	142	36 (25.4)	0.66 [0.41; 1.06]	0.080	
Neither CLD nor CHD <29 Weeks Gestational Age	41	5 (12.2)	38	5 (13.2)	0.93 [0.29; 2.95]	0.898	
Neither CLD nor CHD ≥29 Weeks Gestational Age	265	26 (9.8)	267	32 (12.0)	0.82 [0.50; 1.33]	0.422	

a: Database Cutoff Date: 01AUG2025

b: Number of participants: all-participants-as-treated population

c: Based on 2x2 contingency table, using Wald confidence interval. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

d: Based on Mantel-Haenszel Chi-Squared test. In case of no participant with event in at least one treatment group or all participants with event in both treatment groups, report 'n.a.'

e: Based on Breslow-Day test with subgroup as stratification factor. In case no participant or all participants with event in both treatment groups for a subgroup category, it is excluded from interaction test (if only one subgroup category remaining, report 'n.a.'). In case no participant with event in at least one treatment group across all subgroup categories, report 'n.a.'

f: A system organ class / specific adverse event appears on this report only if its incidence ≥5% or (incidence ≥1% and in at least 10 participants) in one or more treatment groups and p-value of main treatment effect is smaller than 0.05, and the interaction p-value is greater than or equal to 0.05 or not calculated

Reported adverse events include nonserious adverse events that occurred from Day 1 through the day prior to Dose 2, and 14 days after each subsequent dose, and serious adverse events that occurred through the duration of participation in RSV Season 1

CHD: Congenital Heart Disease; CI: Confidence Interval; CLD: Chronic Lung Disease; CTCAE: Common Terminology Criteria for Adverse Events; n.a.: not applicable (when estimation not possible); RSV: Respiratory Syncytial Virus; SOC: System Organ Class